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Anti-oestrogens, such as tamoxifen, are effective agents in the treatment of breast cancer, reducing
recurrence and death with minimal side effects. However, a substantial number of tumours fail to
respond and mechanisms of response and resistance are poorly understood. Angiogenesis, or new
vessel formation, is an essential component of tumour growth and metastasis. Oestrogens act to
preserve endothelial cells by inhibiting their apoptosis. Conversely, tamoxifen exerts an anti-
angiogenic effect. Changes in tumour vascularity during primary tamoxifen treatment may thus
provide an early marker of hormone sensitivity.
The aims of this study were to determine whether changes in tumour vascularity followed primary
treatment with tamoxifen, to ascertain whether such changes were associated with tumour response
and to define chronology of such changes. Potential methodological issues such as observer variation
and reproducibility of counts were addressed. Finally, a study was performed to determine whether
changes in tumour vascularity provided a useful predictor of sensitivity to primary endocrine therapy.
Investigation of observer variation yielded low rates of both inter- and intra-observer variation and
good correlation between counts performed following staining with Factor VIII and CD31 antibodies.
The study undertaken to address reproducibility of microvessel counts in different breast cancer
specimens demonstrated that, although counts were similar in core biopsies and sections taken from
tine same tumour, no significant positive correlation was found. Tins suggested that there might be
difficulty in making comparisons within tumours unless the effects of treatment on vascularity were
large.
Fifty-seven patients with large, oestrogen receptor (ER)-positive breast cancers were treated with
tamoxifen prior to surgery. Tumour vascularity was assessed before and after 3 months' treatment and
changes correlated with response. A significant association was found between change in tumour
vascularity and response, with microvessel counts decreasing in responding tumours (p=0.006) and
tending to increase in non-responding tumours (p=0.036). Thus successful treatment with tamoxifen
resulted in reduced tumour vascularity. Iinmunohistochemical staining for vascular endothelial growth
factor (VEGF) was studied in the same group of tumours and demonstrated a significant reduction in
proportion of tumour cells expressing VEGF in responding tumours.
To determine timing of these changes in relation to the effect on tumour size, mice bearing xenografts
of ER-positive ZR-75 and ER-negative MDA-MB-231 breast cancer cell lines were treated with
tamoxifen and assessed for changes in tumour size and vascularity. After 2 days, there was evidence
of reduced microvessel counts in ZR-75, but not MDA-MB-231 tumours. Clear evidence of tumour
regression in ZR-75 tumours only became apparent after 4 days. These results suggested that changes
in vascularity precede tumour regression.
Forty-two patients were recruited into a prospective study in which patients were treated with primary
tamoxifen. Tumour tissue in the form of core biopsies was available prior to and after fourteen days of
treatment. Patients underwent definitive surgery at the end of three months. Microvessel counts were
compared at the three time points. The only significant difference identified between non-responding
and responding tumours was increased microvessel counts in non-responding tumours following two
weeks of treatment (p=0.01). No significant trends were observed at three months. Changes in
proliferation during treatment with tamoxifen were studied in the same group of patients for
comparison. There was a significant trend for reduction in proliferation in responding tumours which
was maintained throughout the period of treatment.
Response to primary treatment with tamoxifen was associated with reduced tumour vascularity and
xenograft data suggested that such changes occur prior to tumour regression. However, problems with
reproducibility of microvessel counts in small tumour biopsies may limit their role as an early
predictor of sensitivity to endocrine therapy. Preliminary results suggest that early changes in
proliferation may aid in the prediction of endocrine sensitivity.
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Introduction
Incidence of breast cancer:
Breast cancer is primarily a disease of women with only 1% of cases occurring in men. It
poses an important international health care problem, causing immeasurable morbidity and
substantial mortality and economic consequences throughout the world. The age-
standardised incidence rates of breast cancer in the United Kingdom, North America,
Australasia and Scandinavia are approximately 60 to 70 per 100 000 women per annum
(Parkin et al, 1992). In the UK alone, 25 000 new cases are diagnosed and 15 000 women die
from breast cancer each year (Forrest, 1987). It is the commonest cancer to affect women in
Scotland (Sharp et al, 1993). A third of this risk occurs after the age of 75, with a 1 in 15 risk
quoted for women up to the age of 75 (Sharp et al., 1993). Furthermore there is evidence that
the incidence is increasing, both in Scotland (Sharp et al, 1993) and in the US (Feuer et al,
1993). By the year 2000, breast cancer will affect approximately one million women and
cause the death of over 400 000 women per annum (Forbes, 1997). This increase may be due
in part to increased detection, following commencement of the National Screening
Programme, and increased longevity. Despite taking these factors into account, there remains
a steady increase, which may caused by dietary or environmental factors.
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Aetiology;
Although the cause of breast cancer remains unknown, there are a number of factors that
affect risk of developing the disease. It is predominantly a disease ofwomen, living in the
Western world (Forrest, 1997). The incidence rises steadily with age, with one third of breast
cancers being diagnosed after the age of 75 (Henderson, 1990).
Hormonal factors:
Functioning ovaries are a pre-requisite for the initiation of breast cancer; women who
undergo oophorectomy before the age of 35 years reduce their risk by more than half
(Trichopoulos et al, 1972). Women in whom reproductive life is extended, by early
menarche or late menopause, have an increased risk (MacMahon et al, 1982). Reproductive
factors associated with breast cancer risk include older age at first birth and of subsequent
births. There is a dual effect of pregnancy, a transient period of increased risk for the three
years post-delivery is followed by a longer term protective effect (Leon et al., 1995). There
is probably no increased risk with induced abortion (Melbye et al, 1997) and a weak
protective effect of breastfeeding (Thomas & Noonan, 1993).
Genetic factors:
There is no doubt that for some women there is an increased risk of breast cancer related to
the occurrence of disease in other members of the same family. The risk of developing the
disease can be two to five times higher than the normal population if one or more first or
second degree relatives have been affected (Anderson & Badzioch, 1985). There is evidence
to suggest that in families with very high risk of developing breast cancer, an inherited
autosomal dominant gene is responsible (Lynch et al, 1984). Between 5 and 9% of all breast
cancers are due to hereditary causes (Lynch et al., 1992), and inherited factors are thought to
contribute to approximately 25-35% of cases diagnosed before the age of 30 years (Lynch et
al., 1992). Mutations in BRCA-1 (Miki et al, 1994) or BRCA-2 genes (Wooster et al, 1995)
result in a high number of inherited forms of breast cancer. The BRCA-1 gene on
chromosome 17q was identified by positional cloning, and consists of 22 coding exons
distributed over lOOkb of genomic DNA, encoding a protein of 1863 amino acids (Miki et
al., 1994). Evidence suggests linkage to BRCA-1 in families with early onset breast or
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ovarian cancer, or both, occurring in multiple generations (Ford & Easton, 1995). The
cumulative risk of breast cancer development in BRCA-1 carriers is estimated to be in the
range of 55-85%. Carriers may also carry increased risk of developing colon and prostate
cancer (Ford & Easton, 1995). Gene frequency studies of BRCA-1 suggest a frequency of
1:2-400 in the general population (Biesecker et al, 1993), with a higher frequency in
Ashkenazi Jews (Offit et al, 1996). Studies of this group suggest that one fifth of breast
cancers occurring before the age of 50 are due to BRCA-1 mutations (Offit et al., 1996).
Estimates of lifetime risk are based on selected families with high incidence and so should be
considered upper limits.
The BRCA-2 gene is located on chromosome 13ql2-13 and is also associated with early
onset breast cancer (Wooster et al, 1995). Linkage to the BRCA-2 gene is suggested when
male breast cancer occurs in the family. The cumulative risk among carriers is estimated to
be 63% by age 70 and 87% by age 80. A higher proportion of breast cancer cases may be
due to low penetrant susceptibility genes that are more common, such as HRAS1 and ataxia-
telangectasia (Ford & Easton, 1995).
Environmental factors:
Several lifestyle factors contribute to the risk of developing breast cancer. An association has
been found between recent stressful life events and risk (Ginsberg et al, 1996). There has
been much work observing effects of diet on risk, and there is evidence to suggest that diet
rich in fat leads to increased risk (Lubin et al, 1986). This is contentious, and a recent meta¬
analysis suggested that there might be no such increase (Hunter et al, 1996). It may be that
dietary fat is particularly important during youth, and that, if consumed excessively during
this period, it may lead to a slight increased risk in developing breast cancer (Hunter &
Willet, 1996). The type of dietary fat is important, olive oil (Hunter & Willet, 1996) and
milk (Knekt et al, 1996) have a protective effect. Other dietary constituents that may exert a
protective effect are the phytoestrogens, which are found in high concentrations in soya
products (Knight & Eden, 1995), and vitamin A (Hunter & Willet, 1996).
Smoking has not been found to significantly increase risk of developing the disease (Palmer
& Rosenberg, 1993), although most studies have ignored the possible effects of passive
smoking. When this is taken into account, significant risks were observed for both passive
and active smoking (Morabia et al, 1996). Alcohol consumption ofmore than three units a
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day increases breast cancer risk, particularly in women over 50 years (Holmberg et al, 1995).
Regular exercise for longer than 3.5 hours a week appears to have a protective effect (Thune
et al, 1997), although a recent study examining the effect of exercise in late adolescence and
in the recent past failed to identify such an effect (Rockhill et al., 1998).
Th effect of exogenous hormones has been widely investigated both in the context of oral
contraceptive preparations (OCP) and hormone replacement therapy (HRT). In current users
of OCP there is a slight increased risk of developing breast cancer (relative risk 1.24) when
compared with never users. This increased risk ceases 10 years after stopping the pill
(Collaborative Group on Hormonal Factors in Breast Cancer, 1996). Other features of OCP
use identified as risk factors for breast cancer in previous studies such as duration of use (UK
National Case-Control Study Group, 1989), age at first use (Pike et al, 1983) and dose and
type of OCP (Pike et al, 1983) have little effect when compared with current use.
A recent review of literature concerning risk of breast cancer in association with HRT use
has demonstrated an increasing risk per year of HRT use which is equivalent to delaying
menopause by a year (Colditz, 1998). There is a positive relationship between hormone
levels and risk, and risk increases with increasing duration of use (Colditz, 1998).
Whether this increased risk is due to regular surveillance ofwomen on HRT, leading to
detection bias, or is a true biological effect is not known, although an increasing body of
evidence suggests the risk to be true. However, this must be balanced against the benefits of




Some discussion of development of the normal breast is relevant in understanding the role of
oestrogen in breast cancer and thus the rationale behind use of hormonal therapeutic
strategies. The breast is a secretory organ, composed of glandular tissue and ducts contained
in a stroma of supporting fat and fibrous tissue. The primary secreting units consist of groups
of terminal ductules with sac-like ends, embedded in a fine specialized connective tissue to
form breast lobules, or terminal ductal lobular units (TDLU). During lactation these become
dilated to form alveoli which secrete milk. A coalescing system of ducts ofgradually
increasing size drain the TDLU, ending in 12 to 15 main lactiferous ducts which emerge on
the surface of the nipple. With the exception of the main lactiferous ducts, the whole of the
duct system is lined by a single layer of epithelial cells. It is from the luminal epithelial cells
of TDLUs that most pre-invasive and invasive cancers arise (Wellings et al, 1975).
Normal breast development is characterised by three phases of activity: puberty, ovulatory
menstrual cycles and pregnancy. Oestrogen is required for breast development in puberty: in
girls whose breasts do not form because of gonadal dysgenesis, full development may be
induced by administration of oestrogen (Laron et al, 1989), but oestrogen alone is not
sufficient (Bidlinggmaier & Knorr, 1978). Several other factors, such as gonadotrophins,
glucocorticoids and growth factors are likely to play a role (Miller, 1996c). Conversely,
menopause is associated with breast involution; epithelial cell proliferation decreases with
age (Potten et al, 1988), and glandular epithelium is replaced by fat. The timing of such
changes corresponds to a reduction in circulating oestrogens.
The breast responds to the cyclical nature of hormone secretion during the menstrual cycle.
The luminal epithelial cells ofTDLU undergo greater proliferation during the luteal phase,
during which period levels of circulating oestrogen and progesterone are moderately elevated
(Anderson et al, 1982). Oestrogen levels are at their maximum during the follicular phase.
Effects of oestrogen are mediated by oestrogen receptors (ER), which are expressed in
normal breast in lower levels than in cancer (Carpenter et al, 1989), with varying levels of
expression throughout the menstrual cycle. Lowest levels are expressed during the luteal
phase (Battersby et al, 1992), coinciding with maximum levels of circulating oestrogen. A
picture emerges of a constantly changing hormonal milieu resulting in changes in cell
proliferation and gene expression throughout the menstrual cycle.
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Management of breast cancer:
For the purpose of treatment, breast cancer can be divided into two categories: early, stage I
and II disease, which is considered operable, and advanced or inoperable, stage III and IV
disease. The aims of treatment differ between the two groups: in early breast cancer aims are
to achieve local control and treat micrometastatic disease, with the ultimate goal of cure, in
advanced disease aims are to control disease whilst maintaining quality of life. Management
of two areas must be considered in early breast cancer: locoregional and systemic disease. In
advanced breast cancer, management of locoregional disease is not aimed to cure, but to
palliate, so effects of interventions on quality of life must be considered.
Management of locoregional disease:
The mainstay of locoregional treatment of early breast cancer is surgery to the breast and
axilla. There has been a change in pattern of breast surgery over recent decades. Radical
surgical resection has been supplanted by breast conservation surgery (Veronesi et al, 1981).
This change can be attributed to several factors: firstly, a greater understanding that long
term outcome following breast cancer treatment is influenced more by systemic than
locoregional therapies has encouraged surgeons to consider less radical options (Fisher &
Gebhardt, 1978). Secondly, changing patterns in presentation of breast cancer have followed
the advent ofmammographic screening, resulting in earlier diagnosis. Thus an increasing
number of cancers are diagnosed when they are less than 1cm in diameter or at the pre¬
invasive stage (Cady, 1997). Finally, patients are increasingly expressing a wish to undergo
conservative surgery with resultant organ preservation and improved cosmesis.
Trials comparing results of mastectomy and conservative surgery have shown similar rates
of overall survival, but significantly increased local recurrence rates in those undergoing
conservative surgery without postoperative radiotherapy (Fisher et al, 1985). In the large
National Surgical Adjuvant Breast and Bowel Project (NSABP) B-06 study with 12 years of
follow up, the cumulative incidence of recurrence in the ipsilateral breast was 35% in
patients treated with lumpectomy alone versus 10% in the group treated with lumpectomy
and breast irradiation (p<0.001) (Fisher et al, 1995). An important predictor of local
recurrence following conservative surgery is involvement of surgical margins (Smitt et al,
1995; Veronesi et al, 1990). The observed lack of difference in survival between the two
groups was thought to be due to a balance between the slight reduction in breast cancer
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deaths and an increase in the number of cardiac related deaths in the radiotherapy-treated
group (Early Breast Cancer Trialists' Collaborative Group, 1995). However, more recent
trials have confirmed lower mortality from breast cancer and have also suggested a reduction
in cardiac related deaths, possibly due to reduced dosage in radiotherapy regimens (Cuzick et
al, 1994).
Breast conservation has thus become the treatment of choice for patients with a single
clinical and/or mammographic lesion measuring 4cm or less without signs of local
advancement, extensive nodal involvement or metastases. Patients with central lesions,
multicentric disease, extensive ductal carcinoma in situ or large tumours in small breasts are
ineligible (Dixon & Sainsbury, 1998).
Another important aspect of surgical management of breast cancer is the axilla. The
changing pattern of presentation and treatment of breast cancer described above has led to
debate over the necessity of complete (level III) axillary dissection in all patients. The role of
axillary surgery is twofold: to stage the axilla and to treat established disease. In the 1980s,
physicians based decisions regarding administration of adjuvant systemic therapy on
pathologic status of axillary lymph nodes, leading to an increasing number of patients
undergoing axillary dissection, although results did not affect subsequent management in all
patients (Haffty et al, 1998). In those patients with involved nodes, axillary dissection is the
optimal method of treatment but it carries risks of complications including lymphoedema
and damage to nerves of the axilla. Prediction of nodal involvement prior to undertaking
surgery would therefore be valuable. There is a direct relationship between tumour size and
presence of lymph node metastases; those with mammographically detected disease are less
likely to have involved nodes at each individual size. Thus such patients with small tumours
may undergo sampling instead of dissection with reduced morbidity (Dixon & Sainsbury,
1998). Patients undergoing mastectomy should undergo axillary dissection to reduce the
need for postoperative radiotherapy (Dixon & Sainsbury, 1998).
Alternative options for management of the axilla are node sampling or sentinel node biopsy.
Axillary node sampling, involving excision of four nodes, has been compared to level III
dissection in patients undergoing mastectomy for breast cancer: patients with positive lymph
nodes underwent axillary radiotherapy postoperatively. There was a similar rate of detection
of positive lymph nodes and similar rates of relapse-free and overall survival in the two
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groups (Forrest et al, 1995). Radiotherapy reduced arm mobility and axillary dissection
increased rate of arm swelling (Aitken et al, 1989).
The sentinel lymph node is the first node draining the primary tumour in the regional
lymphatic basin and its histologic nature may predict characteristics of the remaining axillary
lymph nodes (Albertini et al, 1996). Sentinel node biopsy is a recently developed technique,
involving injection of radiolabelled sulphur colloid or albumin, blue dye or a combination
into the tumour and skin overlying it, allowing identification of the sentinel node by
radiation monitoring or intraoperative visualization. In one study using a combination of
mapping techniques and sentinel node biopsy followed by axillary clearance, the sentinel
node was successfully identified in 92% of patients; 32% were found to have metastatic
disease, the sentinel node biopsy tested positive in all these cases (Albertini et al, 1996).
Accurate assessment of sentinel nodes intraoperatively may prevent unnecessary axillary
dissection.
Breast biopsy techniques are an important consideration in the management of locoregional
breast cancer. The use of fine needle aspiration cytology is well-established as part of the
triple assessment required for the accurate diagnosis of breast cancer, with a sensitivity of
97% and false negative rate of 3% in one study of screen detected cancers (Yiangou et al,
1996). Core biopsies provide histological information and are being used increasingly in the
diagnostic setting, with improved results of detection of invasive and pre-invasive cancers
(Litherland et al, 1996). Core biopsies are important in the setting of advanced disease,
providing the only tissue available prior to commencement of systemic therapy or
radiotherapy (Pace & Berg, 1997). Assessment of cores can be performed to determine
prognostic markers, such as oestrogen receptor status, that may influence choice of primary
treatment (Zidan et al, 1997). However, reliability of core biopsy specimens in such
assessments requires confirmation because of their relatively small size and tumour
heterogeneity. One study has demonstrated concordance between core and tumour section in
several pathological variables including oestrogen receptor, bcl-2 and p53 (Jacobs et al,
1998). In the same study, assessment of microvessel density in core biopsies following
staining with Factor VIII antibody was not found to be reliable (Jacobs et al, 1998).
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Management of systemic disease:
Adjuvant systemic therapy for early breast cancer began in the early 1970s when it was first
appreciated that loco-regional treatment was frequently insufficient to control disease,
leading to the suggestion that occult micrometastases were present at diagnosis (Valagussa et
al, 1978). Whilst benefits of such therapy has been shown in several clinical trials (Early
Breast Cancer Trialists' Collaborative Group, 1992; Olivotto et al, 1994), its effect on
individual patients cannot be assessed as there is no overt disease to monitor as treatment
follows primary tumour excision. Adjuvant systemic therapy may involve administration of
chemotherapy or endocrine therapy or a combination of both. In an overview from the Early
Breast Cancer Trialists' Collaborative Group, chemotherapy was found to reduce annual risk
of death by 30% in premenopausal patients and was most effective in younger patients with
ER-negative tumours (Early Breast Cancer Trialists' Collaborative Group, 1992). There was
a less marked survival improvement in postmenopausal women given adjuvant
chemotherapy (Early Breast Cancer Trialists' Collaborative Group, 1992). There is a wide
variety of chemotherapy regimens available, which is beyond the scope of this thesis, the
main focus of which is endocrine treatment of breast cancer.
11
Endocrine treatment of breast cancer:
It was Beatson who, in 1896, first noted that ovarian ablation in premenopausal women with
advanced breast cancer resulted in tumour regression (Beatson, 1896). It has become clear
that such regression occurred in approximately one-third of patients with advanced disease
following oophorectomy (Thomson, 1902). Adjuvant intervention in premenopausal women
results in a reduction in odds ratio of death of 28% when compared to women not receiving
adjuvant therapy (Early Breast Cancer Trialists' Collaborative Group, 1992). A Scottish
study compared survival rates in premenopausal women with lymph node positive disease
treated in the adjuvant setting with either ovarian ablation or chemotherapy. No significant
differences in relapse-free or overall survival were observed between the two treatments
(Scottish Cancer Trials Breast Group & ICRF Breast Unit, 1993). Other methods of surgical
endocrine manipulation, such as hypophysectomy and adrenalectomy, have also been shown
to be of benefit. Such manipulations produce benefits in 30-40% of postmenopausal women
with advanced breast cancer (West et al, 1952), but these are associated with high morbidity
and a need for replacement corticosteroid therapy. This has led to the development of more
specific drug therapies to produce hormone deprivation.
Advantages of drug therapy are that it is non-invasive and reversible, so that if endocrine
manipulation fails, the drug can be stopped with cessation of side-effects. LHRH agonist
analogues effect a 'medical oophorectomy', by suppressing oestrogen production in
premenopausal women (Nicholson et al, 1987). LHRH is a decapeptide, intermittently
secreted by the hypothalamus, which, via release of gonadotrophins, stimulates ovarian
oestrogen production. By maintaining continuous occupancy of specific receptors for LHRH.
LHRH agonist analogues cause a fall in oestrogen production (Nicholson &Walker, 1989).
Goserelin (Zoladex), an LHRH agonist, is administered monthly by depot injection and can
be as effective as surgical or radiotherapeutic ovarian ablation with response rates of up to
40% in women with advanced tumours (Santen et al, 1990). This increases to 50% in women
whose tumours are selected based on oestrogen receptor positivity (Santen et al, 1990).
Early development of antioestrogens was based on the rationale that oestrogen exerts its
effects via specific receptors and that disruption of such interaction would produce tumour
regression. Tamoxifen is a partial oestrogen agonist which competes with oestrogen for
binding to the oestrogen receptor, blocking the effect of endogenous oestrogen, although it
exerts a weak agonist effect particularly at low levels of endogenous oestrogen (Jordan &
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Murphy, 1990). Tamoxifen was first used in palliation of advanced disease: in a study of
4000 women treated with the drug, response was observed in one-third of women (Jackson
& Lowery, 1987). Response rates were higher in women with ER-positive disease (Hawkins
& Roberts, 1980). The percentage of ER-positive tumours increases with age independent of
menopausal status, so that elderly women tend to have higher response rates than younger
women (Bradbeer & Kyngdon, 1983). These factors, combined with the fact that tamoxifen
is well-tolerated with few side effects, led to its establishment as first line therapy in those
elderly women for whom surgery is associated with a significantly greater risk of
perioperative morbidity and mortality (Miller, 1996b).
Before exploring the use of tamoxifen in further detail, other endocrine therapies will be
mentioned. Work in this thesis is based primarily on treatment of breast cancers with
tamoxifen so that emphasis will be placed on this, but other drugs warrant a brief outline.
Problems arising from the agonist effects of tamoxifen include increased incidence of
endometrial and hepatic tumours (Jordan & Murphy, 1990), which has led investigators to
explore alternative methods of ER blockade. Pure antiestrogens have been found to be more
effective than tamoxifen in cell culture (Wakeling & Bowler, 1989) and clinical studies
suggest that they produce benefit as second line hormonal therapy following development of
tamoxifen resistance (De Friend et al, 1994).
An alternative strategy to ER blockade for combating oestrogen-stimulated tumour growth is
by the inhibition of oestrogen synthesis. The final step in oestrogen production is conversion
of androgens to oestrogen, catalysed by the aromatase enzyme. Understanding of this
process has led to development of specific aromatase inhibitors (Harvey, 1998). The first to
be used was aminoglutethimide, which induced a clinical response in 33% of patients with
advanced disease, with a median duration of response of 18 months (Griffiths et al, 1973).
Aminoglutethimide lacks specificity and is therefore associated with significant side effects,
requiring concomitant corticosteroid administration (Miller, 1996b). The more recent
development of new specific aromatase inhibitors, such as letrozole and anastrozole, has led
to decreased toxicity and increased efficacy, leading to tumour remission in postmenopausal
patients (Goss & Gwyn, 1994).
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Role of tamoxifen in breast cancer:
The role of tamoxifen is breast cancer management can be divided into two categories:
treatment of established disease, which may be early or advanced, and prophylaxis for
patients at high risk of developing the disease.
Adjuvant therapy:
The aim of adjuvant therapy for patients with early breast cancer is to eradicate or control
occult metastases without significantly worsening quality of life. In a large overview of
37 000 women with early breast cancer treated with 5 years of adjuvant tamoxifen following
surgery, proportional recurrence reductions of 47% and mortality reductions of 26% were
achieved compared with women who received no adjuvant therapy at 10 years follow up
(Early Breast Cancer Trialists' Collaborative Group, 1998). Reductions in recurrence rates
were most evident in the first five years, with main benefits in reducing mortality continuing
to increase up to 10 years after treatment (Early Breast Cancer Trialists' Collaborative
Group, 1998). Absolute benefit was greater in women with lymph node-positive rather than
lymph node-negative disease, and treatment was more effective in women over the age of 50
years (Early Breast Cancer Trialists' Collaborative Group, 1998). A strong indicator of
benefit was ER status, with minimal benefit in those patients with ER-negative tumours
(Early Breast Cancer Trialists' Collaborative Group, 1998), contrary to early evidence (Early
Breast Cancer Trialists' Collaborative Group, 1992).
Other studies investigating the role of tamoxifen have attempted to determine the place of
combined chemoendocrine therapy in the adjuvant setting. Premenopausal women with
lymph node-positive, ER-positive disease derived some benefit from such combined therapy,
with improved relapse-free and overall survival (Fisher et al, 1997; Fisher et al, 1981).
Benefits of adjuvant tamoxifen were greatest for patients over the age of 50 years (Fisher et
al, 1981). Addition of chemotherapy led to a modest improvement in relapse-free survival
(International Breast Cancer Study Group, 1997), but a meta-analysis of quality-adjusted
survival found that chemoendocrine therapy did not provide more quality-adjusted survival
time when compared to tamoxifen alone (Gelber et al, 1996).
Optimal duration of treatment with adjuvant tamoxifen remains controversial. Early studies
involved treatment with tamoxifen for up to two years (Early Breast Cancer Trialists'
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Collaborative Group, 1992). Improved understanding of the action of tamoxifen as a
cytostatic agent led to the suggestion that stopping treatment may lead to early relapse. This
has provoked several studies aimed at determining the optimal duration of adjuvant
tamoxifen (Swedish Breast Cancer Cooperative Group, 1996). Comparison of relapse-free
(RFS) and overall survival (OS) in patients treated with 2 versus 5 years of tamoxifen
showed continued benefits from longer duration of treatment, with improved relapse-free
and overall survival (Swedish Breast Cancer Cooperative Group, 1996). The controversy
over 5 years versus longer continues (Rea et al, 1998). Results from the NSABP-B-14 trial
suggested that continuing tamoxifen beyond 5 years in patients with primary operable,
lymph node-negative, ER-positive tumours was detrimental in terms of RFS, distant disease-
free survival and OS compared with those who stopped at 5 years (Fisher et al, 1996).
Increased rates of thromboembolic episodes and endometrial cancer were observed in the
treated group (Fisher et al, 1996). Tormey et al found that the only group to benefit from
continued tamoxifen beyond five years were those patients with ER-positive disease, who
experienced a longer time to relapse (Tormey et al, 1996). Results from the Scottish trial
suggested that a worthwhile gain from continuing adjuvant tamoxifen beyond five years is
unlikely (Stewart et al, 1996). Two major trials aimed at definitively answering the question
of optimum duration of adjuvant tamoxifen are ongoing (Rea et al, 1998).
Treatment of advanced disease:
Tamoxifen was first evaluated in the setting of advanced disease in postmenopausal women
(Cole et al, 1971). An early review of 1200 patients with advanced disease described a
response rate to tamoxifen of 32% with improved survival in responding patients, compared
with non-responders (Mouridsen et al, 1978). Response rates rose to greater than 50% in ER-
positive patients (Kiang & Kennedy, 1977), and in patients who had previously responded to
other forms of endocrine therapies (Kiang & Kennedy, 1977). Remission rates were found to
be higher in patients with soft tissue or lung metastases than in those with bony metastases,
which responded better to other forms of endocrine treatment such as medroxyprogesterone
(Van Veelen et al, 1986). When compared with other forms of hormonal manipulation,
tamoxifen favoured well with similar response rates and duration of response, but with
considerably fewer side effects (Ingle et al, 1981; Van Veelen et al, 1986). Recent studies
comparing the efficacy of the new generation aromatase inhibitors have yielded interesting
results: they appear to be as effective as tamoxifen with potential for superior tolerability
(Anderson et al, 1998; Goss & Gwyn, 1994).
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Tamoxifen also plays a role in the treatment of premenopausal women with advanced breast
cancer. Studies have shown a remission rate of approximately 30% with a median duration
response of 13 months (Margreiter & Wiegele, 1984). Tamoxifen compared favourably with
surgical oophorectomy, with similar response rates, median duration of response and overall
median survival (Buchanan et al, 1986). Tamoxifen was better tolerated and so provides a
suitable alternative to surgical oophorectomy in these patients (Buchanan et al, 1986).
Tamoxifen as prophylaxis:
The potential role of tamoxifen in the prevention of breast cancer developed as a result of
finding that tamoxifen reduced risk of contralateral cancer by 39% (Early Breast Cancer
Trialists' Collaborative Group, 1992). The effect was found to increase with duration of
tamoxifen treatment. The subject remains contentious and most large multicentre studies are
ongoing. The NSABP study aimed at addressing this issue was closed earlier than planned
this year because of finding a 45% reduction in healthy women given tamoxifen versus
placebo (Stat-Bite, 1998). European trials continue as such clear benefits have not been
observed (Powles et al, 1998).
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Neoadjuvant therapy:
Neoadjuvant therapy, or administration of systemic therapy prior to loco-regional therapy,
has been used increasingly in the management of breast cancer since the 1970s (Forrest et al,
1991) and is based on both biological and clinical rationales. Removal of the primary tumour
may increase the rate of growth of micrometastases, explained by the presence of a
circulating growth factor and prevented by administering chemotherapy prior to surgical
excision (Fisher et al, 1983). More recent work has focused on the role of angiostatin, a
circulating inhibitor of angiogenesis produced by tumour cells. Following primary tumour
removal, levels of angiostatin fall and rapid growth of distant metastases ensues (0' Reilly et
al, 1994). Such rapid growth of metastases is inhibited by administration of recombinant
angiostatin (O' Reilly et al, 1994). Another group has proposed that, as the number of tumour
cells increase, so does the likelihood of development of chemoresistant clones (Goldie &
Coldman, 1979). According to the hypothesis, development of chemoresistant clones may be
minimized by early administration of chemotherapy.
Potential clinical advantages are that early treatment ofmicrometastases may avoid their
rapid growth following tumour removal and prevent emergence of resistant clones. Pre¬
operative reduction in tumour volume may render inoperable tumours operable, or allow
breast conservation when mastectomy had been the only surgical option prior to systemic
treatment. In addition, neoadjuvant therapy allows an objective assessment of response and
allows study of the relationship between pathological and molecular markers and
responsiveness. Most studies of neoadjuvant therapy in breast cancer have focused on the
role of chemotherapy and are worthy of comment to illustrate the role of such treatment.
Neoadjuvant or primary systemic therapy was initially developed in the 1970s for the
management of locally advanced breast cancer when aims of treatment were to prevent
disease progression, with the emphasis on local control rather than on management of
systemic disease. Early studies, however, suggested that, when compared to local treatment
alone, survival was prolonged (Rubens et al, 1980; Valagussa et al, 1990). In addition,
administration of chemotherapy prior to local treatment caused a reduction in the size of
primary tumour, thereby facilitating surgery and/or radiotherapy (Forrest et al, 1991;
Valagussa et al, 1990).
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The advantages of primary chemotherapy in managing locally advanced breast cancer are,
therefore, that it reduces tumour burden leading to improved local control, it checks
postoperative growth in metastases and allows evaluation of its efficacy, which will than
improve selection of subsequent adjuvant therapy (Trimble et al, 1993). Possible
disadvantages of this approach are that, if ineffective, it delays definitive treatment and thus
may compromise local control. Wound healing may be affected due to reduced tumour
vascularity occurring as a consequence of treatment (Trimble et al, 1993).
The potential role of tamoxifen as primary treatment of breast cancer was first proposed in
1982 (Preece et al, 1982). The use of tamoxifen as sole treatment for locally advanced
disease has been explored in two studies: in one study treatment with tamoxifen and
radiotherapy were compared, with similar survival rates in the two groups (Robertson et al,
1994). In the other study tamoxifen and CMF chemotherapy were compared in 181 patients
over 65 years with recurrent breast cancer and it was found that survival rates tended to
favour tamoxifen, with comparable response rates (Taylor, 1986).
The majority of studies aimed at determining the role of tamoxifen in the management of
operable breast cancer have focused on its use as primary treatment in elderly patients, in
whom minimal treatment was considered advantageous (Allan et al, 1985; Helleberg et al,
1982). Such studies reported response rates to primary treatment with tamoxifen ranging
from 40-70% (Allan et al, 1985; Anderson et al, 1991; Horobin et al, 1991; McDonald et al,
1990). However, in most studies of tamoxifen alone or in comparison with surgery,
unacceptably high rates of tumour regrowth occurred (Bergman et al, 1995; Horobin et al,
1991; Robertson et al, 1992). In one study the use of tamoxifen alone was compared with
surgery and adjuvant tamoxifen and a small, but significant survival advantage in the group
who underwent surgery was found (Bates et al, 1991). A more recent study investigating the
role of oestrogen receptor (ER) expression in determining response to primary tamoxifen
found that a significantly higher proportion of ER-positive tumours responded than ER-
negative. Fewer patients developed tumour regrowth in the ER-positive group, particularly in
those patients who responded to tamoxifen in the first six months of treatment (Willsher et
al, 1997). Treatment with tamoxifen alone in elderly women is only acceptable in those who
are very frail and have strongly ER-positive tumours (Dixon, 1992).
The importance ofER expression was further highlighted in a study ofwomen of all ages
with operable breast cancer treated with neoadjuvant systemic therapy (Anderson et al,
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1991). At the commencement of the study all patients were treated with primary tamoxifen,
but initial results demonstrated that ER-poor tumours did not respond to tamoxifen and such
patients were subsequently treated with primary chemotherapy (Anderson et al, 1991). Long-
term follow-up in these patients show similar survival rates in the tamoxifen- and
chemotherapy-treated groups (Cameron et al, 1997a).
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Assessing tumour response to neoadjuvant therapy:
In order to determine the efficacy of neoadjuvant treatment it is necessary to define its
purpose. For patients with large primary breast tumours, tumour regression is an endpoint in
itself, and is used to assess response to therapy. Potential methods of assessment are by
clinical, mammographic and ultrasound measurements of tumour volume. Clinical
measurements are prone to error: the method is indirect, influenced by oedema and obesity
(Dixon et al, 1984) and are observer-dependent (Warr et al. 1984). Mammography is well
established as an objective method of assessing breast tumours, but the frequency with which
it can be performed is limited by radiation dose. In lobular carcinoma, tumour margins are
poorly defined on mammography (Fhlleren et al, 1991) and this precludes estimation of
small variations in size. Ultrasonography is simple to perform, provides a permanent record
of tumour size and may be carried out frequently. It provides an alternative method of
assessment of response to primary systemic therapy. In a study comparing clinical,
mammographic and ultrasonographic tumour measurements and correlating them with
pathological size, the best results were obtained using ultrasound which was applicable to a
larger group of patients than mammography (Forouhi et al, 1994). Clinical size was less
closely correlated with pathological size. Thus serial ultrasound assessments of tumour
volume provide a practical and accurate method ofmonitoring tumour response (Forouhi et
al, 1994).
Definition of response was defined by UICC based on clinical measurements. Response was
defined as a fall of at least 50% in the product of two orthogonal diameters of a tumour for at
least one month (Flayward et al, 1977). This method of assessing response is clearly of
limited value in patients treated for three months. An alternative method is to define the
change in tumour volume by ultrasound. Observer variation is less than 10% (Forouhi et al,
1994), so that changes in volume of greater than 10% are significant. For the purposes of this
thesis, a reduction in tumour volume of 25% or more was classified as a response. Tumour
volume was calculated according to the equation:
Tumour volume = AxBxCx7t/6
where A is the transverse diameter
B is the anteroposterior diameter
C is the depth as assessed on ultrasound.
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Resistance to tamoxifen treatment:
As has been stated, approximately one-third of all breast cancers respond to tamoxifen, the
majority, if not all, of these are oestrogen receptor positive. Response rates of ER-positive
tumours rarely exceed 70% (Allan et al, 1985) and the majority of tumours which do initially
respond to tamoxifen subsequently develop resistance, which may occur following weeks or
years of treatment (Lykkesfeldt, 1996). Between 35 and 60% of those with an initial
response to tamoxifen will respond to second line endocrine therapy, indicating that
development of tamoxifen resistance is not an indicator of complete loss of hormone
responsiveness. Understanding mechanisms of tamoxifen resistance is of value in that it may
identify accurate predictors of response and allow development of drugs that do not lead to
such resistance. With increasing use of tamoxifen in the neoadjuvant setting as outlined
above, tumour responsiveness can be assessed and patients with non-responding tumours
offered alternative therapy.
Resistance to tamoxifen may be primary or acquired. The two major reasons for primary
resistance are that the tumour may be inherently autonomous, or that intra-tumour tamoxifen
levels are insufficient to compete effectively with endogenous oestrogens (Miller, 1996a).
Other mechanisms may be involved in primary resistance and these will be addressed when
considering acquired resistance, which will provide the main focus of the discussion. Since
the main effect of tamoxifen is mediated via the oestrogen receptor (ER) signalling pathway,
change in any step of this pathway may render tumour cells resistant. There may be an
alteration in uptake or metabolism of tamoxifen into the cell, loss or decrease in ER
expression, expression of variant or mutant ER forms, intact ER but loss of co-activators,
modifications of oestrogen response elements (EREs) or altered post-receptor events. Non-
ER related changes may also contribute to tamoxifen resistance (Lykkesfeldt, 1996).
Tamoxifen may exert oestrogen agonistic activity, depending on the organ involved, such as
the endometrium, and variations in local intracellular tamoxifen concentrations (Jordan &
Murphy, 1990). Agonist activity may be observed when tamoxifen is present at low
intracellular concentrations (Osborne et al, 1991; Osborne et al, 1992). Such reduced
intracellular levels following an initial period of successful treatment with tamoxifen may be
due to decreased uptake into or increased efflux of tamoxifen from cells. P-glycoprotein is
involved in efflux of chemotherapeutic agents from cell and elevation in its expression has
been found in non-responders to tamoxifen treatment (Keen et al, 1994).
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About 20-40% of patients who initially present with ER-positive tumours are found to have
ER-negative tumours at the time of recurrence following adjuvant tamoxifen (Johnston et al,
1995). In the majority of cases of resistance, however, ER-positivity is maintained,
indicating that resistance is unlikely to have developed as a result of an outgrowth of ER-
negative clones following response of hormone-dependent clones to tamoxifen (Miller,
1996a).
Expression ofmutant or variant ER in tamoxifen-resistant breast cancers is a rare
phenomenon and cannot account for most oestrogen-independent, tamoxifen-resistant breast
tumours (Karnik et al, 1994). In one study, 18 of 20 tamoxifen-resistant tumours did not
have mutations in any of 8 exons ofER complementary DNA (Karnik et al, 1994). Despite
this, several mutations have been identified in breast tumours, including the exon 5 deletion
splice variant of ER (Daffada et al, 1995), which may be translated into a protein capable of
transcription without ligand binding (McGuire et al, 1991). Another ER mutant which has
been described follows a point mutation in the ER region upon which activity of the AF-2
transcriptional activation domain depends, leading to strong agonist activity of tamoxifen
(Mahfoudi et al, 1995). Relevance of such findings depends on variant ER protein being
translated from RNA and there is little evidence for this (Madsen et al, 1995).
The function of the ER depends on the presence of several co-activators, which associate
with the activated conformation of the ER. Changes or loss of these may render breast cancer
cells resistant to antiestrogens (Lykkesfeldt, 1996). Once ER-bound, ligand-dependent
phosphorylation is important for activating transcription. This phosphorylation may occur
via ligand-independent pathways, with cross-talk between a growth factor signalling
pathway and the ER, rendering tamoxifen ineffective. Alteration in levels of cyclic AMP or
an increased number of protein kinase A catalytic subunits cause cells to respond to
tamoxifen as an oestrogen agonist rather than antagonist (Fujimoto & Katzenellenbogen,
1994). Modification of the oestrogen response elements (ERE), to which the activated ER
dimer binds, may render it more sensitive to agonist activity of tamoxifen (Dana et al, 1994).
Other potential mechanisms of resistance are not mediated by the oestrogen receptor and
include constitutive expression of growth factors such as transforming growth factor-alpha
(Nicholson et al, 1994b), upregulation of growth factor receptors, e.g. epidermal growth
factor receptor (Nicholson et al, 1994a) and c-erbB-2 (Borg et al, 1994).
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This overview of potential mechanisms of tamoxifen resistance demonstrates the complexity
of its action and the inability of ER expression alone to identify likely responders. More
accurate predictors of initial response to treatment and likelihood of development of
resistance would be of benefit.
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Prediction of tamoxifen sensitivity:
Potential mechanisms of resistance, discussed in the previous section, demonstrated the
complexity of interaction between tamoxifen and the oestrogen receptor, with involvment of
other factors. Whilst ER is an important predictor of tamoxifen sensitivity, other more
accurate predictors of response would be of benefit in the clinical setting.
Hormone receptors:
The initial step in oestrogen action is the binding of oestrogen to its receptors. Thus
determination of the presence or absence of such receptors in the breast may provide useful
information on endocrine sensitivity. Between sixty and seventy five percent of breast
cancers are ER-positive; within this group there is a continuous range of values. The level of
oestrogen receptor is affected by age, menopausal status and tumour grade. Expression
increases with increasing age (Clark et al, 1984), is more common in postmenopausal
women and in lower grade tumours (Thorpe & Rose, 1986). Interestingly, the proportion of
ER-positive tumours is increasing; whether this is due to increasingly sensitive assays or a
change in the nature of tumours is unclear (Pujol et al, 1994).
A highly significant correlation has been found between response to neoadjuvant tamoxifen
and ER expression based on immunocytochemical techniques on fine needle aspiration
cytology (Anderson et al, 1989; Coombes et al, 1987; Osborne et al, 1980). Evaluation of
ER content has become standard practice in determining suitability of patients for primary
endocrine treatment. Despite this selectivity, response rates rarely exceed 70% (Allan et al,
1985; Osborne et al, 1980). Lack of ER-expression predicts for tamoxifen insensitivity
(Anderson et al, 1989; Robertson et al, 1994) and this has been demonstrated in a recent
overview of adjuvant tamoxifen (Early Breast Cancer Trialists1 Collaborative Group, 1998).
Previous suggestions that up to 10% of ER-negative tumours respond are now thought to be
related methodological errors of ER assessment. Addition of progesterone receptor (PgR)
assessment provides greater accuracy in predicting response, those tumours expressing both
receptors have response rates of 66-83% (Osborne et al, 1980). However, ER and PgR
positivity as a pre-requisite for primary endocrine therapy would result in failure to respond
in approximately 20% of patients and would exclude ER-positive, PgR-negative tumours
that may respond (Osborne et al, 1980).
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Proliferation:
Following binding of oestrogen to its receptor, it exerts its action at the cellular level by
stimulating proliferation. An alternative strategy in determining sensitivity to endocrine
therapy would be to assess changes in proliferation. Ina study of primary breast cancers a
reduction in proliferation was detected using Ki-S 1 antibody following treatment with
tamoxifen (Keen et al, 1997). In a more recent study, an early reduction in proliferation was
observed using the Ki-67 antibody during treatment with tamoxifen (Makris et al, 1998).
Many potential surrogate markers of proliferation of breast cancers have been studied. The
classic measure in solid tumours that have been fixed and processed is the mitotic index.
Indeed the total number ofmitotic figures in 10-high power fields is one of the three cardinal
features used to assess grade of a clinical breast cancer (Bloom & Richardson, 1957). An
alternative of assessing mitotic figures is the use of immunohistochemistry to identify cells
that express antigens associated with proliferation. A number of such antigens are known,
including Ki-67, PCNA and Ki-S 1. There are data to suggest that PCNA and Ki-S 1 staining
may vary with different concentrations of antibody whereas MIB-1 antibody for Ki-67 is
more robust and not expressed in non-proliferating cells (McCormick et al, 1993). Thus in
the present study, changes in proliferation were assessed with MIB-1 antibody to Ki-67 to
determine whether such a marker predicts sensitivity to tamoxifen.
Other predictors of response have been studied. Bcl-2 is a protein involved in inhibition of
apoptosis and may be important in modulation of hormone responsiveness (Miyashita &
Reed, 1992). Bcl-2 expression has been found to be a highly significant predictor of
endocrine responsiveness (Gee et al, 1994). Another marker which has found significance in
predicting endocrine responsiveness is pS2 protein (Soubeyran et al, 1996) Response rates in
tumours expressing both pS2 and ER were 60%, in those expressing one factor alone were
45% and in tumours expressing neither pS2 or ER were 8% (Soubeyran et al, 1996). In one




In this section the process of angiogenesis is outlined and mechanisms by which a tumour
becomes angiogenic considered. The relationship between oestrogen and angiogenesis is
explored and the clinical applications of the study of angiogenesis are reviewed. Specific
consideration is given to the potential role of angiogenesis as a predictor of sensitivity to
primary endocrine therapy, which provides the basis of this thesis.
Tumour development comprises unregulated growth of the abnormal cell and changes in the
surrounding microenvironment. Thus solid tumours comprise two components: tumour cells
and stromal cells within the surrounding extracellular matrix (Dvorak, 1986). There is
growing experimental evidence demonstrating that stromal and inflammatory cells such as
endothelial cells, fibroblasts and macrophages play an active role in tumour development.
Evidence has been accumulating since the early 1970s that new vessel formation or
angiogenesis is a pre-requisite for tumour growth beyond 2-3mm3 and for metastasis
(Folkman, 1990; Folkman, 1994). This evidence is most clearly illustrated clinically in
malignant melanoma and can be observed from an early stage. Prior to the onset of
angiogenesis, tumours are thin and slow growing, but with the introduction of new vessels
rapid tumour growth and progression take place (Srivastava et al, 1988).
Physiological Angiogenesis:
Angiogenesis plays an essential physiological role in embryogenesis and foetal development
and in the female reproductive cycle. In the normal adult male, angiogenesis is usually
quiescent, but is stimulated during wound healing. As well as being essential for tumour
progression, angiogenesis is involved in certain benign disease states including the
proliferative retinopathies (Gole et al, 1990) and rheumatoid arthritis (Colville- Nash &
Scott, 1992; Peacock et al, 1992).
Angiogenesis is a multistep process involving alterations in endothelial cells and
extracellular matrix remodelling. The process is summarised diagrammatically on the
following page. There is local degradation of basement membrane caused by release of
proteases in the extracellular matrix, and endothelial cells around the site of disruption
change shape and invade stroma. These endothelial cells are stimulated to proliferate at the
leading edge of the migrating column, adhering to each other tightly to form tubes, which






























































































This complex angiogenic process involves multiple paracrine and autocrine interactions of
tumour and stromal components (Casey et al, 1995; Weidner et al, 1992), and the
mechanisms of control involve both stimulatory and inhibitory factors (Hanahan & Folkman,
1996). During tumour development, new vessel formation occurs as an early event, which
precedes tumour invasion and is a discrete component of the tumour phenotype, rather than
resulting from tumour hypoxia as the growing mass outgrows its blood supply. This is
illustrated in experiments based on transgenic mouse models, in which a subset of tumour
cells appeared to stimulate angiogenesis in the neighbouring stroma before tumour invasion
occurred (Hanahan & Folkman, 1996). This concept is supported by the observation that
angiogenesis occurs during the pre-invasive stages of breast and cervical carcinomas: DCIS
(Guidi et al, 1994; Weidner et al, 1992) and CIN II-III respectively (Guidi et al, 1995). Thus,




Experimental evidence suggests that angiogenesis is stimulated by release of soluble factors
produced by tumour cells or surrounding stromal and inflammatory cells. Several angiogenic
factors have been identified: two of current interest because of their potential for therapeutic
use will be described here, the fibroblast growth factors (FGFs) and vascular endothelial
growth factor (VEGF):
Acidic and basic fibroblast growth factors (FGF-1 and FGF-2).
FGF-1 and 2, known as acidic and basic fibroblast growth factors, are members of the family
of fibroblast growth factors, of which nine are currently identified. Family members have
varying degrees of structural homology and are produced by a variety of cells (Christofori,
1997). They are involved in many physiological and pathological processes, with a wide
range of biological activities and target cells, making determination of precise mechanisms
and the roles they play in individual processes difficult. FGF-1 is found in high levels in
neural tissue (Basilico & Moscatelli, 1992) and FGF-2 is more widely distributed, it has been
isolated from brain, kidney, placenta and tumour cells (Christofori, 1997). Both FGF-1 and 2
function through autocrine and paracrine mechanisms, and play an important role in
embryonic development and wound healing. They are mitogenic for endothelial cells
(Christofori, 1997) and induce the endothelial cell production of proteases, which degrade
basement membrane.
FGF-1 and 2 are expressed in a range of tumours (Relf et al, 1997), including breast
carcinoma, although their precise contribution to tumour angiogenesis is difficult to assess
because of the pleiotrophic nature of their actions. In order to exert their angiogenic action,
the FGFs must be released into the extracellular matrix (ECM) and bind to their endothelial
cells receptors. However, they lack the signal sequence for secretion (Mignatti & Rifkin,
1991) and the mechanism of their transport into the ECM is not clearly understood. Two
possible mechanisms of release have been proposed: one involves their release following cell
damage, the second implicates an alternate secretory pathway involving translocation of
molecules. Recently it has been suggested that ECM release of FGF-2 may involve its
displacement from heparin, to which it is bound, by a secreted FGF-binding protein (FGF-
BP). This may be an important component of the angiogenic switch in some cancers
(Czubayko, 1997).
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Vascular endothelial growth factor (VEGF).
VEGF is expressed on a variety of normal cells and is secreted by a number of human
tumour cell lines (Senger et al, 1986). It is of particular interest because it acts specifically
on endothelial cells (Ferrara & Henzel, 1989), binding exclusively to these target cells which
express one of the two endothelial cell specific tyrosine kinase receptors, Fit-1 (VEGFR-1)
and KDR (VEGFR-2) (Jakeman et al, 1992), acting as a paracrine mediator. Production of
VEGF can be induced by a variety of cytokines such as platelet derived growth factor
(PDGF) (Colville-Nash & Willoughby, 1997) and transforming growth factor p (TGF-P)
(Pertovaara et al, 1994), and it works synergistically with FGF-2 (Pepper et al, 1992). In
addition, VEGF is induced by hypoxia, through upregulation of the KDR receptor,
suggesting a role in the maintenance of the normal cellular environment (Dvorak et al,
1995). It is structurally homologous to vascular permeability factor (VPF), which is known
to cause protein extravasation (Dvorak et al, 1995). This process is recognized as an
important early step in angiogenesis, releasing fibrin in the extracellular matrix (ECM)
(Senger, 1996). Fibrin encourages new vessel growth and is structurally important for
changing the ECM.
VEGF occurs as four isoforms generated by the alternative splicing ofRNA, two secreted
and two cell-associated; the secreted forms are heparin bound, like the FGFs. The binding of
heparin is important in reducing proteolytic cleavage, providing an extracellular store of
growth factors that can be rapidly mobilised and facilitating presentation of the growth
factors to the endothelial cell (Vlodavsky et al, 1990).
Increased VEGF expression in tumours has led to study of its potential role as a prognostic
indicator in breast cancer. Several studies have found an association between tumour VEGF
expression and relapse free or overall survival, with significant shorter survival times in
those patients with VEGF-rich tumours. (Gasparini et al, 1997; Toi et al, 1994). Changes in
serum levels of VEGF correlated with response in those patients with metastatic renal
carcinoma treated with interferon a (Vermeulen et al, 1997a).
The role of VEGF in certain benign disorders, in which angiogenesis is known to be
important, such as diabetic proliferative retinopathy (Aiello et al, 1994) and rheumatoid
arthritis (Fava et al, 1994) has led to development of potential therapeutic strategies adopting
the use of VEGF and its antibody. VEGF may play a role in the treatment of limb and
coronary ischaemia, with injection of recombinant VEGF resulting in improved collateral
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circulation in pigs (Pearlman et al, 1995; Takeshita, 1994). Development of an anti-VEGF
antibody may provide an exciting anti-angiogenic drug for the treatment of solid tumours in
which VEGF is overexpressed, including breast cancer (Jin Kim et al, 1993). It is likely to be
ofmost use in combination with other therapeutic strategies as VEGF is only one of several
growth factors involved in the process of tumour angiogenesis. Nevertheless results of the
current Phase I studies of this antibody are awaited with interest.
The increased expression of multiple growth factors, including FGF-1, FGF-2 and VEGF, in
breast cancer cells demonstrates the complexity of the angiogenic response and the difficulty
that therefore arises in attempting to develop anti-angiogenic therapeutic strategies. The
binding of such growth factors to heparin provides a potential common mechanism for their
inhibition and suramin analogues have been developed and are currently in Phase I clinical
trials (Harris et al, 1996).
Angiogenic inhibitors:
Thrombospondin:
Thrombospondin (TSP) is a matrix-bound glycoprotein which plays a role in tumour cell
proliferation, differentiation and angiogenesis (Bornstein, 1992). It is an endogenous
inhibitor of angiogenesis counteracting the action of positive stimulators, and must be
overcome in order for tumour angiogenesis to take place. High levels are produced by
fibroblasts and by some epithelial cells but its production is decreased in malignancy. TSP is
regulated by wild type p53 tumour suppressor gene, and inactivation of this gene leads to
decreased levels of thrombospondin (Rastinejad et al, 1989). Patients with Li Fraumeni
syndrome, characterized by development ofmalignancies of breast, brain and connective
tissue, have only one copy of the p53 tumour suppressor gene and, when this allele is
deleted, TSP production decreases and angiogenesis is switched on (Bouck, 1996). The
therapeutic potential ofTSP in breast cancer is illustrated by an in vivo study in which
human breast cancer MDA-MB-435 cells were transfected with complementary DNA
encoding TSP-1, resulting in a reduction in vessel density and metastasis (Weinstat-Saslow
et al., 1994).
Angiostatin:
Angiostatin is another potent inhibitor of angiogenesis, produced in response to the growth
of a solid tumour and suppressing the growth of distant metastases (O1 Reilly et al, 1994).
Angiostatin was identified using the Lewis lung carcinoma model (O1 Reilly et al, 1994), in
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which removal of the primary tumour stimulated growth of lung metastases. Histologically,
there was intense neovascularization around the metastases. In animals in whom the primary
tumour remained, no such neovascularization was seen and metastases remained small.
These effects appeared to be mediated via a circulating inhibitor of angiogenesis, angiostatin,
which is a fragment of the large protein, plasminogen. Plasminogen itself has no anti-
angiogenic activity (O' Reilly et al, 1994). The existence of angiostatic fragments of larger
protein molecules which do not themselves have any anti-angiogenic activity may indicate a
role of these molecules in maintaining the normal quiescent state of angiogenesis in adults
whilst allowing temporary stimulation of angiogenesis during wound healing. In tumour
formation, it is not clear whether tumour cells produce angiostatin or a protease which
cleaves plasminogen to produce angiostatin (O' Reilly et al, 1994).
Endostatin:
Endostatin is a protein fragment of collagen XVIII and acts in a similar fashion to
angiostatin. It specifically inhibits endothelial cell proliferation and recombinant endostatin
inhibits angiogenesis, growth of primary tumours and metastases. Like angiostatin, it acts by
increasing the apoptotic rate, with little effect on proliferation (0' Reilly et al, 1997).
The identification of circulating stimulators and inhibitors of angiogenesis has led to the
theory that there is a switch from the non-angiogenic to the angiogenic phenotype which
occurs when the balance of concentrations of angiogenic stimulators outweighs the inhibitors
(Hanahan & Folkman, 1996). This then allows tumour growth beyond 2-3mm3 and
facilitates metastasis. The potential benefits of the discovery of such angiogenic and
angiostatic molecules for treatment ofmalignancies are evident; production of antibodies to
inducers and of inhibitory factors may lead to exciting anti-angiogenic strategies, and such
work is ongoing.
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Hormonal Control of Angiogenesis.
The aetiological role played by oestrogen in the development of breast cancer is well
recognised, prolonged exposure to oestrogen resulting in an increased risk of developing
breast cancer of 5% per year (Abeloff et al, 1995). Several manifestations of vascular disease
suggest that endothelial cell activity may also be regulated by hormones, and this has led to
interest in the potential link between hormonal control of tumour growth and tumour
angiogenesis. Thus, systemic lupus erythematosus (SLE) and Takayasu's arteritis, both
characterized by endothelial cell proliferation, commonly affect women of childbearing age.
SLE is exacerbated by pregnancy and by use of the oral contraceptive pill (Ahmed et al,
1985). Additionally, cutaneous haemangiomas are more commonly found in female children
(Ezekowitz et al, 1992), spider naevi characteristic of liver disease are related to high levels
of circulating oestrogens (Sarkany. & Graham-Brown, 1991) and oestrogens protect against
atherosclerosis (Matthews et al, 1989; Williams et al, 1990).
Experimental evidence supports the role of hormones, particularly oestrogens, in
angiogenesis. For example, oestrogen added to human umbilical vein endothelial cells
(HUVECs) grown in culture in oestrogen-free medium increased endothelial cell
proliferation, cell attachment to laminin and enhanced the ability ofHUVECs to organize
into tubular networks, all of which are important components of the angiogenesis process
(Morales et al, 1995). Another experiment in which cultures of HUVECs were exposed
sequentially to tumour necrosis factor-a (TNF-a) and then to oestrogen showed that
apoptosis caused by TNF-a was reversed by oestrogen. This suggests that oestrogen may
play a role in the preservation of endothelial cells by inhibiting apoptosis (Sypridopoulos et
al, 1997). This protection is probably mediated through the oestrogen receptor since a
specific receptor antagonist abrogated the effect.
Other studies illustrate the angiostatic effect of anti-oestrogens, which are of particular
interest in this thesis. Gagliardi and Collins showed that the partial oestrogen antagonists,
clomiphene, tamoxifen and nafoxidene, and the pure oestrogen antagonists, ICI 164, 384 and
ICI 182, 780, inhibited angiogenesis in the chick egg chorioallantoic membrane (Gaghardi &
Collins, 1993). As the effect was maintained despite exposure to high levels of oestrogen it
was unlikely to be mediated via the oestrogen receptor. Follow up work showed that porcine
pulmonary artery endothelial cells, whose growth was stimulated by the angiogenic peptides,
bFGF and VEGF, could be inhibited by tamoxifen in a dose-dependent manner (Gagliardi et
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al, 1995). Inhibition was most impressive in tumours stimulated by both bFGF and VEGF
and was associated with changes in endothelial cells suggestive of apoptosis (Gagliardi et al,
1995). Results from this study suggest that the anti-angiogenic effect of anti-oestrogens is
mediated through direct inhibition ofgrowth factor stimulated endothelial cell growth
(Gagliardi et al, 1995).
Tamoxifen also inhibits angiogenesis in the MCF-7 breast cancer xenografts, which are
oestrogen dependent (Lindner & Borden, 1997). Ten weeks of tamoxifen treatment of nude
mice bearing these tumours resulted in a 68% decrease in the number of vessels at the
tumour periphery and growth inhibition by 85% compared with the control group (Lindner &
Borden, 1997). Similar work in our laboratory compared the effect of tamoxifen (2.5mg over
60 days) following oestrogen stimulation on the oestrogen receptor-positive breast cancer
cell line, ZR-75 and -negative cell line, MDA-MB-231. An early reduction in microvessel
density was observed in ZR-75 but not MDA-MB-231 tumours (Cameron et al, 1996).
Preliminary work on primary oestrogen receptor positive breast cancers treated with three
months' tamoxifen prior to surgery showed a reduction in microvessel density in responding
tumours, compared to no change or an increase in microvessel density in those which did not
respond (Marson et al, 1998). It is not clear whether such changes occurred as a primary
event or as a consequence of tumour regression.
Mechanisms by which oestrogens might control angiogenesis have also been investigated.
Whilst some actions appear to be mediated through the oestrogen receptor (Sypridopoulos et
al, 1997), this is not always how they achieve their effect (Gagliardi & Collins, 1993).
Oestrogen receptor expression by endothelial cells has been demonstrated in cell culture
(Gagliardi & Collins, 1993), but not in primary tumours. An alternative potential mechanism
of action is by enhancement of the action of angiogenic peptides. VEGF is produced in
oestrogen-rich cells and the anatomical and temporal pattern of its expression in the uterus
and ovaries suggest hormonal regulation of its expression (Shweiki et al, 1993). Male rats
treated with tamoxifen or placebo injected with VEGF-impregnated matrigel showed a
reduction in gel microvessel densities in the tamoxifen treated group compared with controls,
suggesting that tamoxifen affects VEGF-mediated angiogenesis (McNamara et al, 1998).
Angiogenesis was decreased in ovariectomised mice despite the presence of bFGF,
suggesting that the angiogenic effects of bFGF may be reduced in the absence of oestradiol
(Morales et al, 1995). Tamoxifen enhanced secretion of transforming growth factor-p (TGF-
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P) in ER positive and negative breast cancer cell lines (Arteaga et al, 1988) and TGF-p
inhibited endothelial cell proliferation induced by bFGF and VEGF (Arteaga et al, 1988).
The potential role of angiogenic factors in the evolution of oestrogen-independent breast
cancers from those which were initially oestrogen dependent has been investigated.
Resistance to tamoxifen presents a major problem in the management of breast cancer, both
in the adjuvant setting and in those patients with advanced disease as previously discussed.
The MCF-7 breast cancer cell line forms slow-growing, poorly-vascularised tumours which
are oestrogen dependent and tamoxifen sensitive when implanted into nude mice. However,
transfection of fibroblast growth factor 4 (FGF-4) into MCF-7 cells produced lines that are
highly tumorigenic and metastatise in ovariectomised or tamoxifen treated nude mice, with
these tumours being paradoxically stimulated by tamoxifen and inhibited by oestrogen
(McLeskey et al, 1993; Kurebayashi et al, 1993). In contrast, transfection of the same cell
line with VEGF resulted in rapidly growing, highly vascular tumours which maintained
oestrogen dependence and tamoxifen sensitivity, with no evidence of metastasis (Zhang et
al, 1995).
These cell lines may be used to mimic progression from oestrogen dependent to oestrogen
independent breast cancer. For example, in one study, MCF-7 cells transfected with VEGF
were mixed with the ER negative cell line MDA-435S and tumour growth in both cell lines
was stimulated by the presence ofVEGF (Macaulay et al, 1995). It seems that production of
angiogenic factors by the ER positive subpopulation of cells influenced ER negative cells.
This is likely to mimic breast cancers that are recognized to show marked heterogeneity. The
addition of tamoxifen in this group inhibited growth stimulation (Macaulay et al, 1995).
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Clinical Applications of Angiogenesis:
Effect of Surgery on Angiogenesis.
There is evidence that the healing wound is a permissive site for tumour metastasis (Murthy
& Goldschmidt, 1989). Tumour cells reaching a colorectal anastomosis or laparotomy
wound within two hours post-operatively have a thousand-fold greater risk of metastasis
compared to normal tissue (Skipper et al, 1989). The timing of development ofmetastases
following breast cancer surgery has two peaks. The first peak occurs during the first three
post-operative years and may be due to the release of angiogenic cytokines during wound
healing; the second is a number of years later, indicating a variable rate of metastasis growth
(Baum & Badwe, 1994). The angiogenic inhibitor, angiostatin, is produced by tumour cells
and is absent following excision of the primary tumour, leading to rapid development of lung
metastases (O' Reilly et al, 1994). The concept that a tumour produces an inhibitor of
angiogenesis has implications for the surgical management of cancer patients. Surgery may
also facilitate metastasis by shedding of tumour cells into the circulation. In the immediate
post-operative period, breast cancers with high vascular density shed more tumour cells into
the circulation than those with low density (McCulloch et al, 1995).
Angiogenesis as a Prognostic Indicator.
Weidner and colleagues were the first to suggest that microvessel density might provide
prognostic information in breast cancer. In a series of forty-nine patients a significant
correlation was found between the presence of metastasis and microvessel density performed
following immunohistochemical staining of endothelial cells with Factor VIII antibody
(Weidner et al, 1991). Since then, numerous studies have been performed, the majority of
which have confirmed these findings and have found correlation between microvessel
density and relapse-free and overall survival (Bosari et al, 1992; Horak et al, 1992). In a
study of lymph node-negative breast cancer patients, microvessel density was found to be an
independent prognostic indicator for relapse free survival (Gasparini et al, 1994). Whilst
some studies have not found microvessel density to be a useful prognostic indicator, these
discrepancies are likely to be due to methodological variation (Hall et al, 1992; Van Hoef et
al, 1993). In this respect, there is debate concerning assessment of tumour vascularity by
microvessel counts, focusing on two main issues: the antibody used to stain endothelial cells
and the method of counting.
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Pan-endothelial cell markers stain all endothelial cells and those most commonly used are
antibodies to Factor VIII, CD31 and CD34. Antibodies that are specific for activated or
proliferating cells are under development. The FVIII antigen plays a role in platelet
aggregation and adhesion (Fajardo, 1989), and its antibody is a commonly used endothelial
cell marker (Burgdorf et al, 1981). Antibodies against FVIII consistently stain endothelial
cells and give more reproducible staining than other markers. They stain large vessels but are
decreased or absent in small microvessels, and also stain lymphatics. CD31 plays a role in
platelet adhesion during inflammatory processes and wound healing (Parums et al, 1990).
Antibody to CD31 was recently recommended in guidelines for a proposed standard method
ofmicrovessel counting (Vermeulen et al, 1996). It is a sensitive, pan-specific marker of
endothelial cells, which gives consistently higher counts than the FVIII antibody (Horak et
al, 1992; Martin et al, 1997). Unlike FVIII antibody, it does not stain lymphatics, but does
stain some inflammatory cells. However, it is associated with more frequent antigen loss
following tumour fixation, and staining tends to be weaker than that obtained by FVIII
antibody (Martin et al, 1997). CD34 is a cell adhesion molecule that plays a role in leucocyte
adhesion and endothelial cell migration (Schlingemann et al, 1990). In a recent study it was
found to be the most strongly expressed antigen, staining more vessels reproducibly than
CD31 and FVIII (Martin et al, 1997).
One of the criticisms levelled at the technique of microvessel counting is that counts include
all vessels and are not specific for new or angiogenic vessels. The importance of this is
uncertain, as angiogenic vessels are often leaky and ineffective in transporting blood and so
are unlikely to affect tumour growth in its early stages. However, attempts have been made
to develop antibodies that are specific to activated/ proliferating endothelial cells. One such
antibody is E-9 and in a comparative study with CD31 was found to stain vessels in or
around the tumour with a consistently greater intensity than CD31 (Wang et al, 1994). More
recently the antibody to CD 105, which preferentially reacts with endothelial cells in
angiogenic tissues, was compared with CD34 antibody in a series of breast tumours and was
found to correlate with tumour prognosis more accurately than CD34 (Kumar et al, 1999).
Further work needs to be carried out on this and other potentially specific markers to
determine their value in clinical practice.
Quantifying angiogenesis requires consideration of several variables, the most notable of
which is choice of counting area. Counts are often performed in the areas of highest
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vascularity or 'vascular hot spots' (Weidner et al, 1991). The rationale behind this is that,
whilst not all tumour cells are angiogenic, it is the highly angiogenic tumour cell clones that
are most likely to behave aggressively and to metastasise. These areas are most commonly
found on the tumour periphery close to viable tumour, but tumour heterogeneity in breast
carcinomas provides particular problems.
To reduce inter-observer variability it is important to define microvessels. The generally
accepted definition is any single stained endothelial cell or cell cluster which is clearly
separate from adjacent microvessels, tumour cells and other connective tissue elements.
Vessels within the sclerotic centre of a tumour are not included. The Chalkley eyepiece
graticule increases objectivity of counting (Fox et al, 1995a). Computerised image analysis,
which allows evaluation of several parameters in addition to microvessel counting, such as
percentage area stained per field, area of vessel lumina (Fox et al, 1995a), and intratumoral
microvessel density grading are also used (Vermeulen et al, 1996). Biochemical assessment
of growth factors in the serum and urine of cancer patients is potentially of use in screening
and provides a non-invasive method for monitoring response to treatment and identifying
recurrence. Elevated levels of bFGF and VEGF have been found in the sera of patients with
metastatic colorectal, breast, ovarian and renal carcinomas (Dirix et al, 1997). bFGF has also
been found to be elevated in the urine of patients with a wide range of malignancies (Nguyen
etal, 1994).
Colour Doppler ultrasound may have a role in the differential diagnosis of breast lesions
(Cosgrove et al, 1990). This allows the non-invasive assessment of breast lesions: malignant
lesions are more likely to be Colour Doppler positive, benign lesions negative. The potential
for colour Doppler ultrasound in monitoring response of tumours to systemic therapy has yet
to be ascertained and will be addressed in a small study in this thesis.
The role of these markers of tumour vascularity in monitoring patients receiving neoadjuvant
systemic treatment has not been elucidated but early markers of response would be of great
value. Assessment of microvessel density on sequential biopsies taken during a course of
primary systemic therapy may provide such a marker.
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Therapeutic applications.
An understanding of the crucial role of angiogenesis in tumour development has led the
impetus to use inhibitors of aniogenesis therapeutically. Naturally occurring inhibitors
include (i) protease inhibitors, the most studied group of which are the metalloproteinase
inhibitors, (ii) cytokine modulators such as interleukin-1 and thalidomide, heparin-like
molecules which cause inhibition of heparin bound growth factors and (iii) vascular growth
factor inhibitors, such as antisense FGF (Bicknell & Harris, 1996). Antiangiogenic therapy
has low toxicity as it acts specifically to inhibit proliferation of endothelial cells,
demonstrated by the action of platelet factor 4 and the fumagillin derivative, AGM-1470
(TNP-470). Extensive pre-clinical studies testing these angiogenic inhibitors have led to the
emergence of general principles guiding their use (Folkman, 1995).
Antiangiogenic therapy appears to have its greatest efficacy ifgiven over a prolonged period
of time. It may play an important role following primary treatment of tumours by
conventional treatment modalities, when it can be given over a long period to prolong
dormancy of microscopic disease. Interferon-a-2a has been used for up to one year to treat
haemangiomas of infancy (Ezekowitz et al, 1992). Angiogenic inhibitors may be particularly
useful in combination with conventional cytotoxic chemotherapy and some evidence
suggests that this combined approach may be curative whilst individual agents alone are not
(Teicher et al, 1994).
In this section the process of angiogenesis was outlined with particular attention to the
relationship between oestrogen, tamoxifen and angiogenesis. Clinical applications that have
developed as a result of improved understanding of the processes of angiogenesis have been
discussed. It is within this background of understanding of the key role of angiogenesis in
tumour growth and the potential direct effect of tamoxifen on tumour vascularity that the
aims of this thesis were undertaken.
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Aims of the thesis
To determine changes in breast tumour vascularity which occur during primary endocrine
treatment and to assess the role of these changes as an early predictor of response to therapy.
These aims are addressed sequentially:
Firstly, reproducibility of the methodology to assess vascularity will be investigated in order
to determine which methodology should be adopted in the main study.
Secondly, changes in tumour vascularity during primary endocrine therapy will be
determined by assessment of pre- and post-treatment tumour specimens.
Thirdly, timing of the changes in tumour vascularity relative to changes in tumour volume
will be investigated in a study of breast tumour xenografts.
Fourthly, a prospective study will be described aimed at determining whether early changes
in tumour vascularity occurring within 10-14 days of starting treatment with primary
tamoxifen can predict response to therapy.
In addition, the study aims to compare effects of tamoxifen on tumour vascularity with its
effects on two other aspects of tumour biology: expression of vascular endothelial growth
factor and the percentage of proliferating cells.
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Materials and Methods
In order to achieve the aims outlined on the previous page, four main studies have been
performed. Methods involved in the studies will be described in this chapter.
(i) Validation of methodology in terms of observer variation, variation due to the use of
two antibodies and reproducibility of microvessel counts in different breast cancer
specimens.
(ii) Changes in breast tumour vascularity following a period of neoadjuvant tamoxifen in
relation to clinical response.
(lii) Sequential changes in tumour vascularity in xenografted breast cancers during
tamoxifen treatment and correlation with changes in tumour volume.
(iv) Sequential assessments of tumour vascularity in patients with primary breast cancers
during treatment with tamoxifen and correlation with response.
Two control experiments were also performed to compare effects of tamoxifen on other
aspects of tumour biology: vascular endothelial growth factor (VEGF) expression, which is
related to angiogenesis, and changes in proliferation, which are independent of it.
(v) Changes in VEGF expression following a period of neoadjuvant tamoxifen in
relation to response.
(vi) Sequential assessment of proliferation in association with response to tamoxifen as a
control study.
Similar methodologies have been adopted throughout the thesis, based on obtaining
specimens of tumour in the form of biopsies or excision specimens. Tumour sections were
immunohistochemically stained with antibodies to elements of the endothelial cell, to VEGF
and to proliferating cells (MIB-1 antibody to Ki-67). Assessments were then made by
microvessel counting or by the estimation of percentage tumour cells staining. Information
regarding tumour response to tamoxifen was collected by clinical, ultrasonographic or
mammographic assessments of changes in tumour volume. Response data were correlated
with changes in vascularity, VEGF and MIB-1 expression.
Methodological details regarding tumour retrieval and assessments of response will initially
be considered in four sections, corresponding to each study performed. This will be followed
by a section describing aspects of the method common to all studies, including histology and





Intra- and interobserver variation: To compare microvessel counts performed by the same
observers at different times and by two different observers, microvessel counts were
obtained following staining of tumour sections with an endothelial cell marker. In thirty-one
tumours, counts performed by the same observers at least a fortnight apart were compared.
Sixteen of these were core biopsies. Counts performed by two observers separately in sixteen
tumour sections were compared.
Comparison of counts obtained following staining with antibody to Factor VIII and
CD31: To compare results obtained from the same tumours following staining with two
different antibodies to endothelial cells, immunohistochemical staining was performed on
sequential sections with antibody to Factor VIII and to CD31 (PECAM). Counts were
compared in core biopsies (n=l 10) and tumour sections (n=164).
Reproducibility of method in different breast cancer specimens: To determine the
relationship between counts obtained from different specimens of the same tumour with no
intervening treatment, three studies were undertaken:
(i) Comparison of counts obtained from core biopsies (MVC1) and tumour sections
(MVC2) taken immediately following tumour excision:
Excised tumour
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(ii) Comparison of counts performed on core biopsies (MVC1) and tumour sections









(iii) Comparison of counts performed on core biopsies obtained at two time points at
least ten days apart, with no intervening treatment:
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Methods:
For determination of intra-observer variation (n=31) and interobserver variation (n=16) and
for comparison of counts performed following staining with two endothelial cell antibodies
in core biopsies (n=l 10) and tumour sections (n=164), specimens collected for other aspects
of the study were studied.
For assessment of reproducibility of methodology in different breast cancer specimens, in
sixteen excised tumours, core biopsies were taken and tumour sections obtained at the same
time. Twenty-one consecutive patients with newly diagnosed breast cancer underwent core
biopsies for confirmation of diagnosis and determination of ER status. Following surgical
excision of tumour between five and thirty-five days later, transverse tumour sections were
collected. In ten additional cases, core biopsies were performed at diagnosis and repeated
immediately following surgical excision, between five and twenty-five days later.
Description of the process of taking core biopsies will be described in a later section.
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Changes in tumour vascularity following neoadjuvant tamoxifen in
relation to clinical response.
To determine whether an association existed between changes in tumour vascularity and
response to primary endocrine therapy, seventy-two patients were recruited into this
retrospective study. Fifty-seven of these postmenopausal women with large, operable, ER-
positive disease were treated with tamoxifen for a period of 3-6 months. Tumour sections
before and after treatment were stained with the endothelial cell markers, antibody to Factor
VIII and CD31, and microvessel counts performed (mvcl and mvc2). Tumours were stained
with antibody to vascular endothelial growth factor (VEGF). Clinical response data were
available and allowed comparison of microvessel counts in relation to response. A further
fifteen patients had been treated with neoadjuvant tamoxifen for longer than six months and
were analysed as a separate group.
In addition, twenty-two patients treated with neoadjuvant letrozole, an aromatase inhibitor,
took part in the study as a separate group. Microvessel counts were compared before and
after treatment and correlated with response as described above. This allowed comparison of




Patient recruitment: Since 1991, it has been policy at the Edinburgh Breast Unit to treat
postmenopausal women with large (>3cm diameter), operable breast tumours or locally
advanced disease (fixed ipsilateral axillary lymph nodes or involvement of skin or muscle)
with primary systemic therapy. Those patients with oestrogen receptor (ER)-rich disease
(defined as greater than 20fmol/mg cytosolic protein) were treated with tamoxifen (20mg
daily) following a wedge biopsy, performed under local anaesthetic, for a minimum period
of three months. Tumour response in these patients was monitored by monthly clinical and
ultrasound measurements of tumour volume. On completion of tamoxifen treatment patients
underwent wide local excision or mastectomy. Seventy-two patients identified by casenote
review have been included in the study. Patients were excluded if there was insufficient
information regarding clinical response and if pre- and post- treatment tumour tissue was not
available from the archives of the Pathology department.
Tumour retrieval: All patients had undergone wedge biopsy following diagnosis of breast
cancer during the period of September 1991 and July 1996. Wedge biopsies had been
performed under local anaesthetic as day case surgery. On completion of a period of
neoadjuvant tamoixfen, patients underwent definitive surgery in the form of wide local
excision or mastectomy with axillary surgery. Tumour sections had been stored in neutral-
buffered formalin or methacarn for 24 hours and were then paraffin-embedded. Patients
eligible for participation in the study were identified by casenote review. Sections stained
with haematoxylin and eosin were retrieved from the Pathology archives and reviewed by a
single pathologist for identification of the block containing the most representative tumour
area. Between fifteen and thirty consecutive 4pm sections were cut from that block and
mounted on Superfrost microscope slides.
Monitoring of clinical response to tamoxifen: Response data were obtained from the
casenotes. Patients were monitored by monthly clinical and ultrasound assessments of
tumour volume. In addition, they underwent mammography before and after treatment. A
responding tumour was defined as one in which there was a greater than 25% reduction in
ultrasound volume over the 3 month period. If information on ultrasound assessment was
incomplete, but there was clear documentation of response in the notes, the patient was
included. Patients in whom such information was insufficient to allow clear definition of
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response were excluded. The methods of clinical and ultrasound assessment will be outlined
in the description of the prospective study.
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Sequential changes in tumour vascularity in xenografted breast
cancers during tamoxifen treatment and correlation with changes in
tumour volume.
To determine chronology of changes in tumour vascularity during primary tamoxifen
treatment relative to tumour response, ER-positive (ZR-75) and ER-negative (MDA-MB-
231) tumours were xenografted in nude mice and animals treated with tamoxifen. Tumours
were excised at several time points during treatment and sections stained with antibody to
endothelial cells (MEC13.3). Microvessel counts were then performed on stained sections
and correlated with changes in tumour volume with treatment.
Study design:
0 I
Where represents a control tumour and represents a treated tumour.
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Assessments of tumour volume carried out with calipers at
each time point and on day 10.
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Methods:
Tumour growth: The oestrogen-sensitive ZR-75 (Engel et al., 1978) and oestrogen-
insensitive MDA-MB-231 (Cailleau et al., 1974) breast cancer cell lines were maintained by
sequential passage in nude athymic mice (HsdOla: ICRF-nu), purchased from Harlan (UK),
Bicester, Oxon. At each passage a 1mm fragment of tumour was inserted subcutaneously in
flanks of animals when the mice were 8-12 weeks old.
On the day of implantation, a slow release oestrogen pellet (0.72mg, released over 60 days,
supplied by Innovative Research of America, Ohio, USA) was inserted subcutaneously in the
midline. All mice were maintained on a standard diet (Harlan, UK) and water ad libitum.
Bidimensional tumour dimensions were recorded weekly, and tumour volumes calculated
according to the equation:
VOLUME= D x d2 x 71/6
Where D was the larger of the two diameters.
When tumour volumes reached an average of 0.25cm3, animals were randomly allocated to
treatment or control groups (Day 0). Animals in treatment groups were treated with a slow
release tamoxifen pellet (0.25mg over 60 days, Innovative Research of America), inserted
subcutaneously in the midline, adjacent to the oestrogen pellet. Animals in control groups
had no further pellet inserted.
Tumour retrieval: Animals were killed by cervical dislocation and tumours excised on days
0, 2, 4 and 7 in the ZR-75 group and days 0, 2, 4, 7 and 14 in the MDA-MB-231 group.
Numbers of tumours excised at each time point were illustrated in the study design. Tumours
were divided in half immediately following excision and were stored in either liquid nitrogen
or in neutral-buffered formalin. Tumours in neutral-buffered formalin were processed in the
routine pathology laboratory into paraffin-embedded blocks. 4pm sections were cut from
these blocks and mounted on Superfrost glass slides.
Response to tamoxifen: Following commencement of the experiment on Day 0, caliper
assessments of transverse and anteroposterior tumour dimensions were measured on days 0,
2, 4 and 7 in the ZR-75 group and days 0, 2, 4, 7, 10 and 14 in the MDA-MB-231 group.
Tumour volumes were calculated from the dimensions as described above.
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Percentage response of tumours to tamoxifen was calculated at each time point, and was
defined as % reduction in volume relative to the initial volume:
% RESPONSE= V,-Vo/Vo xlOO
Where Vo= initial tumour volume on Day 0
Vi= volume at later time point.
This allowed comparison ofmvc in treated and control tumours. In particular, relative
timings of effects of tamoxifen on mvc and tumour volume were compared.
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Sequential assessments of tumour vascularity during treatment with
tamoxifen and correlation with response.
To determine whether early changes in tumour vascularity predict response to primary
tamoxifen treatment, forty-two patients were recruited into this prospective study.
Postmenopausal women with large, operable or locally advanced, ER-positive breast cancer
were treated with three months of tamoxifen prior to surgery. Patients underwent core
biopsies at diagnosis and following two weeks of treatment. At the end of three months,
patients underwent definitive surgery or repeat core biopsies. Assessments of tumour
vascularity were thus obtained before (MVC1), during (MVC2) and after (MVC3) treatment.
Response to tamoxifen was assessed by serial ultrasound measurements of tumour volume.
This prospective study design allowed comparison of early changes in tumour vascularity in
responding and non-responding tumours.
To compare the effects of tamoxifen on another aspect of tumour biology, sections from the
same tumours were stained with an antibody to proliferating cells (MIB-1 antibody) changes













Patient recruitment: Having obtained written or verbal consent, fifty-two postmenopausal
women with large, operable or locally advanced ER-positive breast carcinoma were recruited
into a study of changes in tumour vascularity during primary tamoxifen treatment. The
decision to include an individual in the study was made at the weekly multidisciplinary
Combined Breast Clinic. In addition to the criteria described, tumour dimensions had to be
assessable on ultrasound scan. Presence of regional or distant metastases did not exclude
patients from the study. Patients underwent serial core biopsies before, during and after a
period of three months' tamoxifen treatment and serial assessments of change in tumour
volume, allowing correlation of changes in vascularity with response.
Tumour retrieval:
Core biopsies: These were performed under local anaesthetic in the clinic at the time of
diagnosis and repeated following two weeks of treatment with tamoxifen. In those patients
who continued with tamoxifen beyond three months, core biopsies were repeated at that
time. Having infiltrated the area within and around the tumour with 20mls. 1% lignocaine
and 1:200 000 adrenaline, a single stab incision was made at a point lateral to the tumour
with a Size 15 scalpel blade. Biopsies were carried out using a Pro-Mag gun and a 14 gauge
needle, illustrated on Figure la, which was inserted at the point of incision and biopsies
taken by placing the tip of the needle at the tumour periphery and firing the gun into the
tumour (Figure lb). Between one and ten core biopsies were collected from each tumour. A
single core biopsy is illustrated in Figure lc. Biopsy specimens were placed immediately
into neutral-buffered formalin and processed into paraffin-embedded blocks within 24 hours.
Tumour sections: Immediately following surgical excision, fresh tumour was collected and,
in conjunction with the pathologist, a transverse tumour section was obtained for the
purposes of this study. Specimens contained both central and peripheral tumour areas and
were stored immediately in neutral-buffered formalin. Specimens were processed in the
routine pathology laboratory and were paraffin-embedded within twenty-four hours of
collection. Blocks were assigned a numerical code to allow blind assessment.
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a) Pro Mag gun with 14 gauge needle
b) Core biopsy of a breast tumour performed under
local anaesthetic.
c) An example of a core biopsy.
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Monitoring of tumour response to tamoxifen:
Serial assessments of tumour volume were made by clinical and ultrasound measurements.
In addition, patients underwent mammography before and after treatment. A subgroup of
nine patients also underwent serial colour Doppler ultrasound scans.
Clinical measurements: These were made using calipers to measure tumour dimensions.
Transverse and anteroposterior measurements were obtained at diagnosis and following six
and twelve weeks of treatment.
Ultrasound measurements: All ultrasound scans were performed by a single observer
(L.M.) at diagnosis, and repeated following six and twelve weeks of treatment. Three tumour
dimensions were assessed: the maximum transverse and anteroposterior diameters and
tumour depth. Tumour volumes were calculated according to the equation:
VOLUME= A x B x C x 7i/6
Where A= transverse diameter
B= anteroposterior diameter
C= tumour depth.
Percentage response of tumours to tamoxifen was calculated at each time point, and was
defined as % reduction in volume relative to the initial volume:
% RESPONSE= Vi-Vo/Vo xlOO
Where V0= initial tumour volume
Vi= volume at later time point.
A responding tumour was defined as one in which there was progressive reduction in tumour
volume which, at the end of three months, represented a greater than 25% decrease
compared with initial tumour volume.
Colour Doppler ultrasound: Scans were performed by one of two consultant radiologists in
a subgroup of nine patients. Tumour dimensions were measured as described for
conventional ultrasound and the largest feeding vessel was identified following scanning of
the entire tumour. A colour Doppler waveform was obtained and maximum systolic velocity
determined as the peak velocity of the waveform. This provided non-invasive assessments of




A single section of each tumour was stained with haematoxylin (Sigma) and eosin (Sigma).
This was performed in the routine pathology laboratory.
Immunohistochemistry:
Endothelial cell markers:
Sections of all clinical and xenografted tumours were stained with an endothelial cell marker
highlighting tumour vessels. In this section, a description of the final methods of staining
will be given, followed by explanation of methods used to determine optimal staining
method for each group of tumours. Specific staining protocols are provided in the Appendix.
Clinical tumour sections were stained with two monoclonal antibodies to endothelial cells:
anti-Von Willebrand factor (antibody to Factor VIII) (DAKO) and mouse anti-human CD31
antibody. Similar techniques of antigen retrieval, secondary antibody and visualization were
used for both antibodies. The optimum concentration of anti- Von Willebrand factor (VWF)
was 1: 80, diluted in 20% fetal calf serum (FCS, Gibco) / 0.05M tris-buffered saline (TBS).
TBS was made up with 60.55g Trizma base (Sigma) and 1 litre distilled water. This was
optimized to pH7.6 with concentrated hydrochloric acid and then diluted to 0.05M with
normal saline (lOOmls TBS: 900mls 0.9% sodium chloride). Optimum concentration of
antibody to CD31 was 1:40, diluted as for anti-VWF.
Xenograft tumours were stained with rat anti-mouse CD31 monoclonal antibody (MEC
13.3), adopting a similar protocol as for clinical tumours. Optimum primary antibody
concentration was higher than for clinical tumours: 1:10 diluted in 20% FCS/0.05M TBS.
Following dewaxing of sections through graded xylene, described in detail in the Appendix,
sections were incubated in distilled water warmed to 37°C in an incubator. Antigen was
retrieved using protease (Type XXIV, Sigma). 25mg protease was dissolved in 200ml warm
phosphate-buffered saline (PBS, Dulbecco), and slides were incubated in the solution for 20
minutes.
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Following washing of slides in 20% fetal calf serum in 0.05M TBS, primary antibody was
applied at the optimum concentration. Tumour sections were incubated for 1 hour at room
temperature or overnight at 4°C and were then washed in 0.05M TBS.
The secondary antibody used for clinical tumours was rabbit-anti-mouse immunoglobulin
(DAKO). This was diluted 1:50 in 0.05M TBS and sections incubated for between 30
minutes and one hour. The secondary antibody used for xenograft tumours was rabbit-anti-
rat immunoglobulin (DAKO) at 1:10 in 0.05M TBS. After incubation of slides with
secondary antibody, they were washed in TBS and mouse alkaline phosphatase/anti-alkaline
phosphatase (APAAP, DAKO) was applied for 30 minutes to clinical tumours
(concentration: 1:100 in 0.05M TBS). Rat APAAP was used as a tertiary antibody in
xenograft experiments (concentration: 1:50 in 0.05M TBS).
Application of the secondary and tertiary antibodies was repeated to enhance staining for 10
minutes each. Following washing in TBS for 5 minutes, new fiiclisin substrate (DAKO) was
applied to sections for 20 minutes. Sections were then washed in distilled water and
counterstained in haematoxylin (Sigma) for 5 minutes with differentiation through acid-
alcohol (0.1% hydrochloric acid in 400mls 95% alcohol) and lithium carbonate (Sigma).
Sections were rinsed in running tap water and mounted immediately in aqueous mounting
medium (BDH) using glass coverslips (Mackay and Linn). Stained sections were stored at
4°C.











































Several attempts were made to optimize endothelial cell staining of both clinical and
xenograft tumours. Particular problems were faced with xenograft tumours, in which initial
attempts at staining failed, yielding either negative results or non-specific staining. Thus
several methods other than those described in the previous section were tried for each stage
of the staining process and these will be described. The optimized staining technique was the
one in which clear red staining of vessels was achieved with minimal background staining.
Antigen retrieval: Methods other than retrieval with protease were adopted, involving
microwave in citric acid and various methods of trypsin antigen retrieval.
Microwaving in citric acid: sections were placed in a solution of 1 07g citric acid in 500ml
distilled water. Concentrated hydrochloric acid was added to the solution to reach pH6.0.
Sections were microwaved for 3x5 minutes at full power and allowed to stand in citrate for
20 minutes.
Trypsin: several methods were attempted for the xenograft tumour slides:
Sections were placed in a solution of 0.1% trypsin in 0.1% calcium chloride at pH7.4 for 30
minutes at 37°C and washed in water.
Sections were placed in tissue culture trypsin at either room temperature or at 37°C for
varying lengths of time for optimization (20-50 minutes).
Primary antibody concentrations: These were varied for each antibody to determine optimal
concentrations, in which clear red staining of vessels was obtained with minimal background
staining. Range of concentrations used was 1:10-1:200. Optimal concentrations have been
described.
Secondary antibodies: for xenograft tumours, use of two secondary antibodies was
attempted; both were rabbit-anti-rat immunoglobulins, one linked into the Avidin-Biotin
complex (ABC) and the other into the APAAP system. Concentrations were varied and the
antibody linking into the APAAP system found to provide better staining than that linking
into the ABC system.
Tertiary systems: As has been described, the ABC complex was used in an attempt to
improve staining of xenograft tumours. Following application of the secondary antibody the
APAAP step was replaced by application of the ABC complex. Visualization following use
of the ABC complex was achieved with diaminobenzadine (DAB). Using this technique,
sections were then dehydrated through graded alcohols in the reverse manner to that
described for hydration and mounted using DPX mounting medium.
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Antibody to vascular endothelial growth factor (VEGF):
Tumour sections of fifty-seven patients before and after treatment with tamoxifen were
stained with antibody to VEGF. This work was carried out in collaboration with Dr. J.
Harmey at the Royal College of Surgeons of Ireland, Dublin. Tumour sections were obtained
by the investigator and all staining performed by Miss. D. Foley in Dublin. Assessment of
staining was performed jointly by Dr. J. Harmey and the investigator.
4pm sections mounted on Superfrost slides were dewaxed as for the previous experiment.
Sections were rinsed in running water and then in 0.05M TBS. Sections were incubated in
3% hydrogen peroxide for 5 minutes (Sigma) to quench endogenous peroxidase activity
(3mls Hydrogen peroxide in lOOmls distilled water). This step was repeated, before rinsing
slides in running water, then placing in 0.05M TBS.
Slides were incubated in normal goat serum (DAKO) diluted 1:10 in TBS for 30 minutes to
block non-specific binding. Excess serum was wiped off before incubation of sections in
primary antibody. Primary antibody was polyclonal rabbit anti-VEGF (Santa Cruz
Biotechnology) diluted 1:100 in 0.05M TBS. Sections were incubated in primary antibody
overnight at room temperature. Sections were rinsed in 0.05M for 5 minutes.
Secondary antibody, biotinylated goat anti-rabbit (StrepABComplex/HRP Duet mouse/rabbit
kit) (DAKO) was prepared according to the kit instructions and sections were incubated for
30 minutes at room temperature. Sections were rinsed in 0.05M TBS. Sections were then
incubated in StrepABComplex/ horseradish peroxidase as instructed in Duet kit for 30
minutes and rinsed in TBS.
Visualization was achieved with the chromogenic substrate diaminobenzadine (DAB). The
solution was made up from two DAB tablets dissolved in 20mls. Distilled water and then
aliquoted into 2ml. lots and stored frozen at -20°C. When required, a 2ml aliqout was
defrosted and 2pl hydrogen peroxide added. The resulting solution was applied to sections
for 5 minutes, followed by rinsing in running water. Sections were dehydrated through
graded alcohols and xylene, as detailed in the Appendix. Sections were then mounted in
DPX (Fisher) and dried before visualizing under light microscopy. Cells staining for VEGF
appeared brown.
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MIB-1 antibody to proliferating cells:
A similar method was used for staining with MIB-1 antibody, directed against proliferating
cells. Following blocking of endogenous peroxidase with hydrogen peroxide solution as
described previously, antigen retrieval was performed by microwaving (2x5 minutes at full
power) in citric acid (Sigma) for 10 minutes (1.07g in 500ml distilled water). For this
method a routine Sequenza system was used. The primary antibody was MIB-1 (Biogenex)
diluted to 1:20 with 0.05M TBS. Slides were incubated in primary antibody for 30 minutes,
then rinsed in PBS for 5 minutes. Slides were incubated in Vector anti-mouse secondary
antibody at a concentration of 1:200 in 0.05M TBS for 30 minutes and rinsed in PBS.
Tertiary antibody was applied for 30 minutes followed by visualization with DAB as
previously described. Sections were counterstained with haematoxylin for 5 minutes and
then dehydrated through alcohols and xylene. Sections were mounted in DPX.
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Microvessel counts:
Following immunohistochemical staining of endothelial cells as described, microvessel
counts were performed by two observers, a trainee pathologist and the investigator, who
underwent a period of training with an expert in the field. Counts were performed using a
conference microscope.
An H+E section of the block was initially scanned and the tumour identified. Having
scanned the tumour at low power (x40 and xlOO) the area of highest vascularity was
identified, known as a vascular 'hot spot'. A count was then performed in this area under
high power (x250), using a Chalkley 25-point eyepiece graticule (Fox et al, 1995a). This
graticule with 25 randomly allocated dots was placed in the microscope eyepiece. Vessels
were counted only if they lay under the dots. In order to account for volume occupied by
vessels, those with more than one dot overlaying them were counted more than once. Counts
were performed in three vascular hot spots. The highest, mean and total of three counts were
documented. All sections were labelled with a number and those performing the counts had




Following staining with antibody to VEGF sections were assessed by three observers using a
conference microscope: by Miss. D. Foley, Dr. J. Harmey and by the investigator.
Assessments were made on intensity of staining and on percentage of tumour cells staining
positive for VEGF and scored as described on Table 2.1. Assessments were made in three
random high power (x400) fields and the total of three scores were documented. Intensity of
staining was compared to the positive control for each staining run.






Table 2.1b: Scoring categories for antibody to VEGF-% cells staining:








Assessments were performed by a single observer, Dr. S. Iqbal; in one in four sections,
scores were repeated by Dr. T. Anderson and any discrepancies in the scores between the
two observers were discussed. Scores were based on percentage of tumour cells stained for
MIB-1 as described in Table 2.2. Scores were obtained by scanning the entire tumour
section.
Table 2.2: Scoring categories for MIB-1 assessments:







Data and statistical analysis:
All data were stored on an Excel forWindows version 5.0 database:
(Microsoft Corporation, Redmond, WA, USA).
Statistics were performed using InStat program for Macintosh computers. Comparison of
microvessel counts between non-responding and responding tumours were assessed using
the non-parametric Mann-Whitney test. The paired Wilcoxon signed rank test was applied
for comparison of counts within the same group of tumours at different times. When
determining trends of change in microvessel count with treatment, Chi-squared test for trend
was used. Finally, the Spearman rank correlation test was applied for determination of
correlation between counts and/or other factor.
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1. Reproducibility of microvessel counts in
different breast cancer specimens
Certain methodological issues regarding tumour vascularity assessment by microvessel
counting need to be addressed. Those considered in this chapter are:
Inherent variation in the method: intra-and inter-observer variation.
Variation due to selection of different antibodies to endothelial cells.
Variation due to tumour heterogeneity.




Microvessel counts performed by the same observers on two occasions (mvcl and mvc2) at
least a fortnight apart were compared in 31 tumours, of which sixteen were core biopsies.
The results are shown in Figure 1.1.1. Mvcl ranged from 12 to 28 (median: 16, mean: 16.4)
and mvc2 from 14 to 28 (median: 17, mean: 17.7). There was significant correlation between
the two counts (r=0.84, p<0.001), with a tendency for the later count (mvc2) to be higher
than the first count (mvcl). The standard deviation of difference between the two groups was
1.95, giving an expression of variance of 11%. Data are detailed in the appendix to this
chapter.






















Microvessel counts were performed by two different observers (mvcKK and mvcLM) in 16
tumours, all of which were tumour sections. MvcKK ranged from 12 to 28 (median: 20,
mean: 20.3), mvcLM ranged from 13 to 31 (median: 19.5, mean: 20.5) as shown in Figure
1.1.2. A significant correlation was found between counts of the two observers (r=0.83,
p<0.001). The standard deviation of differences was 3.03, giving an expression of variance
of 15%.
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1.2. Comparison of mvc in core biopsies and tumour sections
following staining with CD31 and FVIII antibodies.
Microvessel counts were performed following endothelial cell staining with two different
antibodies: antibody to CD31 and to Factor VIII in both core biopsies (n=l 10) and tumour
sections (n=164) for comparison, illustrated on Figure 1.2.1. The relationships between
counts performed on serial sections are shown on Figures 1.2.2 and 3. There was a highly
significant correlation in counts using different antibodies in both cores (r=0.40, p<0.0001)
and tumour sections (r=0.30, p=0.0001).
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Fig 1.2.1. Comparison of endothelial cell staining with antibody to factor
VIII and CD31 with vessel highlighted in red.
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Figure 1.2.3: Relationship between invc of tumour sections







Comparison of mvc in core biopsies and tumour cross-sections.
Core biopsies were taken of 16 tumours immediately following surgical excision and counts
were compared in cores and tumour sections, illustrated in Figure 1.3.1. The number of core
biopsies taken from each tumour ranged from 1 to 7 (median: 3, mean: 3.33); all biopsies
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Figure 1.3.2 illustrates the correlation between counts in cores and tumour sections. Mvc in
core biopsies ranged from 13 to 22 (median: 17, mean: 16.53) and in tumour sections from
14 to 24 (median; 18, mean: 18). There was no significant difference in mvc between the two
groups (p=0.1, paired Wilcoxon). Conversely, whilst there was a positive correlation in
counts, this did not reach statistical significance (r=0.44, p=0.091). In nine of sixteen
tumours (56%) mvc was higher in the tumour cross-section whereas it was higher in the core
biopsies in three of sixteen (19%) with no difference in 4 (25%).







Comparison between mvc of core biopsies and subsequent tumour cross-
sections.
Core biopsies were taken for diagnosis in 21 patients who underwent surgery between 5 and
34 days later (median time to surgery: 23 days) with no intervening treatment. One patient
was found to have carcinoma in situ with no evidence of invasion and was excluded from the
study. The number of core biopsies taken ranged from 1 to 6 (median: 3, mean: 2.95).
Transverse sections of the same tumours were taken at surgery.
The relationship between counts of cores and subsequent tumour cross-sections is shown on
Figure 1.3.3. Microvessel counts in core biopsies ranged from 12-25 (median:16, mean:17.1)
and in the later tumour cross-sections from 15-25 (median: 21, mean: 21.1). Although there
is a tight range of mvc values, no positive correlation was found (r=-0.1). There was a
significant difference in the counts (p=0.0065, paired Wilcoxon). Mvc in tumour sections
was higher in 13 of 20 tumours (65%), higher in core biopsies in 4 of 20 tumours (20%) and
the two were the same in 3 tumours (15%).







Comparison between mvc of core biopsies at diagnosis and following surgical
excision.
Multiple core biopsies were taken of tumours in ten patients for diagnosis and were repeated
immediately following surgical excision between two and three weeks later with no
intervening treatment. The number of cores performed ranged from 1-7 (median: 3, mean:
3.05). Figure 1.3.4 illustrates the relationship between counts in cores at the two time points.
Mvc in cores at diagnosis (mvcl) ranged from 10 to 22 (mean: 16.4, median: 16.5) and mvc
in cores at surgery (mvc2) ranged from 13 to 21 (mean: 17.4, median: 18). No correlation
was found between the groups (r=-0.38). There was no significant difference in mvc between
the two groups (p=0.481). Mvc was higher in later cores in 5 of 10 tumours (50%), higher in
initial biopsies in 4 tumours (40%) and the same in one (10%).








Correlation between number of cores performed and difference in mvc between
cores and tumour section.
Analysis was performed to determine whether there was a relationship between number of
cores performed and the difference in mvc between cores and tumour sections. In 37 cases,
cores and tumour section were available for comparison. The number of cores performed
ranged from 1 to 7 (median: 3, mean: 3.13). The difference in mvc was expressed as a
percentage of total mvc count in the tumour section, and its relationship with number of
cores is illustrated on Figure 1.3.5. No significant correlation was identified (r=-0.25,
p>0.05).
Figure 1.3.5: % difference in mvc between two tumour
samples versus number of cores performed.
2 4 6
NUMBER OF CORES (r=-0.25, p>0.05)
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1.4. Discussion:
The present study has attempted to assess the variation in assessment of angiogenesis which
might be caused by (i) inherent variation in the method, (ii) tumour heterogeneity and (iii)
previous surgical manipulation of tumour.
Variation in microvessel counts (mvc) between the same observers performed at different
times was 11% in this study, with a highly significant correlation between the two sets of
counts (r=0.84, p<0.001). Interobserver variation was 15%, which is comparable to another
study which addressed the same issue (Martin et al, 1997). The issue of observer variation
has been raised in several studies as a possible reason why angiogenesis assessment has
failed to provide useful prognostic information in some series of primary breast cancers
(Axelsson et al, 1995; Van Hoef et al, 1993). In both studies, mvc was used as a categorised
rather than a continuous variable (Axelsson et al, 1995; Van Hoef et al, 1993), which may
result in loss of useful prognostic information (Vermeulen et al, 1996). Another study
addressing the issue of observer variation found that mvc provided independent prognostic
information in a series of breast tumours when performed by experienced observers but not
by the least experienced observer (Vermeulen et al, 1997b). The authors therefore
recommended that a period of training with an experienced observer is advisable (Vermeulen
et al, 1997b). In the present study, counts were performed by two observers, a pathologist
and a surgeon who had undertaken a period of training with an experienced observer prior to
embarking on the study. Other methods have been suggested to improve objectivity of
counting such as using a Chalkley eyepiece graticule, as in the present study, or
computerised image analysis (Fox et al, 1995a). In a recently published study comparing
interobserver variability using different counting methods, use of the Chalkley grid yielded
low variability and was found to be more effective in reducing variation than selection of the
same hot spot by different observers (Hansen et al, 1998). Reproducibility was further
optimized by the use of a conference microscope, thereby eliminating subjectivity in hot spot
selection and field sampling (Hansen et al, 1998). The low degree of interobserver variability
observed in the present study would therefore be compatible with the use of the Chalkley
grid by two observers using a conference microscope.
Variation in staining due to use of two endothelial cell antibodies has been assessed. Studies
investigating the role ofmvc as a prognostic indicator in breast cancer have used both CD31
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and FVIII antibodies, in addition to another antibody, CD34 (Van Hoef et al, 1993; Weidner
et al, 1992). Several studies have compared use of different antibodies. In an early study
comparing CD34, CD31 and Factor VIII, CD31 antibody was found to be the most sensitive,
consistently staining more vessels than either antibody to CD34 or Factor VIII (Florak et al,
1992). A later study found CD34 to be most strongly and consistently expressed with little
background staining and no staining of other cells (Martin et al, 1997). Antibody to Factor
VIII stains consistently, but has the disadvantage of staining lymphatic in addition to
vascular endothelium (Martin et al, 1997; Vermeulen et al, 1996). CD31, the most sensitive
marker of endothelial cells, stains microvessels as well as larger vessels but has the
disadvantage of frequent antigen loss due to certain fixatives (Vermeulen et al, 1996). It was
because of these potential problems that sections were stained with both antibodies to CD31
and Factor VIII. There was a highly significant correlation between the two groups of counts
(r=0.4, p<0.0001) in both core biopsy and tumour sections.
Tumour heterogeneity in vasculature has been investigated in the present study by
comparing microvessel counts in core biopsies and tumour sections taken simultaneously.
Whilst the range of counts was similar in the two groups, correlation between counts failed
to reach statistical significance (r=0.44, p=0.09), with vessel counts in tumour sections
tending to be higher than core biopsies. This may be related to the methodology used in
counting. Heterogeneity of tumour vasculature between different areas of the same tumour is
well-recognised (Van Hoef et al, 1993; Weidner et al, 1992) and may be overcome to an
extent by selection of three vascular 'hot spots'. Selection of such 'hot spots' remains the
most subjective aspect of microvessel counting, although a recent study suggested that the
use of a Chalkley grid was more important at improving objectivity than selection of the
same hot spot by different observers (Hansen et al, 1998). The reason given for this was that,
even within the same hot spot, different high power fields were likely to be selected by
different observers (Hansen et al, 1998). Alternatives to the original method proposed by
Weidner have been suggested, which may be ofparticular benefit to the less experienced
observer. Firstly it has been suggested that counts be performed in ten fields of high
vascularity, taking the highest count as the mvc (Martin et al, 1997). An alternative method
would be to perform photomicrographs of the most intensely vascular areas and for
individual observers to count from the photographs (Vermeulen et al, 1997b). Core biopsies
contain a small section of total tumour and are therefore less likely to include vascular 'hot
spots' than a tumour section. This has been bome out in results of the present study, and is
demonstrated in Figure 1.3.1, which illustrated the difference in section obtained from the
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same tumour by core biopsy (a) and tumour cross-section (b), both taken at the time of
surgery. Counts in core biopsies were lower than tumour sections in 56% of tumours studied.
Another study which addressed the role of core biopsies found a similar lack of correlation in
mvc of cores and tumour sections, but found mvc to be higher in core biopsies than tumour
sections in 61.2% of cases (Jacobs et al, 1998).
Problems with tumour heterogeneity are not unique to vascular assessments, but have been
described for several other parameters in breast cancer. Significant variations in mitotic
activity index assessed on haematoxylin and eosin sections (Jannink et al, 1996) and DNA
cell cycle variables (Bergers et al, 1996) were found on assessment of multiple tumour
sections. Conversely, levels ofMIB-1 and oestrogen receptor expression were found to alter
little in assessments of serial tumour sections (Jensen & Ladekarl, 1995).
The issue of the accuracy of core biopsies in providing prognostic information is important
as such specimens are increasingly used in diagnosis and may provide the only pre-treatment
tissue available. Other studies have addressed similar issues for markers other than
angiogenesis and reproducible results have been obtained for determinations ofDNA ploidy,
bcl-2, oestrogen receptor, c-erbB-2 and p53, which are dichotomously scored variables
(Daidone et al, 1991; Jacobs et al, 1998). Jacobs et al failed to produce reproducible results
for microvessel counts and accuracy was not improved by increasing tumour area available
for assessment by performing more core biopsies (Jacobs et al, 1998). This is in keeping
with results from the present study, in which, whilst there is a suggestion from Figure 1.3.5
that difference in mvc may be reduced with an increasing number of the core biopsies, this
correlation failed to reach statistical significance.
Another possible reason for unreliablility of sequential core biopsies in tumour vascular
assessment is the likely induction of angiogenesis following the initial biopsy as part of the
normal process ofwound healing (Folkman, 1971). Comparison of microvessel counts in
core biopsies and subsequent core biopsies with no intervening treatment failed to show any
correlation. In particular, it is worth noting that counts were found to be higher in the later
tumour samples in 65% of cases, which suggests that angiogenesis may well have been
induced following the early biopsy. However, this trend failed to reach statistical
significance.
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Various practical issues regarding the methodology of tumour vascularity assessment by
microvessel counts have been investigated. Intra- and inter-observer variations in counts
were 11 and 15% respectively, which were similar to those described in other studies.
Tumour heterogeneity is a problem when adopting this method in small tumour biopsies,
such as core biopsies, which may not contain vascular 'hot spots'. In addition, angiogenesis
takes place in conditions other than tumour growth, such as wound healing, and is therefore
likely to be stimulated by surgical manipulations of the tumour, affecting subsequent
assessments. Results of the present study suggest that microvessel counts on core biopsy
specimens are unlikely precisely to represent overall vascularity of the individual tumour. In
determining the role of assessment of sequential core biopsies during primary systemic
therapy, the size of the effect of therapy will be important. If tamoxifen exerts a dramatic
effect on tumour vascularity this may be apparent in core biopsies despite the shortcomings
of the technique demonstrated in this study. Against this background a series of studies
aimed at determining the effect of tamoxifen on breast tumour vascularity were undertaken.
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2. Changes in tumour vascularity following primary
tamoxifen treatment and correlation with response.
Having investigated the method of performing microvessel counts in terms of observer
variation and reproducibility in different breast cancer specimens, the focus of the remaining
chapters is the effect of tamoxifen on breast tumour vascularity. The aim of the study
outlined in this chapter was to determine whether changes in tumour vascularity take place
following primary treatment with tamoxifen in relation to response. A study of patients
treated with neoadjuvant tamoxifen has been undertaken, in which tumour tissue was
available before and after treatment, allowing comparison of tumour vascularity in
association with response at the two time points.
Seventy-two post-menopausal women with large (>3cm), operable or locally advanced
(ipsi lateral lymph node or skin involvement) breast cancers which were oestrogen receptor
(ER)-positive (>20fmol/mg cytosolic protein) were recruited into this retrospective study.
Patients were treated with tamoxifen (20mgs daily) for a period of between three and thirty
months, following a wedge biopsy for determination of ER status and prior to definitive
surgery. Tumour response to tamoxifen was determined by monthly clinical, ultrasound and
mammographic assessments of tumour volume. This study design allowed comparison of
tumour vascularity before and after treatment with tamoxifen and correlation with response.
Fifty-seven of the seventy-two patients (79%) were treated with tamoxifen for between three
and six months. Fifteen patients continued to take tamoxifen for between seven and thirty
months. This group of patients had locally advanced disease, with skin or axillary lymph
node involvement. During early treatment with tamoxifen, tumour growth was controlled,
but escaped control subsequently, therefore requiring later surgery. The response patterns of
these tumours were, therefore, complex and will be considered separately.
In this chapter results of 57 patients treated with tamoxifen for between three and six months
will be detailed first, including tumour response data, assessments of tumour vascularity by
microvessel counting and correlation between the two. Raw data are detailed in the
Appendix. In addition, similar analyses were performed on twenty-two patients who were
treated with the aromatase inhibitor, letrozole, allowing comparison of effects of the two
drugs.
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2.1. Clinical assessment of tumour response to tamoxifen.
Patients were assessed following four, eight and twelve weeks' treatment with tamoxifen.
Tumour volumes were assessed by caliper measurements and ultrasound measurements of
anteroposterior and transverse diameters and depth were taken. Patients underwent
mammography before and after treatment. In 30 patients, details of ultrasound assessments
(US) were available and these were used to determine response. In 22 patients, insufficient
ultrasound data were available but there was clear clinical evidence of response (CLIN). In
five patients, manmiographic information alone was available (MAMM.).
A responding tumour was defined as one in which there was a greater than 25% reduction in
tumour volume at the end of three months. Ultrasound measurement of tumour volume was
the preferred method of assessment, but when unavailable, response was defined according
to changes in clinical or mammographic measurements. Sequential ultrasound assessments
of a responding tumour during the course of treatment are illustrated on Figure 2.1.1, and
pre- and post-treatment mammograms are illustrated on Figure 2.1.2.
Details of changes in tumour volume relative to original volume for each assessable patient
are shown on Table 2.1.1. Mean serial reductions in tumour volume in non-responding and
responding tumours are illustrated on Figure 2.1.3. Mean reduction in volume in non-
responding tumours at completion of treatment was 6%, and in responding tumours was
64%. Numbers of patients with responding and non-responding tumours are shown on Table
2.1.2 and demonstrates an overall response rate of 75%.
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Fig 2.1.1. Serial ultrasound assessments
of tumour volume demonstrating a
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Fig 2.1.2. Mammographic evidence of tumour response
a) Tumour volume before treatment b) Reduced tumour volume following
three months of tamoxifen treatment.
Table 2.1.1: Changes in relative tumour volume during treatment with tamoxifen.
Tumour volumes are expressed as % original volume, non-responders shown in bold type.
Tumour vol. l=volume following 1 month of treatment
Tumour vol. 2=volume following two months of treatment
Tumour vol. 3=volume following three months of treatment
Mam. Resp.=response seen on mammography.
NA=results not available
a) Non-responding tumours:
Patient No. Original vol Tumour vol 1 Tumour vol 2 Tumour vol 3 Mam. Resp.. Assessment.
480425W 100 100 70 97 static US
495639K 100 100 100 100 static US
558680X 100 100 70 100 reduction us
495980E 100 100 100 100 NA CLIN
494064R 100 100 100 100 NA CLIN
545602E 100 100 91 81 static CLIN
582565W 100 79 100 100 static us
528456W 100 100 100 82 reduction US
572868X 100 100 87 87 increase US
596319W 100 100 100 79 NA US
522679X 100 100 100 100 NA CLIN
502246A 100 100 100 100 NA CLIN
524732W 100 100 100 100 mcrease MAMM.
52411IX 100 100 88 96 reduction US
b) Responding tumours:
Patient No. Original vol Tumour vol 1 Tumour vol 2 Tumour vol 3 Mam. Resp.. Assessment.
268300H 100 35 24 8 NA US
110258V 100 100 100 59 NA US
528171K 100 100 73 73 NA us
552168H 100 100 79 35 reduction us
52346X 100 100 72 52 reduction MAMM.
560577L 100 100 53 27 NA US
513260L 100 24 12 12 NA CLIN
527028L 100 61 18 9 no lump us
44955M 100 100 54 reduction NA CLIN
395041K 100 100 44 20 NA US
350429H 100 100 73 20 NA US
545123B 100 100 77 9 NA US
520042V 100 100 57 57 progression CLIN
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Patient No. Original vol Tumour vol 1 Tumour vol 2 Tumour vol 3 Mam. Resp.. Assessment.
81364H 100 100 72 47 decrease MAMM.
511159M 100 100 71 55 reduction CLIN
500371K 100 81 73 22 NA CLIN
372859M 100 59 69 55 reduction US
529249W 100 100 38 33 no lump. CLIN
376029R 100 61 61 60 NA US
499870K 100 83 71 71 NA US
520767V 100 100 62 51 NA CLIN
498214W 100 91 51 13 reduction US
498258R 100 100 100 68 NA US
559968K 100 41 23 17 NA US
510657M 100 70 45 28 reduction CLIN
450908A 100 100 45 36 reduction US
155271L 100 100 77 70 NA US
519014W 100 100 100 45 no change CLIN
499532M 100 100 47 35 reduction US
564461M 100 36 36 36 reduction CLIN
515126A 100 100 89 68 NA CLIN
529146X 100 83 38 15 reduction MAMM.
458317M 100 100 24 27 reduction US
548395L 100 33 16 16 increase US
509362K 100 NA NA CLIN
503527E 100 NA NA CLIN
526825K 100 NA reduction MAMM.
488627M 100 38 2 2 NA US
535168M 100 NA NA CLIN
532363A 100 100 58 32 reduction CLIN
527259E 100 52 44 39 NA CLIN
527857A 100 NA NA CLIN
588347R 100 100 100 51 reduction US
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Figure 2.1.3: Mean serial changes in tumour volume in non-
responding (n=14) and responding (n=43) tumours.
Standard error bars shown.





2.2 Microvessel counts following staining with antibody to Factor
VIII.
Assessments of tumour vascularity were made by performing microvessel counts in three
areas ofhigh vascularity in all tumours before and after treatment with tamoxifen for a
period of between three and six months. The microvessel count of each tumour section was
defined as the total of the three counts. Endothelial cell staining was performed using
immunohistochemical techniques as described in the Methods section. Sequential tumour
sections were stained with antibody to Factor VIII (Von Willebrand factor) and antibody to
CD31. Microvessel counts obtained following staining with antibody to Factor VIII will be
considered first.
Figure 2.2.1 illustrates an example of a tumour section following staining with antibody to
Factor VIII.
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Fig 2.2.1. Tumour section following endothelial cell staining with anti¬
body to Factor VIII. Vessels are highlighted in red with haematoxylin
counters taining.
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b) at high power (X 250)
Comparison of pre- and post-treatment mvc in all tumours is illustrated on Figure 2.2.2,
demonstrating no significant difference in counts with treatment. Range ofmvc in all
tumours before treatment was 10-35 (median: 17, mean: 17.3) and after treatment was 7-32
(median: 16, mean: 16.3). Data are summarised on Table 2.2.1.
Figure 2.2.2: Microvessel counts before and after









Table 2.2.1: Summary of pre- and post-treatment mvc in all tumours:




Standard deviation 4.77 5.42
Standard error 0.63 0.72




Microvessel counts and response.
Examples of changes in microvessel counts in individual tumours following treatment are
illustrated on Figures 2.2.3 and 4, demonstrating a reduction in mvc following treatment
(Figure 2.2.3) and an increased mvc (Figure 2.2.4). Such changes were correlated with
response.
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Fig 2.2.3 Reduction in microvessel density following tamoxifen
treatment.
a) Low power (xlOO)
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Fig 2.2.4. Increase in microvessel density following tamoxifen treatment
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Pre-treatment mvc: No difference in pre-treatment mvc between non-responding and
responding tumours (p=0.79) was observed, as illustrated in Figure 2.2.5. The range of pre-
treatment mvc in non-responding tumours was 12-21 (mean: 16.6, median: 17) and in
responding tumours was 10-35 (mean: 17.5, median: 17).
Figure 2.2.5: Comparison of pre-treatment mvc in non-




















Standard deviation 3.52 5.13
Standard error 0.94 0.78
Vlann-Whitney test: p=0.79
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Post-treatment mvc: A significant difference in post-treatment mvc between non-
responders (range: 15-27, mean: 19.9, median: 19) and responders (range: 7-32, mean: 15.1,
median: 15) was identified (p=0.0027) and is illustrated on Figure 2.2.6.
Figure 2.2.6: Comparison of post-treatment mvc in non-













Standard deviation 4.07 5.33
Standard error 1.089 0.814
Mann-Whitney test: p=0.0027
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Changes in microvessel count in responding and non-responding tumours following
treatment with tamoxifen.
Responding tumours: There was a significant reduction in mvc in responding tumours
following treatment, as illustrated on Figure 2.2.7 (p=0.0064). The range ofmvc before
treatment was 10-35 (mean: 17.5, median: 17) and after treatment was 7-32 (mean: 15.1,
median: 15).

















Standard deviation 5.13 5.33
Standard error 0.78 0.81
Paired Wilcoxon signed rank test: p=0.0064
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Non-responding tumours: There was a significant increase in mvc in non-responding
tumours following treatment, as illustrated on Figure 2.2.8 (p=0.036). The range ofmvc
before treatment was 12-21 (mean: 16.6, median: 17) and after treatment was 15-27 (mean:
19.9, median: 19).









PRE- POST- (p=0 036)
TREATMENT TREATMENT
Table 2.2.5: Summary of tumour vascularity data for non-responding tumours:




Standard deviation 3.52 4.07
Standard error 0.94 1.089
Paired Wilcoxon signed ranked test: p=0.036
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Changes in microvessel counts with response to primary tamoxifen treatment.
The numbers of patients in whom mvc increased, decreased or remained static are shown on
Table 2.2.6. In order to be defined as a change in mvc, the difference between pre- and post-
treatment counts had to be greater than 10% of post-treatment count, corresponding to the
degree of interobserver variation, as described previously. A clear trend in change of
microvessel count was identified, with an increase in mvc in the majority of non-responding
tumours and a decrease in the majority of responding tumours. It can be observed, however,
that there is a subset of responding tumours (23%) in which mvc increased, and of non-
responding tumours (21.6%) in which mvc decreased with treatment.






Non-responders 8 (57%) 3 (21.5%) 3 (21.5%) 14
Responders 10 (23%) 6 (14%) 27 (63%) 43
Chi-squared test for trend: p=0.0062
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Percentage reduction in tumour volume and change in microvessel count.
Results detailed in this chapter have demonstrated a significant reduction in mvc following
staining with antibody to Factor VIII in responding tumours and an increase in non-
responding tumours. The relationship between extent of tumour response to treatment and
degree of change in vascularity is now addressed. Tumour response is expressed as a
percentage reduction in original tumour volume determined by ultrasound or clinical
assessments as described previously. Five patients in whom response was determined by
mammographic changes alone were excluded from this analysis. The relationship is shown
on Figure 4.11 and demonstrates a significant association between degree of response to




2.2.9: Relationship between % mvc change and
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2.3 Microvessel counts following staining with antibody to CD31.
Sections of all tumours before and after treatment with tamoxifen were stained with antibody
to CD31 in addition to Factor VIII antibody. Some sections failed to stain positively for
antibody to CD31 despite repeated attempts. In sections that were negative, vessels were
visible on the H and E slide, but failed to stain. Staining was unsuccessful in both pre- and
post-treatment sections of 7 tumours, in pre-treatment sections only of 5 tumours and 8 post-
treatment tumours. Results of CD31 staining are detailed in the following section: in sections
that did not stain mvc was taken as zero. Failure of staining may be due to methodological
problems or may occur as a result of tamoxifen treatment. The possible explanations will be
discussed at the end of the chapter.
Ranges of microvessel count following CD31 staining in all tumours before and after
treatment are illustrated in Figure 2.3.1. The range ofmvc before treatment was 0-35 (mean:
14.7, median: 16) and after treatment was 0-28 (mean: 11.9, median: 12). There was a
significant reduction in mvc following treatment in the total study population (p=0.02). The
data are summarised on Table 2.3.1.
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Figure 2.3.1: Microvessel counts before and after









Table 2.3.1: Summary of pre- and post-treatment mvc in all tumours:




Standard deviation 8.99 9.03
Standard error 1.19 1.20










Microvessel counts and response.
Pre-treatment mvc: Pre-treatment mvc in non-responding and responding tumours are
compared in Figure 2.3.2, demonstrating no significant difference between the two groups.
Range ofmvc in non-responding tumours was 0-29 (median: 15, mean: 12.6), and in
responding tumours 0-35 (median: 17, mean: 15.4). Data are summarised on Table 2.3.2.
Figure 2.3.2: Comparison of pre-treatment mvc in non-






Table 2.3.2: Summary of pre-treatment mvc data:







Standard deviation 10.7 8.39
Standard error 2.86 1.28
Mann-Whitney test: p=0.5
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Post-treatment mvc: Post-treatment mvc in non-responding and responding tumours are
compared in Figure 2.3.3, demonstrating no significant difference between the two groups
(p=0.75). Range ofmvc in non-responding tumours was 0-28 (median: 14.5, mean: 11.6),
and in responding tumours 0-28 (median: 12, mean: 11.6). Data are summarised on Table
2.3.3.
Figure 2.3.3: Comparison of post-treatment mvc in non-
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Standard deviation 10.4 8.7
Standard error 2.79 1-32
Vlann-Whitney test: p=0.75
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Changes in microvessel count in responding and non-responding tumours
following treatment with tamoxifen.
Responding tumours: There was a significant reduction in mvc in responding tumours
following treatment with tamoxifen, as illustrated in Figure 2.3.4 (p=0.02). Range of mvc
before treatment was 0-35 (median: 17, mean: 15.4) and after treatment was 0-28 (median:
12, mean: 11.6). Data are summarised in Table 2.3.4.















Table 2.3.4: Summary of tumour vascularity data for responding tumours:




Standard deviation 8.39 8.65
Standard error 1.28 1.32
Paired Wilcoxon signed rank test: p=0.02
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Non-responding tumours: No significant change in mvc with treatment was observed in
non-responding tumours, as illustrated on Figure 2.3.5. Pre-treatment mvc ranged from 0-29
(median: 15, mean: 12.6) and post-treatment mvc ranged from 0-28 (median: 14.5, mean:
12.8). Data are summarised on Table 2.3.5.
Figure 2.3.5: Comparison of pre- and post-treatment mvc
in non-responding tumours.
Table 2.3.5: Summary of tumour vascularity data for non-responding tumours:




Standard deviation 10.7 10.4
Standard error 2.86 2.79
Paired Wilcoxon signed rank test: p=0.68
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Changes in microvessel counts with response to primary tamoxifen treatment.
Numbers of patients in whom mvc increased, decreased or remained static are shown on
Table 2.3.6. Of 14 non-responding tumours, mvc reduced in seven, remained static in four
and increased in three. These findings differ from the trend observed following staining with
antibody to Factor VIII. A similar trend to that observed following Factor VIII staining was
observed in responding tumours: mvc reduced in 26 tumours, remained static in seven and
increased in ten.






Non-responders 3 (21%) 4 (29%) 7 (50%) 14
Responders 10 (23%) 7 (16%) 26 (61%) 43
Chi-squared test for trend: p=0.0062
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Percentage reduction in tumour volume and change in microvessel count.
There was a significant reduction in mvc in responding tumours following staining with
antibody to CD31. Figure 2.3.6 demonstrates no significant correlation between % change in
mvc with treatment and degree of response as determined by ultrasound (r=-0.08, p=0.57).
These results differ from those obtained following staining with antibody to Factor VIII,
which demonstrated a correlation between the two of borderline statistical significance.
Figure 2.3.6: Relationship between degree of ultrasound response
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Intensity of staining with antibody to CD3L
The staining intensity with antibody to CD31 varied between tumours and in 27 tumours
(18% of total) sections persistently failed to stain despite repeating attempts on at least two
occasions. Results described included sections which did not stain, in which microvessel
counts were zero. In 7 patients, both pre- and post-treatment sections failed to stain, in 5
patients, pre-treatment sections only failed to stain and in 8, post-treatment sections only did
not stain. Of the 8 post-treatment sections failing to stain, 7 occurred in responding tumours.
As the variation in staining intensity was thought to be due to methodological problems,
analyses were performed excluding those patients in whom one or both of pre- and post-
treatment tumours did not stain. Results obtained were not significantly different from those
described. There was a significant difference in mvc following treatment in all patients
(p=0.016) and in pre- and post-treatment mvc of responding tumours (p=0.04). Otherwise no
differences were identified between responding and non-responding tumours as has been
detailed in the previous section.
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2.4 Comparison of counts performed following staining with
Antibody to Factor VIII versus CD31 antibody.
Counts obtained following staining with antibody to Factor VIII and CD31 in the present
study were compared. Both pre- and post-treatment mvc were included in the comparison.
The relationship is illustrated on Figure 2.4.1 and demonstrates a statistically significant
correlation between counts (r=0.21, p=0.01). Data are summarised on Table 2.4.1. When the
sections which failed to stain with antibody to CD31 were excluded from the analysis, the
correlation between counts was highly statistically significant (r=0.4, p<0.0001).
Figure 2.4.1: Comparison of counts performed following
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Table 2.4.1: Comparison of counts obtained following staining with Factor VIII and
CD31 antibodies.




Standard deviation 5.11 8.91
Standard error 0.48 0.84
Spearman correlation: r=0.21, p=0.01











2.5 Microvessel counts and other tumour parameters.
Further analyses were performed to determine whether correlations existed between
microvessel counts and lymph node involvement or level of oestrogen expression, factors
which may affect tumour vascularity or response to treatment. Due to the failure of antibody
to CDS 1 to stain vessels in a number of tumours, results in this section were based on
staining with Factor VIII antibody
Lymph node involvement.
52 of the 57 patients underwent pathological assessment of lymph nodes. Five patients
underwent surgery to the breast alone. The reasons for this were not clear on review of
casenotes, but are likely to be due to the poor general medical condition of these patients.
A total of 23 patients underwent axillary node sampling (6 non-responders and 17
responders) and 29 patients underwent axillary node clearance (7 non-responders and 22
responders). For the purpose of analysis, percentage of excised lymph nodes found to be
positive for tumour was used to define lymph node involvement, as this took account of
number of lymph nodes excised. Figure 2.5.1 illustrates the relationship between % lymph
node involvement and response to tamoxifen. Median values of % lymph node involvement
were 6% in non-responders and 3% in responders. The difference between the two groups
was not significant (p=0.61).
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Standard deviation 171 43.6
Standard error 27.4 12.6
Mann-Whitney test: p=0.61
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Lymph node involvement and microvessel counts.
Relationships between % lymph node involvement and tumour vascularity assessments are
illustrated on Figures 2.5.2-4. There was no significant correlation between pre-treatment
and % lymph node involvement as shown on Figure 2.5.2 (r=0.02, p=0.89). A significant
correlation was identified between post-treatment mvc and % lymph node involvement
(r=0.34, p=0.015), as shown on Figure 2.5.3. Both parameters reflect the tumour status
following tamoxifen treatment. The correlation remained significant when expressed as %
change in mvc following treatment and % lymph node involvement (r=-0.31, p—0.03) as
shown on Figure 2.5.4, although this was less significant and so is likely to reflect the
association between post-treatment mvc and lymph involvement.
Figure 2.5.2: Relationship between % lymph node
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Figure 2.5.3: Relationship between % lymph node
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Figure 2.5.4: Relationship between % lymph node
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Levels of ER expression.
Pre-treatment oestrogen receptor levels (ER), assessed by biochemical methods, were
available in all tumours and were initially compared with tumour response to treatment, as
illustrated in Figure 2.5.5. Range of ER level in non-responding tumours was 25-
673fmol/mg cytosolic protein (median: 111, mean: 180) and in responding tumours the range
was 25-1496 ffnol/mg cytosolic protein (median: 357, mean: 450). The difference between
the two groups was statistically significant (p=0.0074).

























Standard deviation 195 389
Standard error 52 59
Mann-Whitney test: p=0.0074
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ER levels and microvessel counts.
The relationship between ER level and pre-treatment mvc is illustrated on Figure 2.5.6,
demonstrating no significant association between the two variables (r=-0.1, p=0.46). Both
mvc and ER level were determined from the pre-treatment tumour sample, allowing
comparison of the two variables at the same time point.
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No significant association was demonstrated between ER level and % change in mvc, as
illustrated in Figure 2.5.7.
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2.6 Assessment of patients treated with tamoxifen for longer than
six months.
15 patients underwent a longer period of treatment with neoadjuvant tamoxifen. The period
of treatment ranged from 7 to 30 months (median: 10, mean: 11.8). Patients in this group had
locally advanced disease with skin or muscle involvement or malignant ipsilateral axillary
lymph nodes and response patterns varied when compared with the main group. In seven
patients there was no evidence of response, three of these developed progressive disease;
tumours in six patients responded initially, but then progressed, and in two patients response
was maintained throughout treatment (7 and 9 months). For the purpose of the analysis, the
response pattern of the tumour at the time of excision defined response: thus 13 are classified
as non-responders, 2 as responders. Pre- and post-treatment mvc in non-responding and
responding tumours are illustrated in Figure 2.6.1. Despite the complexity of the response, a
similar pattern of change in mvc was seen in this subgroup as that observed in the main
study.
Figure 2.6.1: Pre- and post-treatment mvc in patients









Table 2.6.1: Correlation of change in microvessel counts with treatment response:
Increased mvc Mvc static Decreased mvc TOTAL
Non-responders 8 3 1 12






2.7 Changes in tumour vascularity in patients treated with
neoadjuvant letrozole.
Letrozole is an aromatase inhibitor and offers an alternative strategy for primary endocrine
therapy to tamoxifen. Twenty-two patients were treated with letrozole for three months prior
to surgery and following a wedge biopsy for determination ofER status. Changes in tumour
vascularity have been determined in these tumours to provide comparison with the effects of
tamoxifen.
Twenty-one of the twenty-two patients responded to letrozole, with percentage reductions in
tumour volume ranging from 33 to 96% (median: 70%, mean: 70.1%). Changes in mvc with
response are illustrated in Figure 4.29, demonstrating a clear trend for reduced mvc in
responding tumours and an increase in the non-responder. This just failed to reach statistical
significance due to small numbers (p=0.09).
















Correlation of changes in nivc with response to letrozole.
Numbers of patients with responding tumours in whom mvc decreased, increased or
remained static are shown on Table 2.7.1. There was a reduction in mvc with treatment in the
majority (67%) of patients with responding tumours, mvc increased in the non-responding
tumour. The trend of change in mvc with response just failed to reach statistical significance
(p=0.09), this is likely to be due to the small number of non-responding tumours in the
group. The relationship between % reduction in tumour volume and % change in mvc with
treatment is shown on Figure 4.30 and demonstrates no significant association between the
two.
Table 2.7.1: Changes in mvc observed in patients treated with letrozole:
Increased mvc Mvc static Decreased mvc
Responders 5 (24%) 2 (9%) 14 (67%)
Non-responder 1 (100%) 0 0
Figure 2.7.2: Relationship between % change in mvc and
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2.8 Discussion.
Fifty-seven post-menopausal patients with large, operable or locally advanced ER-positive
primary breast cancer were treated with tamoxifen (20mg daily) for a period of between
three and six months prior to surgery. Forty-three patients (75%) responded to tamoxifen
with a greater than 25% reduction in tumour volume following treatment.
Assessments of tumour vascularity were made before and after treatment following staining
with Factor VIII and CD31 antibodies on sequential tumour sections. Staining with antibody
to CD31 varied in intensity between tumours with negative staining in 27 (18%); therefore,
for completeness, discussion of the results will focus mainly on counts obtained following
staining with antibody to Factor VIII. Possible explanations for the variation in intensity of
CD31 staining will be addressed. Results of this study showed no difference in pre-treatment
mvc between non-responding and responding tumours, indicating that the two groups were
similar in terms of tumour vascularity at the outset. There was, however, a significant
increase in post-treatment mvc in non-responding compared to responding tumours. When
pre-and post-treatment mvcs were compared in responding tumours, there was a significant
reduction in mvc following treatment. In non-responding tumours, treatment with tamoxifen
was associated with increased mvc. There was a significant association between post-
treatment mvc and % lymph node involvement and between % change in mvc and lymph
node involvement. No significant associations were found between microvessel counts and
level of ER expression.
Intensity of staining with antibody to CD31 varied between tumours, which had not been
apparent following staining with antibody to Factor VIII. Twenty-seven tumours (24%)
failed to stain despite repeated attempts on sequential sections: in 7 tumours both pre- and
post-treatment sections failed to stain, 5 pre-treatment sections and 8 post-treatment sections
failed to stain. In all of these tumours, vessels were identified on the H and E sections. It is
of interest to note that, of the post-treatment sections failing to stain, 7 of the 8 were
responding tumours. Whilst this suggests that tamoxifen treatment may result in a reduction
in expression of the CD31 antigen (platelet endothelial cell adhesion molecule), failure of
staining of pre-treatment sections suggests that a methodological problem is the more likely
cause of the absence of staining. All sections were routinely processed in the pathology
laboratory and sections that failed to stain did not correspond to those processed during a
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specific period. Failure of a percentage of tumour sections to stain with CD31 antibody has
been noted in another study which described an 87% success rate, with failure of staining
attributed to antigen loss following tumour fixation (Martin et al, 1997). As the present study
is a retrospective one, involving retrieval of tumour sections from pathology archives dating
from 1990 to 1996, antigen loss due to prolonged storage is a possible explanation for
negative staining. Factor VIII antibody stains more consistently than CD31, but also stains
lymphatics (Horak et al, 1992; Martin et al, 1997). It has, however, been shown to provide
useful prognostic information in a number of studies of breast cancer (Bosari et al, 1992; Toi
et al, 1993; Weidner et al, 1992) and so has been used in addition to CD31 antibody in the
present study.
Having defined a microvessel as any single stained endothelial cell or cell cluster, for those
sections in which there was no staining with antibody to CD31 counts were taken as zero.
Microvessel counts performed following staining with CD31 revealed a significant reduction
in mvc following treatment with tamoxifen in responding but not non-responding tumours, in
keeping with the previously described findings. However, no increase in mvc was observed
in non-responding tumours following treatment.
Due to the disparity of staining patterns between sections stained with Factor VIII and CD31
antibody in this group of tumours, a direct comparison was made between counts obtained
for all tumours (n=l 14). There was a highly significant correlation between counts,
supporting findings described earlier in the thesis. Whilst counts obtained following Factor
VIII staining (mean: 16.8, median: 16) tended to be higher than those following staining with
CD31 (mean: 13.6, median: 14), no significant trend was observed (p=0.33). These
differences are likely to reflect the presence of negatively staining sections in the CD31
group.
The response rate of 75% in the present study compared favourably with other studies (Allan
et al, 1985; Anderson et al, 1991; Horobin et al, 1991), although an unconventional
definition of response was used in the present study. The conventional method of assessment
of tumour response adopts clinical measurements and is defined as a greater than 50%
reduction in tumour volume maintained for at least one month. This definition was based on
assessment of response in the context ofmetastatic disease and would not be practical in this
study, in which patients are treated for three months alone. Ultrasonography is simple to
perform, provides a permanent record of tumour size and may be carried out frequently, in
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contrast to mammography. Ultrasound tumour volume assessments have been found to
correlate more closely with pathological tumour size than clinical measurements (Forouhi et
al, 1994), thus providing a practical and accurate method ofmonitoring response. Observer
variation in volume assessed by ultrasound is less than 10% and thus a definition of response
as >25% reduction in volume indicates a true reduction in volume that cannot be explained
by observer variation alone (Forouhi et al, 1994). In addition, a cut-off of >50% reduction in
tumour volume would have excluded patients from the responding group whose clinical
management had been altered by treatment, rendering tumours amenable to conservation
surgery instead ofmastectomy. It was for these reasons that a cut-off point of >25%
reduction in tumour volume was adopted in the present study to define a responding tumour,
although the continuous variable of percentage tumour volume reduction was also used in
the analysis.
Changes in tumour vascularity in association with response to primary tamoxifen therapy
have not been previously investigated in the clinical setting. However, the finding of a fall in
mvc observed in responding but not non-responding tumours is in keeping with experimental
evidence that oestrogen deprivation causes reduced vascularity (Morales et al, 1995;
Sypridopoulos et al, 1997), and that tamoxifen may exert an anti-angiogenic effect
(Gagliardi et al, 1995). In the present study, whilst a reduction in mvc was observed in the
majority (63%) of responding tumours, there was a subgroup (22%) in whom mvc increased.
This disparity may reflect the problems inherent in observing a dynamic process at a single
time point. Angiogenesis is stimulated by tissue hypoxia (Hlatky et al, 1994), which may
occur for a period of time within a responding tumour. This provides a possible explanation
for the increased mvc detected in 22% of responding tumours following treatment. In
addition, previous surgical manipulation of the tumour is likely to stimulate angiogenesis as
part of the process ofwound healing; the duration of such an effect is unknown.
The pattern of change in tumour vascularity observed in non-responding tumours is also of
interest; mvc increased in the majority (57%) of these tumours, with counts remaining static
in only 3 tumours (21.5%) and decreasing in a further 3 tumours. It is recognised that
increasing tumour vascularity is a component of untreated tumour growth; a switch to the
angiogenic phenotype is accompanied by rapid tumour growth and progression (Hanahan &
Folkman, 1996). Oestrogen exerts a pro-angiogenic effect and it has been suggested that,
under certain conditions such as low concentration, tamoxifen may act as an oestrogen
agonist (Osborne et al, 1992). Thus it is possible that tamoxifen may actually stimulate
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angiogenesis in some non-responding tumours. Such increases in vascularity may also reflect
the development of a resistant phenotype. However, the increased mvc observed in the
majority of non-responding tumours may simply reflect methodological issues, such as the
effect of previous surgical manipulation and tumour heterogeneity. These issues have been
addressed elsewhere in the thesis.
Information about pathological lymph node status was available in 90% of patients in the
study. No correlation was found between % lymph node involvement and response, or
between % lymph node involvement and pre-treatment mvc. This is unexpected as
microvessel counts have been found to provide independent information regarding lymph
node metastasis in primary breast cancers treated surgically (Horak et al, 1992). The
significant correlations between % lymph node involvement and both post-treatment mvc
and % change in mvc are interesting, particularly in the light of the lack of correlation with
pre-treatment assessments of angiogenesis. Correlation of lymph node involvement and post-
treatment mvc is slightly more significant (p=0.015) than the correlation with % mvc change
(p=0.027), suggesting that it is post-treatment mvc which is more influential. Post-treatment
mvc and pathological lymph node status were both determined at surgery and so reflect the
nature of the tumour at the same time point. Clinical assessment of lymph node status is
unreliable and therefore accurate knowledge of lymph node status prior to neoadjuvant
treatment is not available. Thus, the effect of tamoxifen on involved lymph nodes is not
known, but it is possible that, in responding tumours, tamoxifen may render some initially
positive lymph nodes free from tumour.
There was a significant correlation between level of oestrogen receptor (ER) expression and
response (Figure 2.5.5) which supports findings of other studies (Gaskell et al, 1992;
Osborne et al, 1980). The lack of association between ER levels and pre-treatment mvc or %
mvc change is worthy of note. The possible mechanisms of action of tamoxifen on tumour
vascularity have not been addressed in this study as observations of change in vascularity
have been made at an individual time point at the end of the treatment course. It has been
suggested that tamoxifen may exert an anti-angiogenic effect independent of the oestrogen
receptor (Gagliardi & Collins, 1993) and the lack of correlation between mvc and ER
supports this finding. However, it must be noted that all ER-negative and ER-poor tumours
were excluded from the present study.
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In order to determine whether such changes in vascularity were specific to tamoxifen, a
control group of 22 patients with tumours treated with the aromatase inhibitor, letrozole, was
also studied. Although the patient number is small, precluding extensive analysis, a similar
pattern of change in mvc in responders and non-responders was seen. There is no
experimental evidence to suggest that letrozole exerts a direct anti-angiogenic effect,
suggesting that observed changes in tumour vascularity may be a reflection of either
oestrogen deprivation or a component of tumour response to any form of systemic therapy.
'
'v I",
One of the shortcomings of the study is that all observations were made at the end of the
period of neoadjuvant therapy, when clinical response to treatment was already apparent.
Whether the observed changes in vascularity occur as a result of tumour response, or precede
it and contribute to the process of response, cannot be ascertained.
These studies have identified a significant correlation between tumour response to primary
endocrine therapy and changes in tumour vascularity. The timing of such changes cannot be
assessed using the current study design. If such changes occurred early in treatment, they
may provide a useful early predictor of response, which would be of great value in the
clinical setting. This issue is addressed in the later studies within this thesis.
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3. Chronology of changes in tumour vascularity and
response to tamoxifen: a study of breast cancer xenografts.
Results described in the previous chapter demonstrated a change in tumour vascularity in
association with response to primary tamoxifen treatment. A reduction in microvessel
density was observed in responding tumours and an increase non-responding tumours. Such
changes were observed after between three and six months of primary endocrine treatment,
when clinical response was already apparent. It would be of benefit in the clinical setting if
such changes predated clinical evidence of response when they would provide a predictive
marker of sensitivity to hormone therapy.
The aim of the present series of experiments was to determine the chronology of changes in
tumour vascularity relative to tumour response to tamoxifen. In order to achieve this aim
xenograft model systems have been studied, allowing accurate monitoring of changes in
tumour volume and assessments of tumour vascularity at several time points.
Experiments were performed involving the oestrogen receptor-positive breast cancer cell
line, ZR-75, and the oestrogen receptor-negative breast cancer cell line, MDA-MB-231.
Tumours were implanted into the flanks of nude mice bearing slow release oestrogen pellets
and were randomly allocated into treatment and control groups. Slow-release tamoxifen
pellets (0.25mg over 60 days) were inserted alongside tumours of animals in the treatment
groups.
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Tumours were excised from animals at the time points described in Table 3.1, allowing
assessment of tumour vascularity on 2, 4, 7 and 14 days following commencement of
tamoxifen.
Table 3.1: Number of tumours excised at each time point:
DAY 0 2 4 7 14
ZR-75:
control
4 0 0 4 0
ZR-75:
T reated
0 4 4 4 0
MDA-MB-
231: control
4 0 0 4 5
MDA-MB-
231:treated
0 4 4 4 4
Response data on tumours are expressed as the mean relative tumour volume for each time
point before and during treatment. Tumour volumes were calculated according to the
equation:
7c/6. d xD2 where D is the larger of the two diameters.
Tumour volume for each time point was calculated relative to the volume at day 0, and
expressed as a percentage of this. Mean relative tumour volumes were calculated for each
group and these were used in the analysis.
Microvessel counts were performed on tumour sections excised after 2, 4,7 and 14 days of
treatment following staining with the endothelial cell marker, MEC 13.3, and compared with
counts in tumours from the control groups.
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3.1. Tumour growth: ZR-75 xenografts.
The growth curve of ZR-75 tumours in the treatment and control groups is illustrated on
Figure 3.1.1. Tumour volume is expressed as a percentage of the volume at day 0 (100%)
and demonstrated no difference between the two groups prior to commencement of
tamoxifen. A progressive increase in size was observed in both the control and treated
tumours until day 4, following which evidence of tumour regression became apparent in the
treated tumours. Differences in mean relative tumour volume between treated and control
tumours failed to reach statistical significance. Mean relative tumour volumes at each time
point are outlined in Table 3.1.1, with details of individual tumour volume described in the
Appendix to this chapter.
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Table 3.1.1: Mean relative tumour volume of treated and control ZR-75 tumours,
expressed as a percentage of volume at Day 0: (+/-standard error ofmean)
ZR-75 DAY -12 DAY -5 DAYO DAY 2 DAY 4 DAY 7













Tumour volume at Day 2: treated v. control groups: p=0.73
Tumour volume at Day 4: treated v. control groups: p=0.28
Tumour volume at Day 7: treated v. control group: p=0.11
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3.2. Tumour growth: MDA-MB-231 xenografts.
The growth curve of treated compared with control MDA-MB-231 tumours is illustrated on
Figure 3.2.1 and shows that the growth curves follow a very similar pattern in the two groups
throughout treatment. There was no evidence of tumour regression in either treated or
control group in contrast to the ZR-75 tumours. Data are summarised on Table 3.2.1.
Figure 3.2.1: Lack of anti-tumour effect of tamoxifen on MDA






























Table 3.2.1: Mean relative tumour volume at each time point of treated and control
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Mann-Whitney tests: Tumour volume at Day 2: treated v. control groups: p=0.34
Tumour volume at Day 4: treated v. control groups: p=0.13
Tumour volume at Day 7: treated v. control group: p=0.72
Tumour volume at Day 10: treated v. control group: p=0.91
Tumour volume at Day 14: treated v. control group: p=0.91
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3.3. Microvessel counts in treated and control ZR-75 xenografts.
Microvessel counts were performed on all tumours in treated and control groups following
staining with MEC 13.3, the murine equivalent of antibody to CD31. The majority of vessels
were situated at the periphery of the tumours as illustrated on Figure 3.3.1. Mean
microvessel counts (mvc) in treated versus control tumours are shown on Figure 3.3.2,
demonstrating a progressive reduction in mvc during tamoxifen treatment. This was already
apparent following two days of treatment (p=0.03). It should be noted, however, that the
difference in mvc between treated and control tumours at day 7 was not significant (p=0.32).
Data are outlined in Table 3.3.1.
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Fig 3.3.1. Treated ZR-75 tumour following staining with MEC13-3
antibody
'31
Figure 3.3.2: Changes in microvessel count in ZR-75 breast
cancer xenografts during treatment with tamoxifen.
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Table 3.3.1: Microvessel counts in treated and control ZR-75 tumours at different time
points:






























MEAN 16 3.8 6.6
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Mann-Whitney tests:
Microvessel counts: Day 2 treated v. Day 0 control: p=0.027
Day 4 treated v. Day 0 control: p=0.0021
Day 7 treated v. Day 0 control: p=0.00082
Day 0 control v. Day 7 control: p=0.13
Day 7 treated v. Day 7 control: p=0.32
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3.4. Microvessel counts in treated and control MDA-MB-231
tumours.
Staining ofMDA-MB-231 tumour sections with MEC13.3 antibody is illustrated in Figure
3.4.1. Microvessel counts in treated and control tumours are compared in Figure 3.4.2,
demonstrating no significant difference between the two groups or between Day 0 control
and treated tumours. Microvessel counts appeared to decrease in control tumours compared
with treated tumours, but the difference was not significant (p=0.73). Data are outlined on
Table 3.4.1.
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a) At day 0
I34>
Figure 3.4.2: Comparison ofmicrovessel counts in treated and
control groups of MDA-MB-231 tumours.




















Table 3.4.1: Comparison of microvessel counts in treated and control MDA-MB-231
tumours:































MEAN 18.75 4.5 9
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2 treated v. Day 0 control: p=0.49
4 treated v. Day 0 control: p=0.69
7 treated v. Day 0 control: p=0.69
14 treated v. Day 0 control: p=0.49
0 control v. Day 7 control: p=0.63
0 control v. Day 14 control: p=0.91
7 treated v. Day 7 control: p=0.4
14 treated v. Day 14 control: p=0.73
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3.5. Comparison of microvessel counts in ZR-75-1 and MDA-MB-
231 tumours during treatment with tamoxifen.
Figure 3.5.1 illustrates microvessel counts in ZR-75-1 compared with MDA-MB-231
tumours during treatment with tamoxifen, and demonstrates a reduction in mvc at Day 2 in
ZR-75 tumours but not in MDA-MB-231 tumours. Microvessel counts in pre-treatment ZR-
75 tumours were higher than MDA-MB-231 (p=0.03), reflecting differing characteristics of
the tumour types.
Figure 3.5.1: Comparison of microvessel counts in treated ZR
75 and MDA-MB-231 tumours.
□ MDA-MB-231
* ZR-75




Microvessel counts: ZR-75-1 v. MDA-MB-231 tumours: Day 0: p=0.029
Day 7: p=0.34
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3.6, Chronology of changes in microvessel count relative to tumour
volume.
Figure 3.6.1 compares timing of changes in mvc and relative tumour volume during
treatment with tamoxifen of ZR-75 xenografts. Microvessel counts are expressed as a
percentage ofmvc at Day 0. The figure demonstrates that the reduction in mvc occurred as
early as two days into treatment with tamoxifen, whereas tumour regression only became
apparent after four days. Figure 3.6.2 demonstrates a similar comparison of changes in
MDA-MB-231 tumours during tamoxifen treatment and illustrates the lack of effect of
tamoxifen on both tumour growth and microvessel counts.
Figure 3.6.1: Graph to demonstrate timing of changes in relative
tumour volume and microvessel counts in ZR-75 xenografts.
DAYS OF TREATMENT
Figure 3.6.2: Graph to demonstrate timing of changes in relative




A clear association between change in tumour vascularity and response to neoadjuvant
endocrine therapy in primary breast cancers was demonstrated in patients treated with
tamoxifen, with a reduced vascularity in responding tumours and an increased vascularity in
non-responding tumours. The aims of the present study were to confirm that changes in
tumour vascularity occurred in association with response to primary tamoxifen treatment
using a xenograft model system and to determine the chronology of such changes relative to
response.
The ER-positive ZR-75 breast cancer xenografts demonstrated a clear regression of tumour
volume between four and seven days following commencement of treatment with tamoxifen,
compared with control tumours, although the differences were not significant, probably due
to small numbers. Such an effect was not observed in the ER-negative MDA-MB-231
xenografts, in which similar growth rates were observed in treated and control tumours.
Microvessel counts (mvc) were performed following staining with MEC 13.3, the murine
equivalent of antibody to CD31, at several time points during tamoxifen treatment. There
was a significant reduction in mvc following 2 days of treatment of ZR-75 tumours
compared with counts of Day 0 control tumours (p=0.03). Microvessel counts in this group
continued to decrease throughout the duration of the experiment (7 days). Although there
was a fall in mvc in control tumours observed at Day 7 compared with Day 0, this difference
was not significant and only three tumours were available for assessment as Day 7 controls.
There was no difference in mvc between treated and control groups of MDA-MB-231
tumours, with a tendency for mvc to increase in treated tumours. This reflects similar
changes to those described in primary breast cancers, with an increased mvc in non-
responding tumours. The lack of response in the ER-negative tumours is interesting as it has
been suggested that tamoxifen may exert a direct anti-angiogenic effect, independent of its
action as an ER-antagonist (Gagliardi & Collins, 1993). These findings showed that
tamoxifen failed to exert an anti-angiogenic effect on the ER-negative MDA-MB-231
tumours.
Comparison ofmvc in ZR-75 and MDA-MB-231 tumours demostrated a higher pre-
treatment mvc in the ZR-75 tumours (p=0.029). This is likely to reflect a difference in
angiogenic profiles between the two tumours. In the clinical setting, there is marked
variation in mvc between different tumours, and mvc has been shown to provide independent
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significant prognostic information in breast cancer (Fox et al, 1994). ER-positive ZR-75
tumours are likely to be less aggressive than ER-negative tumours and so would be expected
to have a lower pre-treatment mvc. However, the opposite was demonstrated in this study.
The relative timing of changes in tumour growth and vascularity in the ZR-75 tumours are of
interest. Reduction in mvc had reached statistical significance by day 2, whereas tumour
regression only became apparent in the period between 4 and 7 days of treatment. These
changes suggest that reduction in vascularity does indeed precede tumour regression and
may be an early marker of sensitivity to primary endocrine therapy.
Results of this study were similar to those found in another study performed in the
Edinburgh Breast Unit (Cameron et al, 1996). In this study, the same antibody was used on
frozen sections, and required immunofluorescence for antibody visualization. This prohibited
the use of a standard counting method such as the Chalkley count described in the present
study. In addition, in the previous study, the majority of vessels counted lay within the
central area of tumour, whereas in the present study, vascular 'hot spots' were found mainly
at the periphery. Nevertheless, a reduction in mvc was observed in this previous study
following 2 days of treatment ofZR-75 tumours with tamoxifen, but not in the MDA-MB-
231 tumours (Cameron et al, 1996). As in the present study, such changes preceded tumour
regression.
Other studies investigating the effect of tamoxifen on vascularity in breast cancer xenografts
have demonstrated similar results, but tumours were not assessed at early time points.
Changes in mvc have been demonstrated concomitant with tumour regression (Furman-
Haran et al, 1994; Lindner & Borden, 1997). In one study of MCF-7 breast cancer
xenografts, tumour growth was stimulated by oestrogen alone or inhibited with tamoxifen
following removal of the oestrogen pellet (Furman-Haran et al, 1994). A third group was
treated with placebo following removal of the oestrogen pellet, but assessments of
endothelial cell density were not performed in this group. Tumour growth arrest was
observed after one week in the tamoxifen-treated group and tumour regression was seen
following two weeks of treatment. Microvessel counts were performed following two weeks
of treatment and were reduced in the tamoxifen treated group. However, as the oestrogen
pellet was removed at the time of insertion of tamoxifen, such changes may be due to a
combination of removal of oestrogen stimulation and tamoxifen inhibition (Furman-Haran et
al, 1994). In this study, patterns of endothelial cell growth similar to those observed in the
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present study were described, with larger vessels at the periphery (Furman-Haran et al,
1994).
In a similar study ofMCF-7 xenografts, treatment with tamoxifen for ten weeks resulted in a
reduction in the number of vessels by 68% and inhibition of tumour growth by 67% (Lindner
& Borden, 1997). Changes in vessel count in treated tumours were observed following 48
hours of treatment and reached statistical significance by 4 days. Inhibition of angiogenesis
was observed prior to tumour regression, in keeping with the findings of the present study.
Changes in tumour growth and vascularity in MCF-7 tumours were compared with the
oestrogen-independent NIH-OVCAR-3 ovarian cancer cell line. In the latter tumours,
angiogenesis was also effectively inhibited by tamoxifen, suggesting that inhibition of
angiogenesis may have occurred independently of the oestrogen receptor (Lindner &
Borden, 1997). Reduced angiogenesis and tumour volume were observed much later in the
NIH-OVCAR-3 ovarian tumours than the MCF-7 tumours. This contrasts with findings of
the present study, in which there was no apparent reduction in tumour volume or vascularity
in ER-negative tumours over a period of two weeks' treatment.
In summary, this study of breast cancer xenografts treated with tamoxifen demonstrated
tumour regression in ER-positive ZR-75 tumours, but not in ER-negative MDA-MB-231
tumours. Microvessel counts were reduced in ZR-75 tumours following 2 days of tamoxifen
treatment and preceded evidence of growth arrest or tumour regression. There was no
reduction in the mvc of MDA-MB-231 tumours. These results suggest that reduction in
tumour vascularity is an early event in the process of response to tamoxifen and that it may
provide an early marker of sensitivity to primary endocrine treatment.
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4. Sequential changes in tumour vascularity during
treatment with tamoxifen: a prospective study.
Results in this thesis have demonstrated changes in tumour vascularity during response to
primary endocrine treatment. Xenograft studies have suggested that these may occur early
during treatment and thus may provide a useful marker of response prior to clinical evidence.
In an earlier chapter, problems with reproducibility of tumour vascularity assessments in
small tumour biopsies were demonstrated, which may not necessarily be problematic if the
magnitude of effect of primary treatment on vascularity is sufficiently great. The aim now is
to determine whether changes in tumour vascularity detected early in treatment can provide a
useful marker of response before this becomes clinically apparent. Results of a prospective
study are described, in which patients underwent tumour biopsies early during treatment.
Fifty-five patients with large, operable or locally advanced breast cancer were recruited into
this prospective study. Patients underwent an initial core biopsy to obtain a diagnosis and
determination of oestrogen receptor (ER) level. They were then commenced on tamoxifen
(20mg daily) for a period of three months. Following two weeks of tamoxifen treatment core
biopsies were repeated. Patients were monitored with monthly clinical and ultrasound
assessments of tumour volume. In addition nine of the fifty-five patients were assessed by
serial colour Doppler ultrasound, which provides a non-invasive method of assessing tumour
vascularity. Forty-two patients completed the study: reasons for the failure of completion in
thirteen patients are described later.
Response data of these patients were based on changes in clinical and ultrasound
assessments of tumour volume during treatment and tumour vascularity was assessed by
microvessel counts performed following staining with antibody to CD31 and Factor VIII.
Relationships between response and tumour vascularity data were determined. In addition,
lymph node involvement and level of oestrogen expression was correlated with response and
with microvessel counts. Finally, data available in nine patients who underwent sequential
colour Doppler ultrasound scans throughout treatment were described.
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4.1. Clinical assessment of tumour response to tamoxifen.
Patients were assessed following treatment with tamoxifen for two, six and twelve weeks.
Tumour volume was assessed by clinical caliper and ultrasound measurements of
anteroposterior and transverse diameters and depth. In addition, mammography was
performed before and after three months of treatment. Ultrasound assessments of tumour
volume have been found to provide most accurate information as described previously.
Therefore, in those patients with three available ultrasound measurements of tumour volume,
percentage reduction in tumour volume was calculated from these (n=36). In six patients
such information was not available: one patient had an ulcerating tumour, which precluded
use of ultrasound. In three of these patients, clinical assessments only were available for each
time point, because of technical problems with the ultrasound scanner. In another two
patients, casenotes were not available, so tumour response had to be assessed based on
mammographic evidence.
Examples of serial ultrasound assessments of a responding tumour are illustrated on Figure
4.1.1 and mammographic evidence of response is shown on Figure 4.1.2. Serial changes in
tumour volume in all patients are shown on Table 4.1.1, demonstrating a wide range of
response to tamoxifen over three months. The median reduction in tumour volume at six
weeks was 11% (mean: 25%) and at 12 weeks was 46% (mean 40%) for all patients.
A responding tumour was defined as one in which there was a greater than twenty-five
percent reduction in tumour volume at three months on ultrasound assessment (US). Those
patients in whom clinical data alone was available (CLIN), response was defined as a greater
than twenty-five percent reduction in clinical tumour volume. A similar definition was
adopted in two patients assessed by mammography (MAMMO). Figure 6.2 illustrates mean
serial reduction in tumour volume in non-responding and responding tumours. Mean tumour
volumes, expressed as a percentage of the original tumour volume, were 97% in non-
responding tumours at six weeks and 99% at 12 weeks. In responding tumours,
corresponding values were 66.6% and 42%. Details of tumour volume measurements are
described in the Appendix.
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Fig 4.1.1. Serial ultrasound
assessments of tumour volume,
demonstrating reduced tumour
volume during treatment with
tamoxifen.
Tumour dimensions are shown -!-
a) Following two weeks of treatment
b) Following six weeks of treatment
iaa
c) Following twelve weeks of treatment
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Fig 4.1.2. Mammographic evidence of tumour response
a) Before treatment
b) After three months of
tamoxifen treatment
14-S
Table 4.1.1: Changes in relative tumour volume during treatment with tamoxifen.
Where tumour volumes are expressed at each time point as % original volume.








615724L 100 100 121 Decrease US
614905K 100 100 86 Decrease US
296162H 100 100 117 Increase us
143050M 100 100 108 Reduction us
341122W 100 100 81 NA us
624169K 100 100 100 static us
558811X 100 99 100 NA us
422318K 100 100 100 increase CLIN
628483V 100 100 115 static US
D077978R 100 59 88 NA us
629111W 100 100 92 static us
100 100 Static MAMMO
201525A 100 100 100 Static US
625691A 100 100 80 Reduction us
639991L 100 97 75 NA CLIN
120288B 100 89 64 Static US
612031H 100 60 23 NA CLIN
614905K 100 27 22 Decrease US
631385B 100 40 41 Decrease. us
628989R 100 100 37 reduction us
495945A 100 83 45 reduction us




645382X 100 100 50 us
622149X 100 100 23 reduction us
D345548V 100 100 42 reduction us
614975H 100 50 58 reduction us
640026R 100 74 34 static us
639575E 100 100 100 reduction MAMMO
638318X 100 73 51 static US
637345V 100 54 41 reduction us
637357K 100 44 64 static us
84321A 100 44 35 reduction CLIN
643001M 100 52 100 not seen US
484933K 100 100 54 NA us
266308W 100 26 25 Reduction us
622926V 100 49 7 NANA us
625368K 100 100 75 Static us
D528581B 100 48 54 NA us
10046V 100 23 20 Reduction us
629740R 100 25 13 Reduction us
626230E 100 39 25 NA us
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Figure 4.1.3: Mean serial changes in tumour volume with tamoxifen
treatment in non-responding and responding tumours.
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Overall numbers of patients with non-responding and responding tumours are outlined in
Table 4.1.2, demonstrating an overall response rate of 67%.





4.2. Microvessel counts following staining with antibody to Factor
VIII.
Core biopsies of tumour were taken before and following two weeks of treatment with
tamoxifen. Tumour was available following treatment for three months in the form of repeat
biopsies or surgical excision. Fifty-five patients were recruited into the study: of these, 10
patients refused second biopsies and three died during the course of treatment. Thus 42
patients completed the study. Assessments of tumour vascularity were made by performing
microvessel counts (mvc) in three areas of high vascularity in all tumours before, during and
after three month' treatment with tamoxifen. Endothelial cell staining was performed using
immunohistochemical techniques as previously described. Sequential tumour sections were
stained with two endothelial cell antibodies: antibody to Factor VIII (von Willebrand factor)
and antibody to CD31. Results obtained using each antibody will be described separately. In
addition, a subset of nine patients underwent serial monitoring with colour Doppler
ultrasound, providing further information on change in tumour vascularity. Microvessel
counts following staining with antibody to Factor VIII will be considered first.
Ranges of microvessel count during tamoxifen treatment in all patients are illustrated on
Figure 4.2.1. The range of pre-treatment mvc was 6-25 (median: 14, mean: 14.5), of peri-
treatment mvc was 6-22 (median: 15.5, mean: 15.2) and of post-treatment mvc was 0-23
(median: 15.5, mean: 15.1). Data are summarised on Table 4.2.1.
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Figure 4.2.1: Changes in microvessel counts with tamoxifen









Table 4.2.1: Summary of data of microvessel counts following Factor VIII staining:
Pre-treatment mvc Peri-treatment mvc Post-treatment mvc
Range 6-25 6-22 0-23
Median 14 15.5 15.5
Mean 14.5 15.2 15.1
Standard deviation 3.07 3.33 4.26
Standard error 0.47 0.51 0.66
Paired Wilcoxon signed rank test:
Pre- v. peri-treatment mvc: p=0.40
Pre- v. post-treatment mvc : p=0.31
Per- v. post-treatment mvc p=0.90
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Microvesse! counts and response.
Pre-treatment mvc: Pre-treatment mvc were compared in non-responding (n=14) and
responding (n=28) tumours as shown in Figure 4.2.2, illustrating no significant difference
between the two groups. Pre-treatment mvc in non-responding tumours ranged from 6-17
(median: 13.5, mean: 13.3) and in responding tumours from 10-25 (median: 14.5, mean:
15.1). Data are summarised on Table 4.2.2.
Figure 4.2.2: Comparison of pre-treatment mvc in non-






Table 4.2.2: Summary of pre-treatment mvc data:







Standard deviation 3.12 2.92
Standard error 0.84 0.55
Mann-Whitney test: p=0.13
153
Peri-treatment mvc: Peri-treatment mvc in non-responding and responding tumours are
illustrated in Figure 4.2.3, demonstrating no significant difference between the two groups
(p=0.23). Peri-treatment mvc ranged from 12-22 in non-responding tumours (median: 16,
mean: 16.1) and from 6-22 in responding tumours (median: 14, mean: 14.7). Data are
summarised in Table 4.2.3.
Figure 4.2.3:Comparison of peri-treatment mvc in non-





Table 4.2.3: Summary of peri-treatment mvc data:







Standard deviation 2.60 3.58
Standard error 0.69 0.68
Mann-Whitney test: p=0.23
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Post-treatment mvc: Post-treatment mvc in non-responding and responding tumours are
compared in Figure 4.2.4. Range of counts in non-responding tumours is 9-22 (median: 13.5,
mean: 15.6) and in responding tumours 0-23 (median: 16, mean: 15.4). No significant
difference between the two groups was demonstrated (p=0.31). Data are summarised on
Table 4.2.4.
Figure 4.2.4: Comparison of post-treatment mvc in non-


















Table 4.2.4: Summary of post-treatment mvc data:







Standard deviation 3.82 4.51
Standard error 1.02 0.85
Mann-Whitney test: p=0.31
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Changes in microvessel count in responding and non-responding tumours
following treatment with tamoxifen.
Responding tumours: Microvessel counts in responding tumours taken before, during and
after treatment with tamoxifen are compared in Figure 4.2.5. There was no significant
difference in mvc between counts at the three time points. Data are summarised on Table
4.2.5.











Table 4.2.5: Summary of data for responding tumours:
Pre-treatment mvc Peri-treatment mvc Post-treatment mvc
Range 10-25 6-21 0-23
Median 14.5 14 16
Mean 15.1 14.7 15.4
Standard deviation 2.92 3.58 4.51
Standard error 0.55 0.68 0.85
Paired Wilcoxon signed rank test:
Pre- v. peri-treatment mvc: p=0.56
Pre- v. post-treatment mvc: p=0.64




Non-responding tumours: Changes in mvc in non-responding tumours are shown in Figure
4.2.6. There was a significant increase in mvc following 10-14 days of treatment (p=0.03).
No significant difference between the counts taken before and after treatment was
demonstrated (p=0.31) or between counts taken during and after treatment (p=0.33). Data are
summarised on Table 4.2.6.











Table 4.2.6: Summary of data for non-responding tumours:
Pre-treatment mvc Peri-treatment mvc Post-treatment mvc
Range 6-17 12-22 9-22
Median 13.5 16 13.5
Mean 13.3 16.1 14.6
Standard deviation 3.12 2.60 3.82
Standard error 0.83 0.69 1.02
Paired Wilcoxon signed rank test:
Pre- v. peri-treatment mvc: p=0.03
Pre- v. post-treatment mvc: p—0.31




Changes in inicrovessel counts with response to primary tamoxifen treatment.
The number of tumours in which mvc following staining with Factor VIII antibody
increased, decreased or remained static was correlated with response and outlined on Tables
4.2.7a-c. In order to be defined as a change in mvc, the difference between counts had to be
greater than 10%, which corresponded to the degree of inter-observer variation. Changes in
mvc with treatment failed to reach statistical significance.
Table 4.2.7a: Change in mvc during first two weeks of treatment:
Pre- v. peri-treatment mvc.
Increased mvc Mvc static Decreased mvc TOTAL
Non-responders 8 4 2 14
Responders 13 5 10 28
Chi-squared test for trend: p=0.33
Table 4.2.7b: Change in mvc following three months' of tamoxifen treatment:
Pre- v. post-treatment mvc.
Increased mvc Mvc static Decreased mvc TOTAL
Non-responders 5 6 3 14
Responders 13 4 11 28
Chi-squared test for trend: p=0.11
Table 4.2.7c: Change in mvc between two weeks' and three months' tamoxifen
treatment: Peri- v. post-treatment mvc.
Increased mvc Mvc static Decreased mvc TOTAL
Non-responders 4 1 9 14
Responders 11 8 9 28
Chi-squared test for trend: p=0.10
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Percentage reduction in tumour volume and change in microvessel count.
Ultrasound assessments of percentage reduction in tumour volume were available in 12 non-
responding tumours (86%) and in 24 responding tumours (86%). The relationship between %
reduction in tumour volume and degree of change in mvc with treatment is illustrated on
Figure 4.2.7.
Figure 4.2.7: Relationship between degree of ultrasound
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4.3. Microvessel counts following staining with antibody to CD31.
Ranges ofmicrovessel counts in all patients irrespective of response are illustrated on Figure
4.3.1. The range of pre-treatment mvc was 8-22 (median: 14, mean: 14.9), peri-treatment
mvc was 8-22 (median: 14, mean: 14.9) and post-treatment mvc was 0-23 (median: 15,
mean: 14.8). There was no significant difference between the counts. Data are summarised
on Table 4.3.1.
Figure 4.3.1: Changes in microvessel count with tamoxifen










Table 4.3.1: Summary of data of microvessel counts following CD31 staining:
Pre-treatment mvc Peri-treatment mvc Post-treatment mvc
Range 8-22 8-22 0-23
Median 15 14 15
Mean 14.9 14.4 14.8
Standard deviation 3.26 3.69 4.37
Standard error 0.50 0.57 0.67
Paired Wilcoxon signed rank test:
Pre- v. peri-treatment mvc: p=0.26
Pre- v. peri-treatment mvc: p=1.0
















Microvessel counts and response.
Pre-treatment mvc: Pre-treatment microvessel counts (mvc) in non-responding and
responding tumours are compared in Figure 4.3.2. Range of pre-treatment mvc in non-
responding tumours was 9-18 (median: 14, mean: 14.1) and in responding tumours was 8-22
(median: 15, mean: 15.4). No significant difference between the two groups was detected
(p=0.31). Corresponding data are summarised on Table 4.3.2.
Figure 4.3.2:Comparison of pre-treatment mvc in non-












Table 4.3.2: Summary of pre-treatment mvc data:







Standard deviation 3.57 3.09
Standard error 0.95 0.58
Mann-Whitney test: p=0.42
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Peri-treatment mvc: Peri-treatment mvc, taken from core biopsies performed 10-14 days
after commencement of tamoxifen therapy, are compared in Figure 4.3.3. The range ofmvc
in non-responding tumours was 9-20 (median: 14, mean: 14.2) and 8-22 in responding
tumours (median: 14, mean: 14.5). There was no significant difference between the two
groups. Data are summarised on Table 4.3.3.
Figure 4.3.3: Comparison of peri-treatment mvc in non-












Table 4.3.3: Summary of peri-treatment mvc data:







Standard deviation 3.77 3.72












Post-treatment mvc: Post-treatment mvc in non-responding and responding tumours are
compared in Figure 4.3.4. Range ofmvc in non-responding tumours was 11-23 (median:
14.5, mean: 14) and in responding tumours 0-22 (median: 15, mean: 14.1). Figure 4.3.4
demonstrates no significant difference between the two groups (p=0.35). Data are
summarised on Table 4.3.4.
Figure 4.3.4 : Comparison of post-treatment mvc in non-











Table 4.3.4: Summary of post-treatment mvc data:







Standard deviation 3.92 4.51
Standard error 1.05 0.85
Mann-Whitney test: p=0.35
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Changes in microvessel count in responding and non-responding tumours during
tamoxifen treatment.
Responding tumours: Microvessel counts in responding tumour sections taken before,
during and after treatment with tamoxifen are compared in Figure 4.3.5. No significant
trends in the difference between counts at each time point were identified. Data are
summarised on Table 4.3.5.











Table 4.3.5: Summary of mvc data in responding tumours:
Pre-treatment mvc Peri-treatment mvc Post-treatment mvc
Range 9-22 8-22 0-22
Median 15 14 15
Mean 15.3 14.5 14.1
Standard deviation 3.09 3.72 4.51
Standard error 0.58 0.70 0.85
Paired Wilcoxon signed rank test:
Pre- v. peri-treatment mvc: p=0.15
Pre- v. post-treatment mvc: p=0.39




Non-responding tumours: Similar results were obtained in non-responding tumours, with
no significant difference between counts at the three time points, illustrated on Figure 4.3.6.












Table 4.3.6: Summary of mvc data in non-responding tumours:
Pre-treatment mvc Peri-treatment mvc Post-treatment mvc
Range 8-20 9-20 11-23
Median 14.5 14 14.5
Mean 14.1 14.2 16
Standard deviation 3.57 3.77 3.92
Standard error -0.95 1.00 1.05
Paired Wilcoxon signed rank test:
Pre- v. peri-treatment mvc: p=1.00
Pre- v. post-treatment mvc: p=0.22
Peri- v. post-treatment mvc: p=0.64





Changes in microvessel counts with response to tamoxifen treatment.
The number of tumours in which mvc increased, decreased or remained static was correlated
with response and is outlined on Tables 4.3.7a-c. No significant trends were identified.
Table 4.3.7a: Change in mvc during first two weeks of treatment:
Pre- v. peri-treatment mvc.
Increased mvc Mvc static Decreased mvc TOTAL
Non-responders 5 3 6 14
Responders 7 8 13 28
Chi-squared test for trend: p=0.61
Table 4.3.7b: Change in mvc following three months' of tamoxifen treatment:
Pre- v. post-treatment mvc.
Increased mvc Mvc static Decreased mvc TOTAL
Non-responders 6 4 4 14
Responders 11 5 12 28
Chi-squared test for trend: p=0.54
Table 4.3.7c: Change in mvc between two weeks' and three months' tamoxifen
treatment: Peri- v. post-treatment mvc.
Increased mvc Mvc static Decreased mvc TOTAL
NON-RESPONDERS 7 1 6 14
RESPONDERS 11 7 10 28
Chi-squared test for trend: p=0.90
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Percentage reduction in tumour volume and change in microvessel count.
The relationship between extent of tumour response and degree of change in mvc was
investigated, which would identify any trends that may be apparent at extremes of response.
The relationship is illustrated on Figure 4.3.7, and suggests similar ranges ofmvc change in
non-responding and responding tumours.
Figure 4.3.7: Relationship between degree of ultrasound
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4.4 Comparison of microvesse! counts performed following
staining with antibodies to Factor VIII and CD31.
Having described changes in microvessel counts performed following staining with Factor
VIII and CD31 antibodies separately, the following section will compare counts performed
using each antibody. Figures 4.4.1-4.4.3 illustrate correlations between counts performed at
each time point following staining with Factor VIII and CD31 antibodies in non-responding
and responding tumours.
There was a significant correlation in pre-treatment mvc between the two antibodies in
both non-responding and responding tumours, as illustrated in Figure 4.4.1.
Figure 4.4.1: Comparison of Factor VIII versus CD31 pre-
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CD31 COUNTS (1=0-49, p<0.05)
Spearman correlation coefficient for pre-treatment mvcs:
All tumours: r=0.49.
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There was a weaker correlation in Factor VIII versus CD31 counts during treatment, as
shown on Figure 4.4.2, with a tendency for Factor VIII counts to be higher than CD31
counts.
Figure 4.4.2: Comparison of Factor VIII versus CD31 peri-




































Spearman correlation coefficient for peri-treatment mvcs:
All tumours: r=0.19.
Non-responding tumours: r = 0.20.
Responding tumours: r=0.21
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A significant correlation was demonstrated between Factor VIII and CD31 counts after
treatment in responding, but not non-responding tumours, as shown on Figure 4.4.3.
Figure 4.4.3: Comparison of Factor VIII versus CD31 post-
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4.5. Microvessel counts and other tumour parameters.
Further analyses were performed to determine whether correlations existed between
microvessel counts and other tumour parameters which might affect tumour vascularity or
response to tamoxifen treatment. Parameters investigated were lymph node involvement and
level of oestrogen receptor level expression. These were correlated with mvc following
staining with both Factor VIII and CD31 antibodies.
Lymph node involvement.
Nineteen patients underwent surgery at the end of three months of treatment with tamoxifen,
the remainder did not have definitive surgery, but underwent repeat core biopsies for clinical
reasons such as tumour inoperability, frail general medical condition or late response to
tamoxifen warranting its continuation for longer than three months. Thus no information
regarding axillary lymph node status was available in these patients. Nine patients with non-
responding tumours (64%) and ten with responding tumours (36%) underwent axillary
surgery. For the purpose of analysis, percentage of excised lymph nodes found to be positive
was used to define lymph node involvement. Figure 4.5.1 illustrates the relationship between
% lymph node involvement and response. The range of lymph node involvement in patients
with non-responding tumours was 0-100% (median: 35, mean: 40.2) and in those with
responding tumours was 0-61% (median: 6.25, mean: 16.7). Whilst this does suggest a trend
for greater lymph node involvement in non-responding compared to responding tumours,
this failed to reach statistical significance (p=0.29). Data are outlined on Table 4.5 .1.
171
Figure 4.5.1: % lymph node involvement in patients with
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Lymph node involvement and microvessel counts following staining with
antibody to Factor VHL
Relationships between % lymph node involvement and mvcs following staining with Factor
VIII antibody are illustrated on Figures 4.5.2-4.5.4. Relationships between % lymph node
involvement and pre-treatment mvc, post-treatment mvc and % change in mvc with
treatment were investigated. No significant correlation was found between the variables.
Figure 4.5.2: Relationship between % lymph node
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Figure 4.5.3: Relationship between % lymph node



















Figure 4.5.4: Relationship between % lymph node
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Lymph node involvement and microvessel counts following staining with
antibody to CD31:
Relationships between lymph node involvement and tumour vascularity assessments
following staining with CD31 antibody are illustrated on Figures 4.5.5-4.5.7. No significant
correlation was identified between microvessel counts and % lymph node involvement.
Figure 4.5.5: Relationship between % lymph node
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Figure 4.5.6: Relationship between % lymph node
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Figure 4.5.7: Relationship between % lymph node
involvement and % change in mvc.
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Level of oestrogen receptor expression.
Levels of oestrogen receptor (ER) expression assessed by immunohistochemistry were
compared in non-responding and responding tumours, as is shown on Figure 4.5.8. The
range of ER was 165-300 in non-responding tumours (mean: 259, median: 270) and 120-300
in responding tumours (mean: 268, median: 280). There was no significant difference in
level of ER expression between the two groups (p=0.67). Data are summarised on Table
4.5.2.
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Standard deviation 48.0 44.8
Standard error 13.3 8.46
Mann-Whitney: p=0.67
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Level of ER expression and microvessel counts following staining with antibody to
Factor VIII.
The relationship between level ofER expression, and pre-treatment mvc following staining
with Factor VIII antibody, which were both determined on pre-treatment biopsies is
illustrated on Figure 4.5.9, demonstrating no significant correlation between the two
variables (r=0.02, p=0.93).
Figure 4.5.9: Relationship between level of ER
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Level of ER expression and microvessel counts: (CD31 staining)
The relationship between level of ER expression, and pre-treatment mvc following staining
with CD31 antibody is illustrated on Figure 4.5.10, demonstrating no significant correlation
between the two variables (r=0.19, p=0.23).
Figure 4.5.10: Relationship between level of ER
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4.6 Colour Doppler Ultrasound and assessment of tumour
vascularity.
Colour Doppler ultrasound may provide a non-invasive method of assessing changes in
tumour vascularity. Measurements ofmaximum systolic velocity (max. sys. vel.) in vessels
feeding the tumours were made in nine patients. Scans were performed by one of two
consultant radiologists at the time of diagnosis and immediately prior to the second core
biopsy between ten and fourteen days later. In one patient a scan was repeated at completion
of three months' treatment. Changes in maximum systolic velocity with response are
illustrated on Figure 4.6.1. Data are outlined on Table 4.6.1.
Seven of the nine patients had tumours that failed to respond to tamoxifen: in three non-
responders, tumours were negative for Colour Doppler signal, in two tumours there was an
increase in maximum systolic velocity with treatment, velocity remained static in one tumour
and decreased in one. Two responding tumours were assessed: in one tumour, there was a
reduction in maximum systolic velocity observed only after three months of treatment, the
other was negative for colour Doppler signal at diagnosis.
Table 4.6.1: Data for nine patients who underwent colour Doppler ultrasound of
tumours:









614905K 71196 22x24 1 0.17
281196 16x11x17 1 0.17
90197 14x11x17 1 0.09 R
296162H 120997 28x26x24 1 0.21
141097 28x26x24 1 0.21 NR
341122W 290597 28x25x30 1 0.42
180697 29x13x23 1 0.26 NR
55881IX 120597 33x17x34 0 NR
628483V 150797 18x24x17 1 0.1
290797 18x24x17 1 0.11 NR
629111W 150797 28x18x29 0 NR
625368K 100797 12x15x16 1 0.1
310797 20x15x11 0 R
201525A 190198 26 0 NR
625691A 120597 32x12x33 1 0.07
180697 18 1 0.1 NR
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Fig 4.6.1. Reduction in colour doppler
ultrasound assessments of maximum
systolic velocity (max.syst.vel) in a
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4.7. Discussion.
Having demonstrated early changes in tumour vascularity in response to tamoxifen treatment
in ER-positive breast cancer xenografts, a prospective study has been undertaken to
determine whether such changes occurred in clinical tumours, thus providing potentially
useful predictive information of response to primary treatment.
Forty-two patients with large breast cancers were treated with tamoxifen (20mgs daily) for a
period of three months. Response to tamoxifen was defined as greater than 25% reduction in
tumour volume on ultrasound or clinical measurements at three months. Twenty-eight
patients had tumours that responded to tamoxifen according to this definition, giving a
response rate of 67%. Tumour biopsies were performed at diagnosis and following two
weeks of treatment. Patients underwent definitive surgery or repeat core biopsies at the end
of three months of treatment.
Having stained tumour sections from each of the three time points with antibodies to Factor
VIII and CD31, microvessel counts (mvc) were performed. When counts were correlated
with response no significant difference was detected in pre-treatment mvc between non-
responding and responding tumours. Peri-treatment mvc was significantly higher than pre-
treatment counts in non-responding tumours following staining with antibody to Factor VIII
(p=0.03), but not CD31. No overall change in mvc was detected following three months'
treatment in either non-responding or responding tumours. In addition there was no
difference in post-treatment counts between non-responding and responding tumours.
Counts performed following staining with Factor VIII and CD31 antibodies were compared.
There was a significant correlation between counts before and after treatment in all tumours,
but the relationship between counts during treatment failed to reach significance. When non-
responding and responding tumours were analysed separately, peri-treatment mvc tended to
be higher following staining with Factor VIII than CD31 in non-responding tumours. This
was in keeping with changes observed during treatment, with a significant increase in mvc
following two weeks of treatment in non-responders.
Two additional tumour parameters were examined in this study: lymph node involvement
and level of oestrogen receptor (ER) expression. No correlation was identified with response
in either parameter. In addition, there was no significant correlation between % lymph node
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involvement and microvessel counts. In sections assessed following staining with Factor
VIII antibody, there was a trend in the relationship between % lymph node involvement and
post-treatment mvc, with those patients with higher post-treatment mvc more likely to have
lymph node positive disease, but this failed to reach statistical significance (p=0.09). A
similar, but significant trend was observed in the previous study. No significant correlation
was identified between level ofER expression and pre-treatment mvc following staining
with either CD31 or Factor VIII antibody.
The overall response rate of 67% was lower than that described in either the earlier study
(75%) or in previous studies (Anderson et al, 1991). The definition of response as greater
than 25% reduction in tumour volume at three months was unconventional. As discussed
previously, UICC criteria define response as greater than 50% reduction in tumour volume
for longer than one month, but such a definition was inappropriate for this study, in which
the maximum period of treatment was three months. In the study described earlier in the
thesis, patients with inoperable, T4 cancers were excluded and some patients were treated
with tamoxifen for up to six months prior to surgery. Such inoperable cancers were included
in this prospective study, which had a clear endpoint on completion of three months of
treatment.
This study adopted novel methodology in terms of assessing tumour vascularity in sequential
core biopsies during a primary course of tamoxifen treatment. Other studies have adopted the
use of sequential fine needle aspiration for determining changes in hormone receptor level
and proliferation (Makris et al, 1998), but assessment of tumour vascularity was not possible
in such specimens. Previous work on angiogenesis assessment in primary breast cancer has
focused on its role as a prognostic indicator. The majority of studies addressing the issue
have found microvessel counts provided independent significant prognostic information on
lymph node involvement, relapse-free and overall survival (Fox et al, 1995b; Gasparini et al,
1994; Weidner et al, 1992). The finding in the present study that there was no significant
difference in pre-treatment mvc between non-responding and responding tumours is
interesting in light of such studies. Response to tamoxifen has also been found to provide
prognostic information (Cameron et al, 1997a). Pre-treatment mvc might thus have been
expected to be higher in non-responding than responding tumours. However, it must be
remembered that all patients selected for treatment with primary tamoxifen had tumours that
were rich in oestrogen receptors, thus representing tumours with a good prognosis compared
to ER-negative tumours (Thorpe & Rose, 1986).
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In the present study, no significant changes in mvc were detected after treatment with
tamoxifen for three months following staining with either Factor VIII or CDS 1 antibodies.
This is in contrast to the findings of the study described earlier in the thesis, which
demonstrated a significant reduction in mvc in responding tumours and an increase in non-
responding tumours. The nature of pre-treatment biopsies was quite different in the two
studies: the earlier study involved wedge biopsies, which contained a larger tumour volume
than the core biopsies used in the present study. The reason for adopting the use of core
biopsies in the present study is that they can be repeated during treatment with minimal
discomfort to the patients.
Sequential core biopsies taken before, during and after a three month course of tamoxifen
failed to demonstrate a reduction in mvc in responding tumours, as was described in the
earlier study. There was a significant difference in mvc following two weeks' treatment with
tamoxifen in tumour sections stained with antibody to Factor VIII, but not CDS 1 antibody.
Peri-treatment mvc was higher than pre-treatment mvc in non-responding tumours (p=0.03).
There was no difference between pre-and peri-treatment mvc in responding tumours. The
difference was not maintained and post-treatment mvc was not significantly correlated with
response. This is an interesting finding and worthy of comment. The pattern of change in
tumour vascularity described in the first study was a reduction in responding tumours and an
increase in non-responding tumours at completion of the period of treatment.
The failure of the present study to reproduce findings of the earlier study is likely to be
related to methodological issues or to differences in the study populations. Methodological
issues were addressed elsewhere in the thesis and demonstrated problems with
reproducibility of counts performed in cores compared with tumour sections, taken either
simultaneously or at separate time points with no intervening treatment. The technique of
microvessel counting involved selection of areas of high vascularity in order to reduce the
effect of tumour heterogeneity. In the present study, a small volume of tumour was available
for assessment, thus reducing the likelihood that such biopsies contained the areas of highest
vascularity. This is reflected in a difference in range of counts between the two studies: a
maximum count of 23 was obtained in the present study, compared with 35 in the earlier
study.
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In addition to these points, several quantitative studies have shown that, for many
experimental tumours, blood flow is higher in the tumour periphery than in central regions
(Endrich et al, 1979; Tozer et al, 1990). This is in keeping with findings of the xenograft
study described previously, in which the pattern of greater vessel distribution at the
periphery compared with centrally was clearly seen. A similar phenomenon has been
described in other xenograft studies (Furman-Haran et al, 1994; Lindner & Borden, 1997). A
study observing patterns of microvessel density in association with ductal carcinoma in-situ
identified development of a clearly defined rim of neovascularization around the tumour
prior to onset of angiogenesis (Guidi et al, 1994). This pattern of new vessels developing
from the tumour periphery and feeding into the central tumour may provide an explanation
for the failure of the present study to reproduce findings of the earlier retrospective study. In
the retrospective study, mvc performed in wedge biopsies and tumour transverse sections
were compared. Wedge biopsies contain both peripheral and central areas of tumour and are
therefore likely to contain vascular 'hot spots'. In the present study, counts were performed
on core biopsy specimens and compared with cross-sections of tumour. Core biopsies were
taken using a biopsy gun placed percutaneously at the tumour edge and fired into the central
area of tumour. By the nature of this process, core biopsies contained a small sample of the
tumour periphery. Thus, comparison ofmvc in vascular hot spots of the cores and sections
are likely to vary, with a tendency for higher counts to be found in tumour sections, as was
demonstrated previously. It may be that the established method ofmicrovessel counting in
vascular hot spots needs to be amended when performing counts in different breast cancer
specimens and such discrepancies may be less apparent if counts were performed in random
fields.
There was a significant increase in mvc at two weeks of treatment following staining with
antibody to Factor VIII in non-responding tumours. Of 14 non-responders, mvc increased in
8, remained static in 4 and decreased in 2 patients. This finding is in keeping with the earlier
study in which there was a significant increase in mvc in non-responding tumours at three
months. Such findings are of concern in that they suggest that tamoxifen may actually be
exerting a positive effect on tumour growth. This increase may be merely a reflection of
growth of untreated tumours; although no such significant increase was found in counts
performed on cores and subsequent sections taken with no intervening treatment, there was a
trend for counts to be higher in later tumour sections.
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The difference between counts obtained following staining with antibody to CD31 and
Factor VIII is noteworthy. In an earlier chapter, the relationship between counts performed
following staining with the two antibodies was investigated and demonstrated a good
correlation between counts in both core biopsies and tumour sections. This was confirmed in
the present chapter, in which Factor VIII and CD31 counts were compared at each time
point. There was no significant correlation in counts following two weeks of treatment:
indeed, comparison of peri-treatment mvc in non-responding tumours revealed a non¬
significant trend for Factor VIII counts to be higher than CD31 counts. This may be a
reflection of the differing roles of the two antibodies and varying effects of tamoxifen on
their expression. Such variation has not been previously described. Factor VIII antigen plays
a role in platelet aggregation and adhesion (Fajardo, 1989); the antibody stains both blood
and lymphatic vessels and, although staining does not include all microvessels, it is more
reliable than other endothelial cell markers. CD31 plays a role in platelet adhesion during
inflammatory processes and wound healing (Parums et al, 1990) and the antibody has been
shown to give consistently higher counts than Factor VIII (Martin et al, 1997).
Information regarding lymph node status was available in a subgroup of 19 patients, who
were treated by definitive surgery at the end of three months' tamoxifen. No significant
correlation was found between lymph node involvement and response or microvessel counts.
In the retrospective study previously described, a significant association was found between
% lymph node involvement and both post-treatment mvc and % change in mvc. Patients in
whom post-treatment mvc was high were more likely to have lymph node positive disease
than patients with lower mvc. In this study, in sections stained with antibody to Factor VIII,
a similar trend was seen which failed to reach statistical significance (p=0.08). This may
reflect the small number of patients in whom such assessment was available.
Lack of association between ER level and response in the present study is contradictory to
findings in previous studies (Gaskell et al, 1992; Osborne et al, 1980) in addition to that
outlined earlier in the thesis. Standard method of assessment of ER has changed in the
Edinburgh Breast Unit between the period of recruitment into the two studies and now
involves immunohistochemical evaluation of tumour sections. At the time of the earlier
study a biochemical method was adopted and this discrepancy may have led to the different
results. In addition, assessment ofER in the present study was made on core biopsy
specimens; in the previous study assessments were made on tissue from wedge biopsies. The
problems of sampling which have been described in association with tumour vascularity
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assessments in this thesis may exist in the assessment of other parameters including the
oestrogen receptor. However one study addressing this issue described 100% concordance in
ER asessment of cores and tumour sections when an immunohistochemical technique was
adopted (Jacobs et al, 1998). The lack of association between ER level and pre-treatment
mvc was similar in this study to that described previously in the thesis.
It may be that discrepancies in findings of the present study compared with the earlier study
are related to differences in the study populations in addition to the methodological
variations that have been discussed. In the present study, patients with large inoperable T4
were included, in contrast to the earlier study. The lower age limit in the earlier study was 70
years, in the present study patients had to be postmenopausal. In addition patients were
included in the study for three months only, but in the earlier study they may have been
treated for up to six months. These differences may contribute to the discrepancies in mvc
assessments and response and the failure in this study to identify an association between ER
expression and response to tamoxifen.
Other parameters may provide useful information for predicting early response to treatment.
It is possible that other factors relating to angiogenesis may be of use, such as vascular
endothelial growth factor (VEGF) expression, which is expressed in normal cells with
increased expression in some tumours, including breast cancers (Toi et al, 1995). Levels of
VEGF expression have been found to provide significant prognostic information in primary
breast cancers (Gasparini et al, 1997). Alternative, non-invasive methods of assessing
tumour angiogenesis are under development. A study investigating the relationship between
mvc and Doppler flow parameters failed to demonstrate a significant correlation between the
two (Peters-Engl et al, 1998). The authors suggested that the two investigations assess
different aspects of the vasculature: mvc provides information on the microvasculature,
Doppler signals on the macrovasculature (Peters-Engl et al, 1998). The number of patients in
whom serial colour Doppler ultrasound was performed in this thesis is too small to permit
meaningful comment: of nine patients assessed, three had tumours that were colour Doppler-
negative. In the remaining four non-responding tumours, there was an increased maximum
systolic velocity in two. Of two responding tumours, one tumour was rendered colour
Doppler-negative following two weeks of treatment, in the other a reduction in velocity was
observed later. These findings are of interest, suggesting a possible role for colour Doppler
ultrasound in monitoring response to treatment and this warrants further investigation.
Another non-invasive method of angiogenesis assessment currently under investigation is
187
contrast-enhanced magnetic resonance imaging (MRI). MR enhancement has been found to
be associated with high vessel densities, but data showed considerable variation and
therefore was not considered to be an accurate predictor of microvessel density (Buckley et
al, 1997; Stomper et al, 1997). In another study, MRI and a contrast agent directly targeting
the endothelial integrin aVp3 provided enhanced and detailed imaging of rabbit carcinomas,
including identification of angiogenic hot spots, which had not been previously detected by
MRI (Sipkins et al, 1998). The development of new contrast agents and technological
improvements in MRI may provide an important non-invasive method of assessing tumour
angiogenesis. In addition, other parameters unrelated to angiogenesis may provide valuable
information, as they may be less affected by tumour heterogeneity and by previous surgical
manipulation of the tumour.
In summary, the use of sequential core biopsies during treatment with primary tamoxifen has
failed to identify any clear relationship between change in tumour vascularity and response.
In combination with results described in studies ofmethodological issues, it is likely that
small tumour biopsies were not sufficiently accurate in reflecting overall tumour vascularity
to be of value. Tumour heterogeneity poses a particular problem in the method of
microvessel counting as this involves selection of the most vascular areas of tumour. Such
areas are less likely to be present in small biopsies and it may be more appropriate to
perform counts in random fields. In addition, angiogenesis is stimulated in response to injury
and the effect of previous tumour manipulation may mask any early effect of tamoxifen.
Alternative early markers of response to tamoxifen must be sought.
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5. Changes in % tumour cells expressing vascular
endothelial growth factor (VEGF) and tamoxifen treatment.
In this chapter % tumour cells expressing VEGF were compared before and after treatment
with tamoxifen and correlated with response. The study involved assessment of VEGF
expression in those tumours described in Results chapter 2 of this thesis. Staining with
antibody to VEGF was performed in tumours from fifty-seven patients. In nine patients,
staining with VEGF antibody failed despite successful staining of positive controls in the
same run. These comprised sections cut from the oldest tumour blocks that had been stored
for up to six years. Thus the total number of patients studied in this section was forty-eight:
this comprised twelve patients with non-responding (25%) and thirty-six with responding
tumours (75%) according to criteria detailed earlier. Following staining with antibody to
VEGF, assessments were made of % tumour cells staining and intensity of staining as
described in the methods section.
When assessments of intensity were performed it became apparent that there was marked
variation in staining of sections of the same breast tumour used as positive controls between
different batches of antibody, thus rendering such assessments inaccurate. It was, therefore,
decided to score tumours according to % cells staining positive for VEGF only. Tire scoring
system comprised a score of up to 4, where a score of 0 was given if <1% cells staining, 1 if
1-25% cells stained, 2 if 26-50% cells stained, 3 if 51-75% cells stained and 4 if >76% cells
stained positively for VEGF. Scoring was performed on tumour cells only in three high
power field (x400). The total of three scores gave the level of VEGF expression for that
tumour. Thus the highest score was 12.
An example of staining with antibody to VEGF is illustrated in Figure 5 .1, demonstrating
100% tumour cells staining positively.
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Fig 5.1 Tumour staining with antibody to VEGF at high power (x400).
Positively staining cells are highlighted in brown.
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5,1 % VEGF-positive tumour cells and response.
Pre-treatment: All tumours except for two (responders) expressed VEGF in a percentage of
tumour cells. There was no significant difference in % cells staining for VEGF between non-
responding and responding tumours, as illustrated on Figure 5.1.1. Range of values in non-
responding tumours wasl-12 (median: 12, mean: 10.5) and in responding tumours was 1-12
(median: 12, mean: 9.56). Data are outlined on Table 5.1.1. Actual counts are detailed in the
Appendix to this chapter.
Figure 5.1.1: Comparison of% tumour cells staining for











Standard error 0.96 0.66
Standard deviation 3.32 3.97
Mann-Whitney test: p=0.57
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Post-treatment: There was a trend for a reduction in % of cells expressing VEGF in the
total group of tumours following treatment, which was more marked in responding than non-
responding tumours. There was, however, no significant difference in % cells expressing
VEGF between non-responding and responding tumours, as illustrated on Figure 5.1.2.
Range of post-treatment VEGF in non-responding tumours was 0-12 (median: 10, mean:
8.5). Range in responding tumours was 0-12 (median: 8, mean: 7.67). Data are outlined in
Table 5.1.2.
Figure 5.1.2: Comparison of% tumour cells staining for










Standard error 1.13 0.58
Standard deviation 3.90 3.45
Mann-Whitney test: p=0.44
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Changes in % VEGF-positive cells in non-responding and responding tumours
following treatment with tamoxifen.
Changes in % cell staining for VEGF occurred in both non-responding and responding
tumours. An example of reduced VEGF expression following treatment is illustrated in
Figure 5.1.3.
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Fig 5.1.3. Reduction in percentage cells staining for VEGF following
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Responding tumours: The proportion of tumour cells expressing VEGF before and after
treatment in responding tumours are illustrated in Figure 5.1.4, demonstrating a significant
reduction in % cells staining following treatment. Data are outlined in Table 5.1.3.
Figure 5.1.4: Comparison of VEGF expression in responding

















Table 5.1.3: Changes in proportion of cells expressing VEGF in responding tumours





Standard error 0.66 0.58
Standard deviation 3.98 3.45
Mann-Whitney test: p=0.04
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Non-responding tumours: Comparison of level of VEGF expression in non-responding
tumours before and after treatment with tamoxifen is illustrated in Figure 5.15; no
significant difference was detected. Data are outlined on Table 5.1.4.
Figure 5.1.5: Comparison of VEGF expression in non-












Table 5.1.4: Comparison of proportion of cells expressing VEGF before and after





Standard error 0.96 1.13
Standard deviation 3.32 3.90
Mann-Whitney test: p=0.2
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Changes in % of VEGF-postive tumour cells with response to tamoxifen.
The numbers of tumours in which the proportion of tumour cells staining for VEGF
increased, remained static or decreased are tabulated below. No significant trend was
observed in association with response. In both non-responders and responders the proportion
ofpositively staining cells tended to reduce with treatment.
Table 5.1.5: Changes in VEGF expression in non-responding and responding tumours
following treatment with tamoxifen:
Increased VEGF VEGF static Decreased VEGF
Non-responders 2 3 7
Responders 11 6 19
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5.2 % VEGF-positive tumour cells and microvessel counts.
The relationships between %VEGF-positive cells and microvessel counts before and after
treatment with tamoxifen were investigated and are illustrated on Figures 5.2.1 and 5.2.2. No
significant correlation was found. In addition, no significant correlation was found between
the changes in mvc and VEGF expression in each tumour (r=-0.03), as tabulated on Table
5.2.1.
Figure 5.2.1 : Relationship between % VEGF-positive cells




















Figure 5.2.2 : Relationship between % VEGF-positive cells
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Table 5.2.1: Comparison of changes in mvc and VEGF expression following treatment
with tamoxifen: where 0=no change, l=decrease, 2=increase. Non-responders in bold.


















































In addition, there was no correlation between degree of change in mvc and % VEGF-positive
cells, as illustrated in Figure 5.2.3 (r=-0.01).
Figure 5.2.3: Relationship between change in % tumour cells




CELLS STAINING FOR VEGF (r=-0.01, p>0.05)
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5.3. Discussion:
Work described in this thesis has focused on changes in breast tumour vascularity with
tamoxifen by the assessment of microvessel densities in tumour specimens. An alternative
method of assessing changes in tumour vascularity is to study growth factors responsible for
stimulating tumour angiogenesis. Many such growth factors exist: in the majority, their
effect on endothelial cells represents only a part of their total action. Vascular endothelial
growth factor (VEGF) is unusual in that it acts solely on endothelial cells (Ferrara & Henzel,
1989). Produced by normal cells, its expression is markedly increased in breast cancers (Relf
etal, 1997).
In this study, changes in the number of cells staining for VEGF that occurred following
treatment of breast cancers with tamoxifen for between three and six months were
investigated and correlated with response. In addition, the relationship between number of
VEGF-positive cells and microvessel counts performed on the same tumours was studied.
Forty-eight patients were studied: 12 (25%) had non-responding and 36 (75%) had
responding tumours. Prior to treatment, the majority of tumour cells expressed VEGF and
there was no difference in % positive cells between non-responding and responding tumours.
Changes in the number of VEGF-positive cells were observed following treatment with
tamoxifen. In both non-responding and responding tumours, there was a trend for a reduction
in the number of cells staining for VEGF following treatment, but this was more marked in
responding than in non-responding tumours. There was a significant reduction in number of
cells staining in responding tumours (p=0.03) following treatment, but the change in non-
responding tumours failed to reach statistical significance.
There was no significant correlation between microvessel counts and % VEGF-positive
tumour cells before or after treatment. In addition no correlation was found between the
degree of change in number of cells expressing VEGF and the difference in mvc following
treatment.
In colorectal carcinomas, VEGF expression correlated with the extent of neovascularization
and proliferation, whereas bFGF did not (Takahashi et al, 1995). In a study of small cell lung
cancer microvessel counts were strongly associated with VEGF and altered p53 expression,
suggesting that wild type p53 regulates angiogenesis through VEGF (Macchiarini et al,
1992). Indeed mutations of p53 result in increased VEGF expression (Keiser et al, 1994).
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Several studies have found an association between VEGF expression and relapse-free or
overall survival in breast cancers, with significantly shorter survival times in patients with
VEGF-rich tumours (Gasparini et al, 1997; Toi et al, 1995). Studies investigating effects of
tamoxifen on VEGF expression have been limited to experimental systems, but have
demonstrated inhibition of VEGF-stimulated endothelial cell growth (Gagliardi et al, 1996;
McNamara et al, 1998). The reduction in number of cells expressing VEGF in treated breast
cancers observed in the present study is in keeping with these findings.
A clear pattern of change in number of cells staining for VEGF was observed in the present
study, with a reduction in % cells staining in the majority of tumours, regardless of response.
The more marked reduction ofVEGF-expressing tumour cells in responding than non-
responding tumours suggests that a percentage of tumour cells respond to tamoxifen by
"switching off" VEGF expression but some cells fail to do so. It may be that cells continuing
to express VEGF after treatment represent clones that are resistant to tamoxifen.
The failure of the present study to demonstrate a positive correlation between VEGF
expression and microvessel density is in contrast to most other published series (Anan et al,
1996; Toi et al, 1995). This may be related to the methods adopted to assess VEGF, which
vary markedly, including frequency of mRNA expression, in which VEGF was either
present or absent (Anan et al, 1996) and enzymatic immunoassay of tumour cytosol
(Gasparini et al, 1997; Toi et al, 1996). In studies adopting immunohistochemical techniques
for assessment of VEGF, intensity of staining alone has been most commonly used (Toi et
al, 1995). Not all studies have found a correlation between VEGF expression and mvc: de
Jong et al investigated a range of growth factors in relation to proliferation and angiogenesis
and VEGF expression failed to correlate with either parameter (de Jong et al, 1998).
Changes in number of positively staining cells for VEGF in this group of patients were less
significant than changes in microvessel count, as detailed earlier in the thesis. VEGF is one
of several growth factors known to stimulate angiogenesis. The process of angiogenesis
represents a balance in activity of inhibitors and inducers, which is affected by processes
other than tumour growth. Angiogenesis is stimulated by hypoxia, mediated by VEGF, and
forms part of the physiological processes ofwound healing. Changes in VEGF thus form a
small part of the processes occurring within the responding tumour, which may provide an
explanation for it being less significant than mvc in determining response. In addition, it
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must be noted that the number of tumours, particularly non-responding tumours, is small for
statistical analysis.
In summary, the proportion of tumour cells staining for VEGF was reduced following
treatment of primary breast cancers with tamoxifen in responding tumours. There was also a
trend for reduction in % cells staining in non-responding tumours. Cells which were
rendered VEGF-negative following treatment with tamoxifen may represent those that were
sensitive to treatment. Failure of correlation of%VEGF-positive cells and mvc is contrary to
the findings ofmost published series but these have varied in methodology and in definition
of VEGF expression.
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6. Changes in tumour ceil proliferation during
tamoxifen treatment.
The main focus of this thesis has been on changes in tumour vascularity in association with
primary tamoxifen treatment. Results described previously have demonstrated that
assessments of tumour vascularity failed to provide a useful early marker of response to
tamoxifen. Reasons for this are thought to be due to problems of reproducibility of counts in
different breast cancer specimens, but it may be that changes do not occur in tumour biology
early in the course of treatment. A study has been undertaken to determine whether an
alternative marker of response assessed on small tumour biopsies may provide useful early
information regarding response to tamoxifen.
The % of tumour cells undergoing proliferation was assessed following staining with MIB-1
antibody before, during and after treatment with tamoxifen. These assessments were made
on tumours that were previously studied in Results chapter 4 of the thesis. Forty-one patients
were studied: one patient was excluded due to technical problems with the staining. Thirteen
patients had tumours that failed to respond to tamoxifen and twenty-eight had responding
tumours, yielding an overall response rate of 67%.
Following immunohistochemical stainign with MIB-1 antibody to Ki67, assessments were
made of % positively staining tumour cells staining in the entire tumour section. An example
ofMIB-1 staining is illustrated in Figure 6.1. Tumours were scored in categories up to a
maximum score of 5. A score of 0 was given if no cells stained positively, 1 if <1% cells
were positive, 2 if 1-10% cells were positive, 3 if 11-33% cells were positive, 4 if 34-66%
cells were positive and 5 if >67% cells were positive for MIB-1 antibody. Scores were
compared before, during and after completion of treatment with tamoxifen and correlated
with response.
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Fig 6.1. Example of staining with proliferation marker Mib-1 antibody
(low power x 40)
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6.1. Proliferation scores and response.
Pre-treatment MIB-1 scores: The proliferation scores in non-responding and responding
tumours prior to treatment are compared in Figure 6.1.1, demonstrating no significant
difference between the two groups (p=0.25). The range of score in non-responding tumours
was 2-4 (median: 3, mean: 2.9) and in responding tumours was 2-5 (median: 2, mean: 2.6).
Data are summarised on Table 6.1.1 and detailed data are shown in the appendix to this
chapter.
Figure 6.1.1: Comparison ofMIB-1 expression in non-










Standard error 0.21 0.16
Standard deviation 0.76 0.83
Mann-Whitney test: p=0.25
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Peri-treatment MIB-1 scores: MIB-1 scores of tumour sections taken following two weeks'
treatment with tamoxifen are compared in non-responding and responding tumours in Figure
6.1.2. The range of scores in non-responding tumours was 1-4 (median: 3, mean: 2.67) and in
responding tumours was 1-5 (median: 2, mean: 2.16). There was no significant difference
between the two groups (p=0.11). Data are outlined in Table 6.1.2.
Figure 6.1.2: Comparison of MIB-1 expression in non-
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Post-treatment MIB-1 scores: MIB-1 scores were compared in non-responding and
responding tumours on completion of three months' treatment with tamoxifen, and
demonstrated a significant difference between the two (p=0.023). The range ofMIB-1 scores
in non-responding tumours was 2-5 (median: 3, mean: 3.17) and in responding tumours was
1-4 (median: 2, mean: 2.11). Data are outlined on Table 6.1.3.
Figure 6.1.3: Comparison ofMIB-1 expression in non-
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Changes in MIB-1 expression during treatment with tamoxifen.
Changes in % proliferating cells occurred in non-responding and responding tumours, as
demonstrated in Figure 6.1.4.
209
Fig 6.1.4-Reduction in proliferation following two weeks treatment with
Tamoxifen, (high power xlOO)
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Non-responding tumours: MIB-1 scores were compared in non-responding tumours before,
during and after treatment with tamoxifen. There was no significant trend in change ofMIB-
1 score throughout treatment, as illustrated on Figure 6.1.5. Data are outlined on Table 6.1.4.
Figure 6.1.5: Changes in MIB-1 expression in non-responding












Table 6.1.4: Changes in MIB-1 expression in non-responding tumours:
Pre-treatment Peri-treatment Post-treatment
Range 2-4 1-4 2-5
Median 3 3 3
Mean 2.9 2.67 3.17
Standard error 0.21 0.26 0.34
Standard deviation 0.76 0.89 1.19
Paired Wilcoxon signed rank test:
Pre- v. peri-treatment MIB-1 expression: p=0.44
Pre- v. post-treatment MIB-1 expression: p=0.58
Peri- v. post-treatment MIB-1 expression: p=0.47




Responding tumours: There was a significant reduction in MIB-1 expression following two
weeks' treatment with tamoxifen (p=0.015). This reduction persisted throughout treatment
and remained significant at three months (p=0.006). There was no significant difference in
count in tumour taken following two weeks of treatment and tumour taken on completion of
three months' treatment (p=0.85). Changes in MIB-1 expression are illustrated on Figure
6.1.6, with data outlined on Table 6.1.5.
Figure 6.1.6: Changes in MIB-1 expression in responding
tumours during treatment with tamoxifen.
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Table 6.1.5: Changes in MIB-1 expression in responding tumours:
Pre-treatment Peri-treatment Post-treatment
Range 2-5 0-5 0-4
Median 2 2 2
Mean 2.6 2.16 2.11
Standard error 0.16 0.19 0.17
Standard deviation 0.83 0.94 0.89
Paired Wilcoxon signed rank test:
Pre- v. peri-treatment MIB-1 expression: p=0.02
Pre- v. post-treatment MIB-1 expression: p=0.006
Peri- v. post-treatment MIB-1 expression: p=0.85
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Changes in MIB-1 expression with response to tamoxifen.
The number of patients in whom MIB-1 expression increased, remained static or decreased
between the different time points is outlined in Tables 6.1.6 and 6.1.7. Whilst there was no
significant trend observed at the early time point in responding tumours, there was a
significant trend for change in MIB-1 expression at three months (p=0.047).
Table 6.1.6: Early changes in MIB-1 expression in non-responding and responding
tumours (Pre v. peri-treatment scores):
Increased MIB-1 MIB-1 static Decreased MIB-1
Non-responders 2 6 4
Responders 5 9 11
Chi squared for trend: p=0.78
Table 6.1.7: Changes in MIB-1 expression in non-responding and responding tumours
at three months (Pre v. post-treatment scores):
Increased MIB-1 MIB-1 static Decreased MIB-1
Non-responders 4 5 3
Responders 1 15 11
Chi squared for trend: p=0.047
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6.2 Discussion,
In the prospective study described earlier in the thesis, changes in microvessel count in
sequential tumour biopsies failed to provide early predictive information on response to
tamoxifen. Indeed results of the study failed to reproduce findings of the previous
retrospective study in which changes in mvc occurred in association with response to
tamoxifen. This is likely to be related to methodological problems due to the small size of
tumour biopsies taken.
In the present study an alternative potential marker of early response was investigated which
is not dependent on selection of 'hot spots' for the assessment and is less susceptible to
tumour heterogeneity. Changes in percentage of proliferating cells following staining with
MIB-1 antibody were determined and correlated with response in the same cohort of patients
as detailed previously.
There was no difference in MIB-1 scores between non-responding and responding tumours
at any of the three time points. There was, however, a significant reduction in score in
responding tumours following two weeks of treatment, a change that became more
significant following three months' treatment with tamoxifen. The difference in score in
responding tumours between the biopsy at two weeks and that taken at three months was not
significant. No significant change in proliferation in non-responding tumours was observed
at any of the time points. There was no significant trend in change in responding tumours at
the early time point but the trend reached statistical significance following three months of
treatment.
The anti-proliferative action of tamoxifen has been well-documented. It was first
demonstrated in vitro for the hormone-sensitive human breast cancer derived cell line, MCF-
7: an effect that could be reversed by addition of oestrogen (Lippman & Bolan, 1975).
Studies have demonstrated a reduction in proliferation in xenograft (Cameron et al, 1997b)
and clinical tumours (Keen et al, 1997) following treatment with tamoxifen. In the study of
clinical tumours, there was no correlation between the reduction in proliferation and
percentage reduction in tumour volume. Proliferation was assessed following staining with
KiS 1 antibody, which may vary with different concentrations of antibody (Keshgegian &
Cnaan, 1995). Ki-67 (MIB-1) is more robust and is not expressed in non-proliferating cells.
A recent study has adopted use of sequential fine needle aspirations to obtain samples prior
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to commencement, at 14 days and at eight weeks' post-treatment with tamoxifen (Makris et
al, 1998). There was a significant difference in Ki-67 expression in responding versus non-
responding tumours at the early time point that was not maintained throughout the study.
This evidence from previous studies suggested that changes in proliferation during treatment
with tamoxifen might indeed provide a useful early marker of response. The present study is
the first to adopt the methodology of performing sequential core biopsies during treatment.
Findings in the present study are in keeping with previously published work, with a
reduction in percentage of proliferating cells in responding tumours. In the present study
such a reduction was maintained throughout the study, with increasing significance. There
were, however, some patients with non-responding tumours in whom MIB-1 expression fell,
particularly in the first two weeks of treatment. This is in keeping with the findings of the
study of FNA samples in which there was a slight fall in Ki-67 expression in non-responding
tumours following 14 days of treatment (Makris et al, 1998). Thus it may be that the degree
of reduction in expression is important. The current method of categorising scores may not
be sufficiently sensitive to detect such differences; it may be that a continuous method would
provide more information. The current method of assessment is under consideration.
These findings are of interest and suggest that changes do take place within the tumour early
during treatment with tamoxifen in association with subsequent response, although such
changes were not demonstrated in tumour vascularity. The potential role of changes in MIB-
1 expression as an early marker of response warrants further investigation. In particular it
will be important to assess the reproducibility of the method in a similar manner to the study
of reproducibility of microvessel counting as described in this thesis. Such work is ongoing.
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Discussion
This study focused on changes in tumour vascularity that are consequent upon tamoxifen
treatment of breast cancer and aimed to determine whether early changes in tumour
vascularity during neoadjuvant tamoxifen treatment provided a useful predictor of response.
Before embarking upon studies investigating the effect of tamoxifen on angiogenesis, a
series of control experiments was undertaken. The aims of these were to validate the
methodology of microvessel counting, to assess reproducibility of counts in different breast
cancer specimens and to compare the use of two antibodies to endothelial cells, antibody to
Factor VIII andtoCD31.
Results of the studies aimed at validating the methodology demonstrated low observer
variation, in keeping with other studies (Martin et al, 1997), and a highly significant
correlation in counts performed following staining with antibody to Factor VIII and CD31,
which has also been previously demonstrated (Horak et al, 1992). Comparison of counts in
core biopsy specimens versus tumour cross-sections has not been previously described in
detail. A positive correlation was found between the two counts when they were performed
simultaneously, but there was no correlation when they were performed two weeks apart
with no intervening treatment. This lack of reproducibility of counts in different specimens is
likely to be related to sampling problems due to tumour heterogeneity and to the small size
of core biopsy specimens. It may be that the accepted method of performing microvessel
counts in areas ofhigh vascularity is not appropriate in small tumour specimens, particularly
in the present study, in which the focus has not been to assess the prognostic value of
microvessel counts.
A series of experiments was undertaken to assess the effect of tamoxifen on tumour
vascularity. In order to overcome problems ofmethodology, tamoxifen would have to exert a
dramatic effect on vascularity. A comparison of microvessel counts before and after
treatment in a retrospective study of fifty-seven patients demonstrated a significant reduction
in mvc in responding tumours and a significant increase in non-responding tumours
following treatment. These changes were observed when clinical behaviour of the tumours
was already known and may be the result of response or failure of response rather than the
precedent of it. In order to be of value as a predictor of response to therapy, changes at an
early time point would be required.
216
To assess the timing of such changes in tumour vascularity relative to tumour regression a
series of xenograft studies was undertaken. The study ofER-positive and ER-negative breast
cancer xenografts treated with tamoxifen revealed a reduction in microvessel counts in ZR-
75 ER-positive tumours but not in MDA-MB-231 ER-negative tumours. The reduction
occurred following two days' treatment with tamoxifen and preceded tumour regression.
These findings supported both the results of the early clinical study and the hypothesis that
early changes in tumour vascularity may predict for response to endocrine therapy.
It was against this background of reduced mvc in responding tumours on completion of
primary tamoxifen and evidence from an animal model that such a reduction occurred as an
early event during the course of treatment that a prospective study was undertaken. The aim
of the study was to determine whether, in the clinical setting, early changes predicted for
response, despite limitations in the methodology detailed previously. Sequential core
biopsies were performed during a three month course of primary treatment with tamoxifen,
and microvessel counts carried out at the three time points. The study demonstrated
increased mvc in non-responding tumours following two weeks' treatment when compared
with pre-treatment counts, following staining with antibody to Factor VIII but not CD31. No
significant trend in responding tumours was observed at the early time point. In addition, the
study failed to reproduce findings of the earlier retrospective study in which there was a
significantly reduced mvc in responding tumours and an increase in non-responding tumours
at the end of three months' treatment.
The increase in mvc in non-responding tumours found on completion of three months'
treatment in the retrospective study and seen as an early change following staining with
antibody to Factor VIII in the prospective study is worthy of note. It may be a reflection of
growth of the unresponsive tumour, but there is a possible concern that tamoxifen may be
stimulating tumour growth in this subgroup of patients. It is possible that such stimulation
occurred as a result of tamoxifen exerting oestrogenic action in this subgroup of patients.
The reasons for the failure of the prospective study to either identify early changes in tumour
vascularity in association with response or to reproduce findings of the earlier study are
likely to be related to the methodology. Core biopsies are easy to perform in the out-patient
setting and can be repeated, but provide less volume of tumour than the wedge biopsies
which were performed in the retrospective study. Tamoxifen does not exert a sufficiently
large effect on tumour vascularity to overcome problems with reproducibility that were
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identified in the studies addressing this issue detailed earlier in this thesis. The problems of
heterogeneity of tumour vascularity and the likely effect of previous surgical manipulation in
stimulating angiogenesis as part ofwound healing, mask any effect of tamoxifen in these
biopsy specimens. It may be more appropriate to perform random counts in these specimens
rather than adhering to the recommendations made by previous authors that counts should be
performed in vascular 'hot spots', particularly as this study did not attempt to address the
prognostic value of microvessel counting.
In studies addressing the issue of prognosis, not all have found microvessel counts to
correlate with prognosis or with other prognostic indicators (Costello et al, 1995). A possible
explanation for this is that, until recently, microvessel counts have been performed following
staining with a pan-endothelial cell marker. A recent study has suggested that the ability to
distinguish between tumour neovascularization and pre-existing new vessels may be
important and demonstrated the potential role of an antibody (CD 105) that specifically stains
angiogenic endothelial cells (Kumar et al, 1999). This new antibody requires further study
and whilst such controversy remains it may that an alternative method of assessment of
tumour vascularity may provide an early marker of response to primary therapy: for
example, the expression of angiogenic factors.
Tumour expression of the angiogenic inducer, vascular endothelial growth factor (VEGF), is
likely to be less susceptible to the effect of tumour heterogeneity than the vessels themselves
as assessment does not require selection of vascular 'hot spots'. VEGF is expressed by
tumour cells and acts as a specific endothelial cell mitogen. Thus, having identified that the
assessment of tumour vascularity by microvessel counting is unlikely to provide useful
information as a predictor of response to endocrine therapy, the % of VEGF-positive tumour
cells was investigated in the same tumours. There was a significant reduction in % cells
staining in responding tumours following three months' treatment with tamoxifen, but no
significant change was observed in non-responding tumours. In the majority of tumours
studied, VEGF was expressed in nearly all tumour cells before treatment, but there was a
reduction in percentage cells staining after treatment in both non-responding and responding
tumours. This suggests that a percentage of tumour cells were sensitive to tamoxifen in both
groups and one aspect of their response was to "switch off' VEGF expression. It may be that
the cells that persisted in VEGF expression may represent resistant clones, which were more
numerous in non-responding than responding tumours. However, the number of non-
responding tumours studied was small.
218
Despite the lack of clear difference in the effect of tamoxifen on % tumour cells staining for
VEGF in non-responding and responding tumour in this study it would be of value to
investigate its reproducibility in breast cancer specimens, which may be less affected by
tumour heterogeneity. The value of early changes in VEGF expression as an early predictor
for response could then be investigated. Such work is ongoing.
Work in this thesis has not attempted to ascertain the mode of action of tamoxifen on tumour
angiogenesis. Other investigators have addressed this issue in experimental systems and have
demonstrated a direct anti-angiogenic effect that was not mediated by the oestrogen receptor
(Gagliardi et al, 1995). Tamoxifen inhibited endothelial cell growth stimulated by
angiogenic growth factors such as VEGF and bFGF (Gagliardi et al, 1996; McNamara et al,
1998). Results of the xenograft studies detailed in this thesis suggest that effects of
tamoxifen were related to ER expression because no reduction in mvc was observed in ER-
negative MDA-MB-231 tumours. In the clinical studies letrozole appeared to exert a similar
effect on tumour angiogenesis, suggesting that the effect was not specific to tamoxifen, but
may be a reflection of oestrogen deprivation.
The main focus ofwork in this thesis has been based on a single method of assessing tumour
vascularity: microvessel counting. Changes in % tumour cells expressing VEGF following
treatment have also been studied, but were found to be less significant than mvc in the
retrospective study. Further investigation of VEGF expression in the prospective study
would be of value, however, particularly as the effects of tumour heterogeneity are likely to
be less marked. An alternative method of assessing angiogenic factor expression would be
by serial biochemical measurements of growth factors in the serum or urine of patients
during treatment. Elevated levels of VEGF and bFGF have been found in sera of patients
with metastatic colorectal, ovarian and renal carcinomas (Dirix et al, 1997). Another non¬
invasive method of angiogenesis assessment includes colour Doppler ultrasound that was
studied in too small a number of patients in this thesis for meaningful comment. An
alternative method is contrast-enhanced magnetic resonance imaging (MRI), which is
currently under investigation. MR enhancement has been found to be associated with high
vessel densities, but data showed considerable variation and was therefore not considered to
be an accurate predictor of microvessel density (Buckley et al, 1997; Stomper et al, 1997). In
another study ofMRI in combination with a contrast agent directly targeting the endothelial
integrin aVp3 provided enhanced and detailed imaging of rabbit carcinomas, including
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identification of angiogenic hot spots, which had not been previously detected by MR1
(Sipkins et al, 1998). The development of new contrast agents and technological
improvements in MRI may provide an important non-invasive method of assessing tumour
angiogenesis.
The strength of the model adopted in the present study is that tumour biopsy samples were
available at the early time point of 14 days after commencement of endocrine treatment in
addition to those available before and after completion of primary endocrine therapy. Few
patients invited to participate in the study declined a second biopsy, despite explanation of
the research role of such biopsies. The use of local anaesthetic before performing the
biopsies is thought to be an important factor for the patient. Local anaesthetic infiltration is
not performed prior to FNAs.
This study has provided a valuable source of material for investigation of other potential
early markers of sensitivity. Before embarking on further studies, however, it is important to
determine whether the failure of microvessel counts to provide an early marker of response
was related to the methodological issues described within this work, or whether the time
point of two weeks was too early to detect any changes in tumour biology. It is for this
reason that changes in tumour cell proliferation during treatment were studied. In this study,
there was a significant reduction in MIB-1 expression in responding tumours at two weeks,
but not in non-responding tumours. This reduction persisted throughout the course of
treatment, in contrast to a previous study in which early reduction in proliferation assessed
on FNA samples did not persist at eight weeks (Makris et al, 1998). This finding of reduced
MIB-1 expression early in the course of treatment is encouraging and confirms that early
changes in tumour biology do take place which can be detected on core biopsy specimens.
Studies assessing the reproducibility ifMIB-1 assessments are ongoing. In addition, other
potential early markers of response are being investigated in the same group of patients.
Current work involves assessment of apoptosis, which will enable calculation of the
apoptotic: mitotic ratio, which has been shown to be important in predicting response to
endocrine therapy in xenograft studies (Cameron et al, 1997b). It is hoped that assessment of
a range of potential markers of sensitivity will lead to the establishment of a predictive index
of sensitivity, which will enable clinicians to stop ineffective treatment at an earlier time
point than is currently possible.
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In conclusion, the studies described in this thesis have demonstrated a change in vascularity
of primary breast cancers following three months' treatment with tamoxifen. Xenograft
studies showed these changes occurred early during treatment with tamoxifen in ER-positive
ZR-75 tumours, but not ER-negative MDA-MB-231 tumours, suggesting that such changes
may be of benefit in the clinical setting as an early predictor of response to endocrine
therapy. However, a prospective study adopting the use of sequential core biopsies before,
during and after primary treatment with tamoxifen failed to demonstrate early changes in
tumour vascularity which would predict for response. Results of a series of control
experiments suggested that lack of reproducibility ofmvc in different breast cancer
specimens might be the cause of this failure. However, tumour biopsies collected during the
study provide valuable material for evaluation of other potential markers. Other methods of
assessing angiogenesis are available, as well as markers of proliferation and apoptosis. It is
hoped that ongoing work adopting the model outlined in this thesis may yield a clinically
useful index for predicting sensitivity to primary endocrine therapy.
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Appendices




HsdOla: ICRF-nu mice HARLAN (UK)
Standard diet HARLAN (UK)
Slow-release oestrogen pellet INNOVATIVE RESEARCH OF AMERICA
(0.72mg, released over 60 days)
Slow-release tamoxifen INNOVATIVE RESEARCH OF AMERICA
(2.5mg, released over 60 days)







Reagents for dewaxing of sections:
Xylene: FISHER X/0100/17
Absolute alcohol: FISHER E/0600/17 Lot number: 9751849 307
Staining for histological assessment:
Haematoxylin solution SIGMA HHS-32
Eosin solution SIGMA HT 110-1-32
Reagents for immunohistochemstry:
Tris buffered saline (TBS):
TRIZMA base. SIGMA T-1503 Lot number: 16H5738
Sodium chloride. FISHER S/3120/53 Lot number: 9741598 227
0.9% solution prepared in distilled water, by adding 9g sodium chloride to 1 litre distilled
water.
Hydrochloric acid FISHER H/1000/PB17
To make up TBS: 60.55g Trizma base was added to 1 litre distilled water and pH optimized
to
7.6 by addition of concentrated hydrochloric acid.
0.05M TBS was used for staining; to achieve this concentration, lOOmls TBS was added to
900ml 0.9% sodium chloride.
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Phosphate buffered saline.
Dulbecco 'A' tablets: DULBECCO BlR14a Lot number: R035614-002.
OVOID Unipath Ltd.
A single tablet was dissolved in lOOmls distilled water to make up PBS solution.
Fetal calf serum. GIBCO
Hydrogen peroxide. SIGMA H-1009 Lot number: 16H0355
Reagents for antigen retrieval:
Protease Type XXIV SIGMA P-8038
Citric acid SIGMA C-7129
Trypsin powder DIFCO 0152-13-1
Trypsin tissue culture (xlO) SIGMA T-4549






Mouse anti-human CD31 monoclonal antibody. Clone JC/70A
DAKO M0823 Lot number: 016 (201)
Anti-Von Willebrand factor monoclonal antibody. Clone F8/86.
DAKO M0616 Lot number: 126 (101)
Rat anti-mouse CD31 monoclonal antibody (MEC13.3).
PHARMINGEN 0195 ID Lot number: M022293
Polyclonal rabbit anti-VEGF antibody
SANTA CRUZ BIOTECHNOLOGY Code sc: 507
MIB-1 antibody BIOGENEX
Secondary antibodies:
Rabbit anti-mouse immunoglobulin: DAKO Z0259 Lot number: 067 (101)
Rabbit anti-rat immunoglobulin (APAAP): DAKO Z0494 Lot number: 072 (401)
Rabbit anti-rat immunoglobulin (biotin): DAKO E0468 Lot number: 045 (301)





APAAP, mouse, monoclonal: DAKOD0651
APAAP, rat, monoclonal: DAKO D0488
Lot number: 106(101).
Lot number: 046 (102).
Streptavin Peroxidase (HRP cone) BIOGENEX LP000-UL
Visualization systems:
New Fuchsin Substrate system: DAKO K698
Diaminobenzidine: (DAB) Kem-En-Tec 4240
Mounting media:
Aquamount BDH 362262H Lot number: 70213773.
DPX mounting medium: FISHER D/5319/05 Lot number: 9624511 386.
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APAAP STAINING PROTOCOL USING JC 70 ANTI-CD31 MOUSE ANTIBODY.
1. Freshly excised breast tissue fixed in 10% formal saline, processed and embedded in
paraffin wax.
2. 5pm paraffin sections cut in routine histology laboratory.
3. Dewax in xylene (xylene 1: 5 minutes, xylene 2: 5 minutes) and rehydrate through graded
alcohols (100% ethanol: 5 minutes, 99% ethanol: 5 minutes, 95% ethanol: 5 minutes,
distilled water: 10 minutes).
4. Pre-incubate sections in distilled water warmed to 37°C.
5. Make up 200ml PBS (pH7.4) and pre-warm to 37°C in incubator.
6. Dissolve 25mg protease type XXIV in 200ml warm PBS and incubate slides in protease
solution for 20 minutes at 37°C.
7. Transfer slides to distilled water at room temperature.
8. Circle sections with Dako pen.
9. Wash in 20%fetal calf serum (FCS)/0.05M TBS pH7.6 for 5 minutes.
10. Apply CD31 antibody at 1:40 diluted in 20%FCS/TBS. Leave for one hour, then wash in
TBS for 5 minutes.
11. Apply rabbit-anti mouse immunoglobulin diluted 1:50 in TBS for 30 minutes, then wash
in TBS for 5 minutes.
12. Apply mouse APAAP diluted 1:100 in TBS for 30 minutes then wash in TBS for 5
minutes.
13. Re-apply rabbit anti-mouse immunoglobulin 1:50 in TBS for 10 minutes then wash in
TBS for 5 minutes.
14. Re-apply mouse APAAP diluted 1:100 in TBS for 10 minutes, then wash in TBS for 5
minutes.
15. Apply new fiichsin substrate for 20 minutes.
16. Wash in distilled water.
17. Counterstain in Gill's no. 3 haematoxylin solution for 1-2 minutes with differentiation.
18. Rinse in running tap water.
19. Mount in aqueous mounting medium.
APAAP STAINING PROTOCOL FOR FACTOR VIII ANTIBODY.
The same protocol is used as for CD31, applying FVIII antibody 1:80 diluted in
20%FCS/TBS in place of CD31.
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PROTOCOL FOR VEGF STAINING OF PARAFFIN EMBEDDED TUMOUR
SECTIONS.
1. Mount 4-6pm thick tumour sections onto poly-L-lysine slides.
2. Deparaffinate slides as follows: xylene for 5 minutes x2 changes, absolute alcohol for 5
minutes x2 changes, 70% alcohol for 5 minutes x2 changes. Rinse sections in running
water, then rinse in TBS.
3. Incubate sections in fresh 3% hydrogen peroxide for 5 minutes x2 changes to quench
endogenous peroxidase activity. Rinse slides in running water, then TBS.
4. Incubate slides in normal goat serum diluted 1:10 in TBS for 30 minutes to block non¬
specific binding. Tap off serum and wipe away excess.
5. Incubate with primary antibody diluted 1:100 in TBS overnight at room temperature. Do
not allow slides to dry out. Substitute TBS for primary antibody for the negative control.
6. Rinse in TBS three times and place in a TBS bath for 5 minutes.
7. Prepare secondary antibody (biotinylated goat anti-rabbit) as instructed in Dust kit and
incubate for 30 minutes at room temperature. Repeat step 6.
8. Prepare StrepABComplex as instructed in Duet kit and incubate for 30 minutes at room
temperature. Repeat step 6.
9. Incubate with DAB chromogenic substrate for 30 minutes at room temperature. Rinse in
running water.
10. Counterstain lightly in haematoxylin for 3 minutes to stain cell nuclei.
11. Clear non-nuclear staining by incubating in acid alcohol for 2-3 minutes (0.5% in
hydrochloric acid in 70% ethanol)
12. Incubate in water for 5-10 minutes at room temperature.
13. Dehydrate sections as follows: 70% alcohol for 5 minutes x2 changes, absolute alcohol
for 5 minutes x2 changes, xylene for 5 minutes x2 changes.
14. Mount sections immediately in DPX and allow to dry before visualizing staining under a
microscope. Cell staining positive for VEGF appear brown.
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Appendix 2.3: ROUTINE SEQUENZA METHOD FOR STAINING WITH MIB-1
ANTIBODY.
1. Dewax paraffin slides (5 minutes) and take through alcohols to water.
2. Block endogenous peroxidase-3% hydrogen peroxide for 10 minutes. Wash in
running water.
3. Perform antigen retrieval by microwaving sections in 1,07g. citric acid for
3x5minutes. Allow sections to stand in citric acid for 20 minutes. Rinse in tap water.
4. Load slides onto Sequenza. Apply PBS for 5 minutes.
5. Apply primary antibody: MIB-1 (Biogenex) 1:20 in 0.05M TBS for 30 minutes.
6. Apply PBS for 5 minutes.
7. Apply secondary antibody: Vector anti-mouse 1:200 in 0.05M TBS for 30 minutes.
8. Apply PBS for 5 minutes.
9. Apply tertiary reagent for 30 minutes.
10. Apply PBS for 5 minutes, followed by distilled water for 5 minutes.
11. Prepare DAB (2mls in 2pi hydrogen peroxide) and immerse sections in DAB for 5
minutes.
12. Rinse slides in tap water.
13. Counterstain with haematoxylin for 5 minutes. Differentiate in acid alcohol.
14. Dehydrate, clear in xylene and mount in DPX.
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Appendix to Results.
1. Reproducibility of microvessel counts in breast cancer
specimens.
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Table A.l: Comparison of mvc performed by same observers at two time points.

































Table A1.2: Comparison of mvc performed by two observers.
Observers LM and KK


















Table A1.3: Microvessel counts following staining with CD31 and FVIII antibodies on
core biopsies and tumour sections.
SECTIONS CORES
Tumour No. MVC CD31 MVCFVm Tumour no. MVC CD31 MVCFVin
4809/95 16 24 11253/96 16 16
282/92 19 10 247 17 17
12243/93 16 12 274 16 14
UB15222/91 26 21 6 13 16
3294/93 13 35 1A 13 12
5086/94 29 21 64 12 12
UB 14022/91 11 19 9367/97 18 16
9286/92 12 17 275 14 13
919/94 22 15 196 14 17
10748/92 25 16 157 16 14
5432/94 14 17 6368/97 9 17
7435/92 22 19 115 12 18
1548/93 19 21 248 18 19
2767/93 35 18 136 9 10
466/94 21 23 293 12 10
960/95 28 26 94 15 15
9504/93 23 16 237 16 14
6640/95 23 19 11402/96 21 17
11247/92 17 17 249 16 14
10230/92 14 13 3987/97 15 14
3291/93 11 13 243 22 25
5383/92 25 21 12588/97 15 14
349/92 14 17 242 17 18
884/96 18 14 130 15 11
282/94 19 10 229 16 14
848/92 12 10 111 8 6
10750/92 19 18 8 17 12
UB 19363/90 17 15 164 18 17
UB20711/91 18 23 279 17 16
885/96 19 17 287 20 16
4206/92 8 9 163 11 11
5372/92 22 16 277 14 15
2676/93 20 21 294 20 16
5851/95 18 13 117 13 14
9963/92 16 16 159 14 14
10749/92 11 11 PB2645/98 15 10
10708/94 18 16 271 14 14
7766/94 14 18 14 13
2653/94 13 17 250 11 13
7980/92 24 22 167 13 15
6221/92 15 12 131 20 14
3197/93 14 16 134 10 15
4982/93 17 13 32 10 14
9451/94 12 15 262 14 14
10781/93 11 18 291 14 18
5392/92 17 13 7 14 13
UB 15071/91 15 23 IB 12 13
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SECTIONS CORES
Tumour no. MVC CD31 MVC FVIII Tumour no. MVC CD31 MVC FVIII
7057/95 10 16 206 16 15
5270/93 19 10 288 8 6
4684/93 23 18 208 11 12
2768/93 14 15 173 22 12
3977/93 19 15 160 17 12
89/93 20 12 122 21 12
849/92 14 12 261 13 14
2618/94 18 20 144 17 15
6093/92 15 15 301 14 12
5262/92 28 11 113 14 16
5176/94 6 15 238 13 14
436/92 24 26 34 11 21
9741/94 21 24 258 13 17
437/92 7 16 135 19 18
6291/94 16 11 256 17 19
10758/94 9 11 236 15 11
401/93 13 11 235 18 20
7618/93 12 14 145 13 12
5178/94 12 21 232 12 12
6082/95 11 12 116 12 16
2475/95 25 21 10 19 16
2652/94 14 19 172 9 18
11532/95 21 15 290 16 17
4773/96 27 28 295 16 18
6930/96 28 27 179 9 16
2487/93 23 8 289 15 14
10584/92 26 18 298 22 15
6240/92 12 15 133 10 9
8388/95 20 32 171 12 16
5247/96 23 25 296 14 18
5483/94 18 12 273 17 19
10812/96 26 14 13 22
6239/92 15 15 265 20 16
3523/93 12 16 182 10 19
UB27088/90 27 19 147 19 18
850/92 22 19 155 8 11
5991/96 11 16 302 10 10
2834/93 11 10 311 6 14
10263/92 18 15 1C 12 14
9484/94 19 26 309 13 13
9654/95 10 9 214 12 13
2292/93 12 15 300 16 18
9656/95 18 15 195 13 13
1672/95 10 11 320 10 13
2855/95 17 22 165 10 10
1365/93 23 17 304 13 18
9739/94 0 18 194 11 10
7927/94 19 17 284 17 16
5917/95 9 22 314 13 14
8845/92 13 11 315 15 12
2819/94 24 21 312 13 16
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SECTIONS CORES
Tumour no. MVC CD31 MVC FVIII Tumour no. MVC CD31 MVC FVIII
11971/95 13 17 313 0 0
10293/93 10 13 308 18 18
10063/93 14 14 307 18 15
8384/93 11 12 215 13 12
6141/93 20 20 220 13 17
4485/92 11 17 1 14 12
8114/96 18 18 68 18 19
2037/95 13 20 19 21 21
1831/96 7 15 91 16 15
435/92 14 21 14 17 20
2 18 19 23 13 14
69 18 18 99 17 14
20 18 21 101 17 18
92 19 14 79 14 16
10547 18 20 87 19 20
102 19 19 81 18 15
78 19 22 76 16 15
88 20 18 3 14 14
82 18 17 72 14 13
77 16 15 89 15 13


























Table A1.4: Counts performed in core biopsies and tumour sections taken
simultaneously.
Tumour no. No. cores MVC of
cores
Tumour no. MVC of
section
1 2 14 2 18
68 6 18 69 18
19 3 21 20 18
91 4 16 92 19
56 3 18 57 24
14 2 17 10547 18
99 2 17 100 16
101 2 17 102 19
79 1 14 78 19
87 7 19 88 20
81 3 18 82 18
76 3 16 77 16
3 4 14 4 14
72 4 14 73 17
89 3 15 90 17
13 5 14 10548 16
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Table A1.5: Comparison of counts performed on core biopsies and later tumour
sections.
Tumour No. cores MVC of LM No. 2 MVC of
no. cores section
223 2 19 12852 15
181 3 20 8972 22
51 2 18 69 18
41 4 15 57 22
11543 6 18 27 18
110 2 17 4785 25
55 3 13 82 21
207 3 20 210 18
59 2 21 88 16
83 3 16 2455 25
170 3 14 8791 23
86 2 16 3145 24
28 1 11 310 17
46 3 13 66 22
112 5 25 127 20
96 3 12 3073 17
11708 3 21 12025 21
26 1 19 102 19
107 4 15 187 22
264 2 16 267 21
128 5 14 140 16
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Table A1.6: Comparison of mvc performed on core biopsies of same tumour at
separate times.
Tumour no. No. cores 1 MVC of Tumour no. No. cores 2 MVC of
cores 1 cores 1 cores 2 cores 2
41 4 15 56 4 18 !
51 2 18 68 6 18
55 3 13 81 3 18
59 2 21 87 7 18
317 2 18 6525 2 14
316 3 17 5816 2 19
318 2 20 6334 4 15
319 2 16 6643 1 21
I 321 2 10 6418 3 20
| 322 3 16 7095 4 13
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Table A1.7: Relationship between number of cores and % change in mvc.
Number of cores MVC1 of cores MVC difference % MVC
MVC1-MVC2 difference
1 14 -5 35.7
1 11 6 54.5
1 19 0 0
2 14 -4 28.6
2 17 -1 5.88
2 17 1 5.88
2 17 -2 11.8
2 19 4 21.1
2 18 0 0
2 17 8 47.1
2 21 -5 23.8
2 16 8 50
2 16 5 31.2
3 21 3 14.3
3 18 -6 33.3
3 18 0 0
3 16 0 0
3 15 -2 13.3
3 20 -2 10
3 13 7 53.9
3 20 -2 10
3 16 9 56.3
3 14 9 64.3
3 - 13 9 69.2
3 12 5 41.7
3 21 0 0
4 16 -3 18.8
4 14 0 0
4 14 -3 21.4
4 15 7 46.7
4 15 7 46.7
5 14 -2 14.3
5 25 -5 20
5 14 2 14.3
6 18 0 0
6 18 0 0
7 19 -1 5.3
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2. Changes in tumour vascularity following primary tamoxifen
treatment and correlation with response.
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Table A2.1: Tumour volume during treatment with tamoxifen.
Where method of assessment is US: ultrasound, CLIN: clinical, MAMM: mammography.
Patient no. Clin, size 1 US size 1 Turn vol 1 Clin, size 2 US size 2 Turn vol 2 Clin, size 3 US size 3 Turn vol3 Assess.
480425W 37x35x38 11x13x17 1256 37x35x33 14x11x11 875 32x28x34 13x14x13 1222 US
495639K 40x38 NS NS 34x38 26 9203 32x32 19x16 2865 US
558680X 32x31x30 15x13x22 2217 34x30x29 17x13x14 1577 24x28x25 23x18x11 2277 US
495980E NS NS NS NS NS NS NS NS NS CLIN
494064R 54x35 NS NS 52x33 NA NS 56x41 NS NS CLIN
545602E 58x58 NS 102160 59x60x50 NS 92677 56X53X53 19x16 82364 CLIN
582565W 35x38x34 21x8x10 1890 32x33x29 21x17x18 3213 30x38x31 20x19x17 3383 US
528456W NS min. red. NS min. red. NS NS US
572868X 55x62 48x28x27 19000 57x65 30x33x27 13996 US
596319W 50x40x45 39x26x36 18252 32x37x34 33x24x31 24552 35x31 38x24x32 14592 US
522679X 47x47 NS NS NS NS NS NS NS NS CLIN
502246A 49 NS NS 52x48x50 NS NS 50x47x50 39x38x32 NS CLIN
524732W NS NS NS NS NS NS NS NS NS MAM
MO
52411IX NS NS NS 23x25x26 16x14x6 704 26x23x26 15x14x7 770 US
268300H 45x60x53 28x13x17 3240 45x45x55 14x15x18 1979 20x20 10x12x12 754 US
110258V 37 22x15x18 3110 30 NS NS NS 13x10x11 749 US
528171K 26x28x29 17x16x18 2330 NS 17x11x15 1470 US
552168H 35x39 20x16x18 3016 28x30x31 19x16x15 2388 NS 12x13x12 1062 US
52346X 45 NS NS 46 NS 41 NS MAM
MO
560577L 19X24X17 17X13X11 1273 14X20X12 12X9X12 679 14X15X18 8X9X9 US
513260L 32 17X12.5 NS NS NS NS CLIN
527028L 26 NS NS NS 10 524 NS 7.5x6 165 US
44955M 34x36 NS NS 26x32 15x17x13 1736 CLIN
395041K 44X38X39 17X23X29 5937 30X30 13X20X19 2587 40X35X39 21X14X25 1200 US
350429H 43x41x45 22x16x23 5280 40x31x28 21x16x23 3864 36x32x31 15x10x14 1050 US
545123B 30x42x38 37x39x15 11333 32x37x37 28x26x12 8736 27x23x20 7x15x18 990 US
520042V NS NS NS NS NS NS CLIN
81364H 36 NS 30X28 static 23x22 NS MAM
MO
511159M NS NS NS 33 20x12 NS 33 NS NS CLIN
500371K 26 NS NS 20 NS CLIN
372859M 30x35x34 14x19x23 3203 35x25x22 19x17x22 3721 30x28 16x17x21 2991 US
529249W NS NS NS 24X22 NS NS NS NS CLIN
376029R 25X26X34 18X18X12 2036 35X30X23 NS NS 27X25X27 10X19X20 1990 US
499870K 44x38 NS NS 40X37 NS 40X40 NS US
520767V NS NS NS 28x18 NS NS NS CLIN
498214W NS 15x14x15 1649 NS 15x9x13 919 NS 16x3x10 251 US
498258R NS 30x21 8247 38 34x37x42 27665 31x35 26x19x23 5949 US
559968K 41x45x36 27x32x18 8143 29x35x35 30x23x13 4697 25x28x30 11x19x31 3392 US
510657M NS NS NS NS NS NS NS NS NS CLIN
450908A 40x38x30 17x15x27 3605 13x16x15 40x34x34 1634 13x12x16 32x30x28 1307 US
155271L 36x34x35 14x16x18 2111 37x30x29 13x14x17 1620 20x20 NA US
519014W NS NS NS NS NS NS NS NS NS CLIN
499532M 38x40x38 17x18x16 2564 35x34x35 15x14x11 1210 34x32x29 11x13x12 899 US
564461M 34x32x29 12x12x14 1056 34x30x27 NA 30 NA CLIN
515126A NS NS NS NS NS NS 30 NS NS CLIN
529146X 49X33X51 NS NS 44X48X48 NS 33X34X37 NS NS MAM
MO
458317M 47x44x38 25x23x27 11140 35x30x25 18x15x19 2686 38x35x42 10x23x25 3011 US
548395L 46x51x46 32x34x21 11963 43x44x40 22x17x31 6071 US
509362K NS reduced excellent CLIN
503527E NS static 35x37 NS reduction CLIN
526825K NS NS NS NS NS NS CLIN
488627M 45x50x44 33x29x20 10022 33x35x27 20x10x14 1047 31x31x29 NA US
535168M NS NS NS NS NS NS NS 22x30 CLIN
532363A NS NS NS NS NS NS NS NS NS CLIN
527259E 34 NS NS NS NS NS NS NS NS CLIN
527857A NS NS NS NA 12x9x11 622 NS NS NS CLIN
588347R 38x40x37 16x17x17 2421 35x34 16x17x17 2421 25x25 15x12x13 1225 US
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Microvessel counts following staining with antibody to Factor VIII.
Table A1.2: Pre-and post-treatment mvc following staining with antibody to Factor









480425W 12 15 81364H 13 10
495639K 21 26 511159M 21 18
558680X 21 24 500371K 17 15
495980E 19 16 372859M 19 32
494064R 21 19 529249W 18 9
545602E 16 17 376029R 10 12
582565W 19 15 499870K 10 15
528456W 13 19 520767V 18 16
572868X 16 27 498214W 15 19
596319W 14 25 498258R 23 19
522679X 12 20 559968K 17 16
502246A 12 17 510657M 16 15
524732W 18 18 450908A 13 9
524111X 19 20 155271L 13 9
268300H 24 7 519014W 16 15
110258V 10 11 499532M 24 22
528171K 35 18 564461M 18 11
552168H 15 11 515126A 22 17
52346X 16 18 529146X 16 27
560577L 17 11 458317M 24 18
513260L 19 11 548395L 18 21
527028L 18 14 509362K 13 11
44955M 23 21 503527E 23 12
395041K 26 12 526825K 11 7
350429H 25 21 488627M 16 17
545123B 16 19 535168M 10 13
520042V 13 8 532363A 18 14
588347R 15 15 527259E 15 12
527857A 15 23
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Table A2.3: Comparison of pre-and post-treatment mvc in responding tumours:













































Table A2.4: Comparison of pre-and post-treatment mvc in non-responding tumours.
















Table A2.5: % reduction in tumour volume and change in mvc with treatment in
responding tumours:
RESPONDERS








































Table A2.6: % reduction in tumour volume and change in mvc with treatment in non-
responding tumours:
NON-RESPONDERS

















Microvessel counts following staining with antibody to CD31.
Table A2.7: Pre- and post-treatment mvc in all tumours following staining with
antibody to CD31:
Patient no. Pre-treatment Post- Patient no. Pre-treatment Post-
mvc treatment mvc mvc treatment mvc
480425W 16 6 511159M 25 26
495639K 26 24 500371K 14 12
558680X 29 21 372859M 0 20
495980E 11 7 529249W 0 0
494064R 19 0 376029R 19 18
545602E 0 0 499870K 12 15
582565W 23 21 520767V 19 12
528456W 0 0 498214W 17 27
572868X 0 28 498258R 18 22
596319W 18 23 559968K 19 11
522679X 20 20 510657M 22 18
502246A 14 11 450908A 0 0
524732W 0 18 155271L 18 10
524111X 0 0 519014W 16 12
268300H 16 0 499532M 0 0
110258V 19 28 564461M 14 10
| 528171K 13 0 515126A 24 23
552168H 22 16 529146X 14 0
52346X 25 0 458317M 0 0
560577L 14 9 548395L 11 24
513260L 22 13 509362K 17 13
527028L 35 12 503527E 15 8
44955M 21 12 526825K 20 0
395041K 28 11 488627M 10 13
350429H 0 25 535168M 19 10
545123B 23 14 532363A 23 14
520042V 14 23 527259E 14 11
81364H 11 0 527857A 19 0
588347R 0 7
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Table A2.8: Comparison of pre-and post-treatment mvc in responding tumours:






























Table A2.9: Comparison of pre- and post-treatment mvc in non-responding tumours:


























































































12 16 15 6
21 26 26 24
21 29 24 21
19 11 16 7
21 19 19 0
16 0 17 0
19 23 15 21
13 0 19 0
16 0 27 28
14 18 25 23
12 20 20 20
12 14 17 11
18 0 18 18
20 18 20 13
24 16 7 0
10 19 11 28
35 13 18 0
15 22 11 16
16 25 18 0
17 14 11 9
19 22 11 13
18 35 14 12
23 21 21 12
26 28 12 11
25 0 21 25
16 23 19 14
13 14 8 23
13 11 10 0
21 25 18 26
17 14 15 12
19 0 32 20
18 0 9 0
10 19 12 18
10 12 15 15
18 19 16 12
15 17 19 27
23 18 19 22
17 19 16 11
16 22 15 18
13 0 9 0
13 18 9 10
16 16 15 12
24 0 22 0
18 14 11 10
22 24 17 23
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Pre-treatment mvc Pre-treatment mvc Post-treatment mvc Post-treatment mvc
Factor VIII
CD31 Factor VIII CD31 |
16 14 27 0
24 0 18 0
18 11 21 24
13 17 11 13
23 15 12 8
11 20 7 0
16 10 17 13
10 19 13 10
18 23 14 14
15 14 12 11
15 19 23 0
15 0 15 7
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Table A2.13: Percentage lymph node involvement and tumour response to tamoxifen:












































Table A2.14: Microvessel counts and % lymph node involvement in responding
tumours: Lymph node status=number of nodes involved/number excised.
Pre-treatment Post-treatment mvc difference Lymph node % Lymph node
mvc (mvcl) mvc (mvc2) (mvc2-mvcl) status involvement
24 7 -17 0/18 o
35 18 -17 0/4 0
16 18 2 0/4 0
17 11 -6 1/4 25
19 11 -8 0/5 0
18 14 -4 0/2 0
23 21 -2 5/15 33
26 12 -14 0/5 0
25 21 -4 0/16 0
16 19 3 7/15 47
13 8 -5 1/14 7
13 10 -2 0/9 0
21 18 -3 1/4 25
17 15 -2 2/15 13
19 32 13 16/25 64
18 9 -9 0/6 0
10 15 5 0/4 0
18 16 -2 8/14 57
15 19 4 1/8 13
23 19 -4 11/24 46
17 16 -1 0/3 0
16 15 -1 1/18 6
13 ■ 9 -4 0/6 0
13 9 -4 2/9 22
16 15 -1 0/10 0
24 22 -2 0/4 0
18 11 -7 0/34 0
22 17 -5 0/4 0
16 27 11 1/6 17
24 18 -6 5/12 42
18 21 3 0/4 0
13 11 -2 2/17 12
23 12 -11 0/16 0
11 7 -4 0/16 0
10 13 3 1/4 25
18 14 -4 3/18 17
15 12 -3 0/3 0
15 23 8 0/2 0
15 15 0 5/17 29
19 20 1 0/4 0
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Table A2.15: Microvessel counts and % lymph node involvement in non-responding
tumours:
Pre-treatment Post-treatment mvc difference Lymphnode % lymph node
mvc (mvcl) mvc (mvc2) (mvc2-mvcl) status involvement
12 15 3 0/5 0
21 26 5 7/16 44
21 24 3 0/6 0
19 16 -3 0/15 0
21 19 -2 23/23 100
16 17 1 0/25 0
13 19 6 0/4 0
16 27 11 10/13 77
14 25 11 1/18 6
12 20 8 16/19 84
12 17 5 0/4 0
18 18 0 6/6 100
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Table A2.16: Level of ER expression and response:
ER in ffnol/mg cytosolic protein.
ER level in non-responding
tumours














































Table A2.17: Microvessel counts and level of ER expression in responding tumours:
Pre-treatment mvc mvc difference %mvc change ER level
(mvcl) (mvc2-mvcl) (mvc2-mvcl/
mvcl%)
24 -17 -70.8 324
10 1 10 606
35 -17 -48.6 325
15 -4 -26.7 363
16 2 12.5 605
17 -6 -35.3 254
19 -8 -42.1 444
18 -4 -22.2 445
23 -2 -8.7 42
26 -14 -54 221
25 -4 -16 379
16 3 18.75 288
13 -5 -38.5 620
13 -2 -15.4 186
21 -3 -14.3 510
17 -2 -11.8 72
19 13 72 33
18 -9 -50 964
10 2 20 96
10 5 50 262
18 -2 -11 463
15 4 26.7 53
23 -4 -17.4 837
17 -1 -5.9 58
16 -1 -6.25 557
13 -4 -30.8 739
13 -4 -30.8 1455
16 -1 -6.25 25
24 -2 -8.33 546
18 -7 -38.9 51
22 -5 -22.7 76
16 11 68.75 1292
24 -6 -25 166
18 3 16.7 762
13 -2 -15.4 623
23 -11 -47.8 166
11 -4 -36.4 386
16 1 6.25 197
10 3 30 292
18 -4 -22.2 1496
15 -3 -20 306
15 8 53 1388
15 0 0 357
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Table A2.18: Microvessel counts and level of ER expression in non-responding
tumours:
Pre-treatment mvc mvc difference %mvc change ER level
(mvcl) (mvc2-mvcl) (mvc2-mvcl
/mvcl%)
12 3 25 140
21 5 23.8 113
21 3 14.3 398
19 -3 -15.8 29
21 -2 -9.5 87
16 1 6.25 109
19 -4 -21 132
13 6 46.2 68
16 11 68.75 33
14 11 78.6 673
12 8 66.7 40
12 5 41.7 201
18 0 0 465
19 0 0 25
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4. Sequential changes in tumour vascularity during treatment
with tamoxifen: a prospective study.
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Table A4.1: Tumour response data for patients treated with tamoxifen (where method
of assessment is classified as US: ultrasound, CLIN: clinical or mammo:
mammographic)
Patient Clinical US sizel Clinical US size2 Clinical US size3 Mammo Mammo Assess.
no. sizel size2 size3 resp.
615724L 50x60 43x50 50x65 43x50 55x53 53x46 30397 si deer. US
639991L 41x28
(ulcer)
NA 42x34 NA 41x28
(ulcer)
NA NA CLIN
120288B 38x38 21x17x19 30x30 21x16x18 30x30 18x16x15 150698 static US
612031H 41x40 NA 34x32x36 NA 30x27x28 NA NA CLIN
614905K 24x22x26 24x22x23 23x21x25 16x11x17 14x10 14x11x17 100297 decrease US
614905K 70x68x72 53x21x25 68x66x70 62x51x27 66x68x70 43x16x35 300597 decrease US
296162H 48x38 28x26x24 NA 28x26x24 38x28 28x28x26 80198 increase US
631385B 28x35 27x21x19 24x26 25x15x17 25x24 27x16x15 150698 sl.red. US
143050M 40x40 25x15x20 35x25 27x22x27 33x22 13x27x25 40298 reduction US
628989R 25x20 20x11x15 25x20 19x11x18 15x20 13x11x9 221097 reduction US
495945A 24x22x26 26x15x21 26x27 26x20x13 20x25 16x11x21 31197 reduction US
623397B 25x25 25x22x21 23x25 18x19x18 33x25 22x14x12 200897 reduction us
561829A 59x58 31x40x22 54x55 17x60x14 40x40 20x33x24 NA us
341122W 35x40 29x13x23 35x45 31x29x14 30x32 25x18x17 NA us
645382X 29x29 20x13x19 29x29 20x13x19 30X27 15X18X8 NA us
622149X NA 43x40x20 45x25 43x24x20 NA 27x19x13 150797 reduction us
D345548 34x30 23x20x12 32x30 21x20x19 28x22 18x13x10 30398 reduction us
614975H 40x40 24x26x25 35x35 23x20x17 impalp. 20x18x15 140597 reduction us
640026R 50x37 28x27x30 47x42 27x23x30 30x35 20x18x24 110598 static us
624169K 20x20 34x13x18 30x25 34x13x18 30x25 34x13x18 180797 static us
639575E 46x28 19x34x18 reduction mammo
638318X 22x22 18x28x18 28x33 20x24x13 25x16 19x9x20 90498 static US
637345V 45x30 18x16x29 37x24 15x20x15 26x19 24x9x16 200498 reduction us
558811X 52x35 32x47x20 50x42 35x23x37 52x52 43x39x18 NA NA us
637357K 40x48 25x18x28 40x32 19x19x15 43x35 20x22x18 160398 static us
422318K 30x28x25 NA 24x22x20 NA 28x30x32 NA 10997 increase CLIN
84321A 25x27x23 NA 18x20x19 16X20 16x19x18 NA 290197 reduction CLIN
628483V NA 24x18x17 45x50 24x31x18 38x35 26x18x17 31197 static US
D077978 42x45 19x20x13 34x40 15x14x14 30x38 19x11x17 NA NA US
643001M 32x32 33x15x17 30x20 33x12x10 NA 33x12x10 230798 not seen US
629111W 42x34 25x12 42x35 39x26x23 30x25 25x10x22 131097 static US
484933K 17x21 15x16x11 16x17 15x7x12 16x16 11x6.2 NA US
266308W 32x33 24x33x25 26x26 17x19x16 22x24 19x20x13 290698 reduction US
622926V NA 30x44x18 NA 26x16x28 NA 14x9x14 NA NA us
625368K 30x30 20x15x11 30x33 29x14x16 30x25 20x22x11 20298 static us
D528581 19x23 15x24x13 11x26 12x8x11 12x14 11x14x13 NA us
10046V 41x50 22x24x29 40x41 22x11x21 36x35 21x11x15 150698 reduction us
static mammo
201525A 35x33 28x10x19 30x25 30x12x20 31x28 20x19x14 60598 static US
629740R 45x55 28x27x17 35x32 22x16x9 22x30 18x14x7 61197 reduction us
625691A 40x45 27x41x15 35x45 35x38x22 45x55 30x26x17 41197 reduction us
626230E 35x35 38x18x29 34x30 31x15x17 35x20 25x18x11 NA us
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Microvessel counts following staining with antibody to Factor VIII.
Table A4.2: Pre-, peri-and post-treatment mvc in all patients:
Patient no. Pre-treatment mvc Peri-treatment mvc Post-treatment mvc
615724L 16 14 18
639991L 17 14 10
120288B 14 18 14
612031H 16 13 13
614905K 12 13 14
614905K 12 17 13
296162H 16 15 22
631385B 13 6 13
143050M 17 12 20
628989R 14 12 13
495945A 17 12 13
623397B 18 12 18
561829A 19 14 18
341122W 10 15 13
645382X 10 12 13
622149X 15 16 10
D345548V 14 14 17
614975H 17 21 18
640026R 14 17 18
624169K 14 18 16
639575E 25 19 16
638318X 14 11 22
637345V 18 20 16
55881IX 11 12 10
637357K 14 12 16
422318K 6 16 18
84321A 12 16 19
628483V 17 18 11
D077978R 16 17 14
643001M 16 18 12
629111W 11 16 13
484933K 15 14 20
266308W 16 15 16
622926V 14 9 21
625368K 14 16 14
D528581B 10 18 0
10046V 14 19 18
13 22 9
201525A 13 16 15
629740R 15 19 23
625691A 14 18 12
626230E 15 11 17
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Table A4.3: Pre-, peri- and post-treatment mvc in non-responding and responding
tumours:
(Non-responding tumours in bold type)












































Table A4.4: Relationship between degree of ultrasound response and % mvc change
with tamoxifen
(% mvc change=mvc3-mvcl/mvcl% where mvc3 is post-treatment mvc and mvcl is pre-
treatment mvc) Non-responding tumours are shown in bold type.









































Microvessel counts following staining with antibody to CD31.
Table A4.5: Pre-, peri-and post-treatment mvc in all patients:
Patient no. Pre-treatment Peri-treatment Post-treatment
mvc mvc mvc
615724L 16 10 20
639991L 17 14 10
120288B 16 14 6
612031H 13 14 16
614905K 13 12 12
614905K 12 15 19
296162H 18 16 18
631385B 14 8 13
143050M 14 11 15
628989R 16 22 13
495945A 9 17 12
623397B 12 21 19
561829A 18 13 16
341122W 9 17 13
645382X 12 14 10
622149X 15 14 10
D345548V 16 13 17
614975H 21 11 16
640026R 16 13 13
624169K 15 19 14
639575E 22 17 15
638318X 15 15 22
637345V 17 18 20
55881IX 15 13 11
637357K 16 12 17
422318K 8 12 13
84321A 17 19 21
628483V 18 9 22
D077978R 17 16 13
643001M 20 16 15
629111W 11 9 23
484933K 14 15 15
266308W 20 22 13
622926V 13 10 15
625368K 14 12 16
D528581B 15 14 0
10046V 14 17 18
14 13 12
201525A 11 20 18
629740R 13 10 13
625691A 20 19 13
626230E 10 8 13
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Table A4.6: Comparison of microvessel counts in non-responding and responding
tumours before, during and after treatment with tamoxifen.
(Non-responding tumours shown in bold type)












































Table A4.7: % reduction in tumour volume and % change in mvc with treatment
(% mvc change=mvc3-mvcl/mvcl%, where mvc l=pre-treatment mvc and mvc3=post-
treatment mvc. Non-responding tumours are shown in bold type).










































Microvessel counts and other tumour parameters.
Table A4.8: % lymph node involvement and tumour response to tamoxifen












Table A4.9: Microvessel counts and lymph node involvement (Factor VIII):







% mvc change % lymph node
involvement
16 18 2 12.5 77
12 13 1 8.33 100
16 22 6 37.5 0
17 20 3 17.7 0
14 16 2 14.3 53
11 10 -1 -9.09 100
6 18 12 200 0
17 11 -6 -35.2 36
11 13 2 18.2 44
16 13 -3 -18.75 25
14 13 -1 -7.14 0
18 18 0 0 0
17 18 1 5.88 0
14 22 8 57.1 0
18 16 -2 -11.1 12.5
12 19 7 58.3 50
14 21 7 50 0
14 14 0 0 18
15 23 8 53.3 61
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Table A4.10: Microvessel counts and lymph node involvement (CD31 staining):
Non-responders in bold type
Pre-treatment Peri- Post- Change in % mvc % lymph
mvc (mvcl) treatment treatment mvc (mvc3- change node
mvc (mvc2) mvc (mvc3)) mvcl) involvement
16 10 20 4 25 77
12 15 19 7 58 100
18 16 18 0 0 o
14 11 15 1 7.1 0
15 19 14 -1 -6.7 5.3
15 13 11 -4 -26.7 100
8 12 13 5 62.5 0
18 9 22 4 22 36
11 9 23 12 109 44
13 14 16 3 23 25
16 22 13 -3 -18.8 0
12 21 19 7 58 0
21 11 16 -5 -23.8 0
15 15 22 7 46.7 0
17 18 20 3 17.7 12.5
17 19 21 4 23.5 50
13 10 15 2 15.4 0
14 12 16 2 14.3 18
13 10 13 0 0 61
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Table A4.ll: Level of ER expression (Histoscore) and response:






























Table A4.12: Pre-treatment mvc and level of ER expression (Factor VIII staining)
Non-responders in bold type:











































Table 4.13: Pre-treatment mvc and levels of ER expression: (CD31 staining):
Non-responders shown in bold type.











































5. Changes in proportion of tumour cells expressing vascular
endothelial growth factor and tamoxifen treatment.
293
Table A5.1: Proportion of VEGF-positive tumour cells before and after treatment with


















































Table A5.2: Relationship between proportion of VEGF-positive tumour cells and
microvessel counts before treatment:
a) Non-responders





















































Table A5.3: Relationship between % VEGF-positive tumour cells and microvessel
counts after treatment.
a) Non-responders





















































6. Changes in tumour cell proliferation during treatment with
tamoxifen.
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Table A6.1: Changes in MIB-1 expression during treatment with tamoxifen in non-
responding tumours:















Table A6.2: Changes in MBB-1 expression during treatment with tamoxifen in
responding tumours:
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